AbbVie (ABBV) 10-K 17 Feb 23 2022 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2022	Jan. 31, 2023	Jun. 30, 2022
Entity Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-35565
Entry Registrant Name	AbbVie Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	32-0375147
Entity Address, Address Line One	1 North Waukegan Road
Entity Address, City or Town	North Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60064-6400
City Area Code	847
Local Phone Number	932-7900
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 268,252,598,311
Entity Common Stock, Shares Outstanding		1,769,399,971
Documents Incorporated by Reference	Portions of the 2023 AbbVie Inc. Proxy Statement are incorporated by reference into Part III. The Definitive Proxy Statement will be filed on or about March 20, 2023.
Entity Central Index Key	0001551152
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Common stock | NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	ABBV
Security Exchange Name	NYSE
Common stock | CHICAGO STOCK EXCHANGE, INC
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	ABBV
Security Exchange Name	CHX
Sec 1.500 Senior Notes Due 2023 | NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	1.500% Senior Notes due 2023
Trading Symbol	ABBV23B
Security Exchange Name	NYSE
Sec 1.375 Senior Notes Due 2024 | NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	1.375% Senior Notes due 2024
Trading Symbol	ABBV24
Security Exchange Name	NYSE
Sec 1.250 Senior Notes Due 2024 | NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	1.250% Senior Notes due 2024
Trading Symbol	ABBV24B
Security Exchange Name	NYSE
Sec 0.750 Senior Notes Due 2027 | NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	0.750% Senior Notes due 2027
Trading Symbol	ABBV27
Security Exchange Name	NYSE
Sec 2.125 Senior Notes due 2028 | NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	2.125% Senior Notes due 2028
Trading Symbol	ABBV28
Security Exchange Name	NYSE
Sec 2.625 Senior Notes Due 2028 | NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	2.625% Senior Notes due 2028
Trading Symbol	ABBV28B
Security Exchange Name	NYSE
Sec 2.125 Senior Notes Due 2029 | NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	2.125% Senior Notes due 2029
Trading Symbol	ABBV29
Security Exchange Name	NYSE
Sec 1.250 Senior Notes Due 2031 | NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	1.250% Senior Notes due 2031
Trading Symbol	ABBV31
Security Exchange Name	NYSE

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2022
Auditor Information [Abstract]
Auditor Name	Ernst & Young LLP
Auditor Location	Chicago, Illinois
Auditor Firm ID	42

Consolidated Statements of Earn

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Net revenues	$ 58,054	$ 56,197	$ 45,804
Cost of products sold	17,414	17,446	15,387
Selling, general and administrative	15,260	12,349	11,299
Research and development	6,510	6,922	6,379
Acquired IPR&D and milestones	697	1,124	1,376
Other operating expense, net	56	432	0
Total operating costs and expenses	39,937	38,273	34,441
Operating earnings	18,117	17,924	11,363
Interest expense, net	2,044	2,384	2,280
Net foreign exchange loss	148	51	71
Other expense, net	2,448	2,500	5,614
Earnings before income tax expense	13,477	12,989	3,398
Income tax expense (benefit)	1,632	1,440	(1,224)
Net earnings	11,845	11,549	4,622
Net earnings attributable to noncontrolling interest	9	7	6
Net earnings attributable to AbbVie Inc.	$ 11,836	$ 11,542	$ 4,616
Per share data
Basic earnings per share (in dollars per share)	$ 6.65	$ 6.48	$ 2.73
Diluted earnings per share (in dollars per share)	$ 6.63	$ 6.45	$ 2.72
Weighted-average basic shares outstanding (in shares)	1,771	1,770	1,667
Weighted-average diluted shares outstanding (in shares)	1,778	1,777	1,673

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Comprehensive Income [Abstract]
Net earnings	$ 11,845	$ 11,549	$ 4,622
Foreign currency translation adjustments, net of tax expense (benefit) of $(10) in 2022, $(35) in 2021 and $28 in 2020	(943)	(1,153)	1,511
Net investment hedging activities, net of tax expense (benefit) of $152 in 2022, $193 in 2021 and $(221) in 2020	555	699	(799)
Pension and post-employment benefits, net of tax expense (benefit) of $272 in 2022, $124 in 2021 and $(47) in 2020	1,088	521	(102)
Cash flow hedging activities, net of tax expense (benefit) of $5 in 2022, $20 in 2021 and $(23) in 2020	0	151	(131)
Other comprehensive income (loss)	700	218	479
Comprehensive income	12,545	11,767	5,101
Comprehensive income attributable to noncontrolling interest	9	7	6
Comprehensive income attributable to AbbVie Inc.	$ 12,536	$ 11,760	$ 5,095

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Comprehensive Income [Abstract]
Foreign currency translation adjustments, tax expense (benefit)	$ (10)	$ (35)	$ 28
Net investment hedging activities, tax expense (benefit)	152	193	(221)
Pension and post-employment benefits, tax expense (benefit)	272	124	(47)
Cash flow hedging activities, tax expense (benefit)	$ 5	$ 20	$ (23)

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and equivalents	$ 9,201	$ 9,746
Short-term investments	28	84
Accounts receivable, net	11,254	9,977
Inventories	3,579	3,128
Prepaid expenses and other	4,401	4,993
Total current assets	28,463	27,928
Investments	241	277
Property and equipment, net	4,935	5,110
Intangible assets, net	67,439	75,951
Goodwill	32,156	32,379
Other assets	5,571	4,884
Total assets	138,805	146,529
Current liabilities
Short-term borrowings	1	14
Current portion of long-term debt and finance lease obligations	4,135	12,481
Accounts payable and accrued liabilities	25,402	22,699
Total current liabilities	29,538	35,194
Long-term debt and finance lease obligations	59,135	64,189
Deferred income taxes	2,190	3,009
Other long-term liabilities	30,655	28,701
Commitments and contingencies
Stockholders' equity
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,813,770,294 shares issued as of December 31, 2022 and 1,803,195,293 as of December 31, 2021	18	18
Common stock held in treasury, at cost, 44,589,000 shares as of December 31, 2022 and 34,857,597 as of December 31, 2021	(4,594)	(3,143)
Additional paid-in capital	19,245	18,305
Retained earnings	4,784	3,127
Accumulated other comprehensive loss	(2,199)	(2,899)
Total stockholders' equity	17,254	15,408
Noncontrolling interest	33	28
Total equity	17,287	15,436
Total liabilities and equity	$ 138,805	$ 146,529

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	4,000,000,000	4,000,000,000
Common stock, issued (in shares)	1,813,770,294	1,803,195,293
Common stock held in treasury, at cost (in shares)	44,589,000	34,857,597

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) shares in Millions, $ in Millions	Total	Common stock	Treasury stock	Additional paid-in capital	Retained earnings	Accumulated other comprehensive loss	Noncontrolling interest
Beginning balance at Dec. 31, 2019	$ (8,172)	$ 18	$ (24,504)	$ 15,193	$ 4,717	$ (3,596)	$ 0
Beginning balance (in shares) at Dec. 31, 2019		1,479
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	4,616	$ 0	0	0	4,616	0	0
Other comprehensive income, net of tax	479	0	0	0	0	479	0
Dividends declared	(8,278)	0	0	0	(8,278)	0	0
Common shares and equity awards issued for acquisition of Allergan plc	24,409	$ 0	23,166	1,243	0	0	0
Common shares and equity awards issued for acquisition of Allergan plc (in shares)		286
Purchases of treasury stock	(978)	$ 0	(978)	0	0	0	0
Purchases of treasury stock (in shares)		(10)
Stock-based compensation plans and other	1,000	$ 0	52	948	0	0	0
Stock-based compensation plans and other (in shares)		10
Change in noncontrolling interest	21	$ 0	0	0	0	0	21
Ending balance at Dec. 31, 2020	13,097	$ 18	(2,264)	17,384	1,055	(3,117)	21
Ending balance (in shares) at Dec. 31, 2020		1,765
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	11,542	$ 0	0	0	11,542	0	0
Other comprehensive income, net of tax	218	0	0	0	0	218	0
Dividends declared	(9,470)	0	0	0	(9,470)	0	0
Purchases of treasury stock	(934)	$ 0	(934)	0	0	0	0
Purchases of treasury stock (in shares)		(8)
Stock-based compensation plans and other	976	$ 0	55	921	0	0	0
Stock-based compensation plans and other (in shares)		11
Change in noncontrolling interest	7	$ 0	0	0	0	0	7
Ending balance at Dec. 31, 2021	15,436	$ 18	(3,143)	18,305	3,127	(2,899)	28
Ending balance (in shares) at Dec. 31, 2021		1,768
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	11,836	$ 0	0	0	11,836	0	0
Other comprehensive income, net of tax	700	0	0	0	0	700	0
Dividends declared	(10,179)	0	0	0	(10,179)	0	0
Purchases of treasury stock	(1,487)	$ 0	(1,487)	0	0	0	0
Purchases of treasury stock (in shares)		(10)
Stock-based compensation plans and other	976	$ 0	36	940	0	0	0
Stock-based compensation plans and other (in shares)		11
Change in noncontrolling interest	5	$ 0	0	0	0	0	5
Ending balance at Dec. 31, 2022	$ 17,287	$ 18	$ (4,594)	$ 19,245	$ 4,784	$ (2,199)	$ 33
Ending balance (in shares) at Dec. 31, 2022		1,769

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net earnings	$ 11,845	$ 11,549	$ 4,622
Adjustments to reconcile net earnings to net cash from operating activities:
Depreciation	778	803	666
Amortization of intangible assets	7,689	7,718	5,805
Deferred income taxes	(1,931)	(898)	(2,325)
Change in fair value of contingent consideration liabilities	2,761	2,679	5,753
Stock-based compensation	671	692	753
Acquired IPR&D and milestones	697	1,124	1,376
Other charges related to collaborations	0	500	0
Gain on divestitures	(172)	(68)	0
Non-cash litigation reserve adjustments, net of cash payments	2,243	163	(31)
Impairment of intangible assets	770	50	0
Other, net	(150)	(213)	863
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(1,455)	(1,321)	(929)
Inventories	(686)	(142)	(40)
Prepaid expenses and other assets	(264)	(197)	134
Accounts payable and other liabilities	1,605	1,628	1,514
Income tax assets and liabilities, net	542	(1,290)	(573)
Cash flows from operating activities	24,943	22,777	17,588
Cash flows from investing activities
Acquisition of businesses, net of cash acquired	(255)	(525)	(38,260)
Other acquisitions and investments	(539)	(1,377)	(1,350)
Acquisitions of property and equipment	(695)	(787)	(798)
Purchases of investment securities	(1,438)	(119)	(61)
Sales and maturities of investment securities	1,530	98	1,525
Other, net	774	366	1,387
Cash flows from investing activities	(623)	(2,344)	(37,557)
Cash flows from financing activities
Proceeds from issuance of long-term debt	2,000	1,000	3,000
Repayments of long-term debt and finance lease obligations	(14,433)	(9,414)	(5,683)
Debt issuance costs	0	0	(20)
Dividends paid	(10,043)	(9,261)	(7,716)
Purchases of treasury stock	(1,487)	(934)	(978)
Proceeds from the exercise of stock options	262	244	209
Payments of contingent consideration liabilities	(1,132)	(698)	(321)
Other, net	30	24	8
Cash flows from financing activities	(24,803)	(19,039)	(11,501)
Effect of exchange rate changes on cash and equivalents	(62)	(97)	(5)
Net change in cash and equivalents	(545)	1,297	(31,475)
Cash and equivalents, beginning of year	9,746	8,449	39,924
Cash and equivalents, end of year	9,201	9,746	8,449
Other supplemental information
Interest paid, net of portion capitalized	2,546	2,712	2,619
Income taxes paid	2,988	3,648	1,674
Supplemental schedule of non-cash investing and financing activities
Issuance of common shares associated with acquisitions of businesses	$ 0	$ 0	$ 23,979

Background and Basis of Present

Background and Basis of Presentation	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background	Background Background The principal business of AbbVie Inc. (AbbVie or the company) is the discovery, development, manufacturing and sale of a broad line of therapies that address some of the world's most complex and serious diseases. AbbVie's products are generally sold worldwide directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers from AbbVie-owned distribution centers and public warehouses. Certain products (including aesthetic products and devices) are also sold directly to physicians and other licensed healthcare providers. In the United States, AbbVie distributes pharmaceutical products principally through independent wholesale distributors, with some sales directly to retailers, pharmacies, patients or other customers. Outside the United States, AbbVie sells products primarily to wholesalers or through distributors, and depending on the market works through largely centralized national payers system to agree on reimbursement terms. AbbVie was incorporated in Delaware on April 10, 2012. On January 1, 2013, AbbVie became an independent, publicly-traded company as a result of the distribution by Abbott Laboratories (Abbott) of 100% of the outstanding common stock of AbbVie to Abbott's shareholders. On May 8, 2020, AbbVie completed its acquisition of Allergan plc (Allergan). Refer to Note 5 for additional information regarding this acquisition.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Use of Estimates The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and necessarily include amounts based on estimates and assumptions by management. Actual results could differ from those amounts. Significant estimates include amounts for rebates, pension and other post-employment benefits, income taxes, litigation, valuation of goodwill and intangible assets, contingent consideration liabilities, financial instruments and inventory and accounts receivable exposures. Basis of Consolidation The consolidated financial statements include the accounts of AbbVie and all of its subsidiaries in which a controlling interest is maintained. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, where AbbVie is determined to be the primary beneficiary. Investments in companies over which AbbVie has a significant influence but not a controlling interest are accounted for using the equity method with AbbVie's share of earnings or losses reported in other expense, net in the consolidated statements of earnings. Intercompany balances and transactions are eliminated. During 2022, AbbVie revised its classification of development milestone expense associated with licensing and collaboration arrangements in the consolidated statements of earnings. Milestone payments incurred prior to regulatory approval, which were previously included in research and development (R&D) expense, are now presented as acquired IPR&D and milestones expense in the consolidated statements of earnings. The reclassification decreased R&D expense and increased acquired IPR&D and milestones expense by $162 million in 2021 and $178 million in 2020. The company believes this presentation assists users of the financial statements to better understand the total upfront and subsequent development milestone payments incurred to acquire in-process research and development projects. Prior periods have been reclassified to conform to the current period presentation. Certain other reclassifications have been made to conform the prior period consolidated financial statements to the current period presentation. Revenue Recognition AbbVie recognizes revenue when control of promised goods or services is transferred to the company’s customers, in an amount that reflects the consideration AbbVie expects to be entitled to in exchange for those goods or services. Sales, value add and other taxes collected concurrent with revenue-producing activities are excluded from revenue. AbbVie generates revenue primarily from product sales. For the majority of sales, the company transfers control, invoices the customer and recognizes revenue upon shipment to the customer. The company recognizes shipping and handling costs as an expense in cost of products sold when the company transfers control to the customer. Payment terms vary depending on the type and location of the customer, are based on customary commercial terms and are generally less than one year. AbbVie does not adjust revenue for the effects of a significant financing component for contracts where AbbVie expects the period between the transfer of the good or service and collection to be one year or less. Cash discounts, rebates and chargebacks, sales incentives, product returns and certain other adjustments are accounted for as variable consideration. Provisions for variable consideration are based on current pricing, executed contracts, government pricing legislation and historical data and are provided for in the period the related revenues are recorded. Rebate amounts are typically based upon the volume of purchases using contractual or statutory prices, which may vary by product and by payer. For each type of rebate, factors used in the calculation of the accrual include the identification of the products subject to the rebate, the applicable price terms and the estimated lag time between sale and payment of the rebate, which can be significant. In addition to revenue from contracts with customers, the company also recognizes certain collaboration revenues. See Note 6 for additional information related to the collaborations with Janssen Biotech, Inc. and Genentech, Inc. Additionally, see Note 16 for disaggregation of revenue by product and geography. Research and Development Expenses Internal R&D costs are expensed as incurred. Clinical trial costs incurred by third parties are expensed as the contracted work is performed. Acquired IPR&D and Milestones Expenses In an asset acquisition, payments incurred prior to regulatory approval to acquire rights to in-process R&D projects are expensed as acquired IPR&D and milestones expense in the consolidated statements of earnings unless the project has an alternative future use. These costs include upfront and development milestone payments related to R&D collaborations, licensing arrangements, or other asset acquisitions that provide rights to develop, manufacture and/or sell pharmaceutical products. Where contingent development milestone payments are due to third parties, prior to regulatory approval, the payment obligations are expensed when the milestone results are achieved. Regulatory and commercial milestone payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized to cost of products sold over the remaining useful life of the related product. Business Combinations AbbVie utilizes the acquisition method of accounting for business combinations. This method requires, among other things, that results of operations of acquired companies are included in AbbVie's results of operations beginning on the acquisition date and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Any excess of the fair value of consideration transferred over the fair value of the net assets acquired is recognized as goodwill. Contingent consideration liabilities are recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent consideration liabilities are recognized in other expense, net in the consolidated statements of earnings. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other business acquisition costs are expensed when incurred. In a business combination, the fair value of IPR&D projects acquired is capitalized and accounted for as indefinite-lived intangible assets until the underlying project receives regulatory approval, at which point the intangible asset will be accounted for as a definite-lived intangible asset, or discontinuation, at which point the intangible asset will be written off. R&D costs incurred by the company after the acquisition are expensed to R&D as incurred. Collaborations and Other Arrangements The company enters into collaborative agreements with third parties to develop and commercialize drug candidates. Collaborative activities may include joint research and development and commercialization of new products. AbbVie generally receives certain licensing rights under these arrangements. These collaborations often require upfront payments and may include additional milestone, research and development cost sharing, royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development and commercialization. Upfront payments associated with collaborative arrangements and subsequent payments made to the partner for the achievement of development milestones prior to regulatory approval are expensed to acquired IPR&D and milestones expense in the consolidated statements of earnings. Regulatory and commercial milestone payments made to the partner subsequent to regulatory approval are capitalized as intangible assets and amortized to cost of products sold over the estimated useful life of the related asset. Royalties are expensed to cost of products sold in the consolidated statements of earnings when incurred. Advertising Costs associated with advertising are expensed as incurred and are included in selling, general and administrative (SG&A) expense in the consolidated statements of earnings. Advertising expenses were $2.0 billion in 2022, $2.1 billion in 2021 and $1.8 billion in 2020. Pension and Other Post-Employment Benefits AbbVie records annual expenses relating to its defined benefit pension and other post-employment benefit plans based on calculations which utilize various actuarial assumptions including discount rates, rates of return on assets, compensation increases, turnover rates and health care cost trend rates. AbbVie reviews its actuarial assumptions on an annual basis and makes modifications to the assumptions based on current rates and trends. Actuarial gains and losses are deferred in accumulated other comprehensive income (loss) (AOCI), net of tax and are amortized over the remaining service attribution periods of the employees under the corridor method. Differences between the expected long-term return on plan assets and the actual annual return are generally amortized to net periodic benefit cost over a five-year period. Income Taxes Income taxes are accounted for under the asset and liability method. Provisions for federal, state and foreign income taxes are calculated on reported pre-tax earnings based on current tax laws. Deferred taxes are provided using enacted tax rates on the future tax consequences of temporary differences, which are the differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases and the tax benefits of carryforwards. A valuation allowance is established or maintained when, based on currently available information, it is more likely than not that all or a portion of a deferred tax asset will not be realized. Cash and Equivalents Cash and equivalents include money market funds and time deposits with original maturities of three months or less. Investments Investments consist primarily of equity securities, held-to-maturity debt securities, marketable debt securities and time deposits. Investments in equity securities that have readily determinable fair values are recorded at fair value. Investments in equity securities that do not have readily determinable fair values are recorded at cost and are remeasured to fair value based on certain observable price changes or impairment events as they occur. Held-to-maturity debt securities are recorded at cost. Gains or losses on investments are included in other expense, net in the consolidated statements of earnings. Investments in marketable debt securities are classified as available-for-sale and are recorded at fair value with any unrealized holding gains or losses, net of tax, included in AOCI on the consolidated balance sheets until realized, at which time the gains or losses are recognized in earnings. AbbVie periodically assesses its marketable debt securities for impairment and credit losses. When a decline in fair value of marketable debt security is due to credit related factors, an allowance for credit losses is recorded with a corresponding charge to other expense, net in the consolidated statements of earnings. When AbbVie determines that a non-credit related impairment has occurred, the amortized cost basis of the investment, net of allowance for credit losses, is written down with a charge to other expense, net in the consolidated statements of earnings and an available-for-sale investment's unrealized loss is reclassified from AOCI to other expense, net in the consolidated statements of earnings. Realized gains and losses on sales of investments are computed using the first-in, first-out method adjusted for any impairments and credit losses that were recorded in net earnings. Accounts Receivable Accounts receivable are stated at amortized cost less allowance for credit losses. The allowance for credit losses reflects the best estimate of future losses over the contractual life of outstanding accounts receivable and is determined on the basis of historical experience, specific allowances for known troubled accounts, other currently available information including customer financial condition and both current and forecasted economic conditions. Inventories Inventories are valued at the lower of cost (first-in, first-out basis) or market. Cost includes material and conversion costs. Inventories consisted of the following: as of December 31 (in millions) 2022 2021 Finished goods $ 1,162 $ 932 Work-in-process 1,417 1,193 Raw materials 1,000 1,003 Inventories $ 3,579 $ 3,128 Property and Equipment as of December 31 (in millions) 2022 2021 Land $ 286 $ 287 Buildings 2,737 2,791 Equipment 7,107 6,850 Construction in progress 856 799 Property and equipment, gross 10,986 10,727 Less accumulated depreciation (6,051) (5,617) Property and equipment, net $ 4,935 $ 5,110 Depreciation for property and equipment is recorded on a straight-line basis over the estimated useful lives of the assets. The estimated useful life for buildings ranges from 10 to 50 years. Buildings include leasehold improvements which are amortized over the lesser of the remainder of the lease term or the useful life of the leasehold improvement. The estimated useful life for equipment ranges from 2 to 25 years. Equipment includes certain computer software and software development costs incurred in connection with developing or obtaining software for internal use and is amortized over 3 to 10 years. Depreciation expense was $778 million in 2022, $803 million in 2021 and $666 million in 2020. Leases Short-term leases with a term of 12 months or less are not recorded on the balance sheet. For leases commencing or modified in 2019 or later, AbbVie does not separate lease components from non-lease components. The company records lease liabilities based on the present value of lease payments over the lease term. AbbVie generally uses an incremental borrowing rate to discount its lease liabilities, as the rate implicit in the lease is typically not readily determinable. Certain lease agreements include renewal options that are under the company's control. AbbVie includes optional renewal periods in the lease term only when it is reasonably certain that AbbVie will exercise its option. Variable lease payments include payments to lessors for taxes, maintenance, insurance and other operating costs as well as payments that are adjusted based on an index or rate. The company's lease agreements do not contain any significant residual value guarantees or restrictive covenants. Litigation and Contingencies Loss contingency provisions are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information. When a best estimate cannot be made, the minimum loss contingency amount in a probable range is recorded. Legal fees are expensed as incurred. AbbVie accrues for product liability claims on an undiscounted basis. The liabilities are evaluated quarterly and adjusted if necessary as additional information becomes available. Receivables for insurance recoveries for product liability claims, if any, are recorded as assets on an undiscounted basis when it is probable that a recovery will be realized. Goodwill and Intangible Assets Intangible assets acquired in a business combination are recorded at fair value using a discounted cash flow model. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, risk, the cost of capital and terminal values of market participants. Definite-lived intangibles are amortized over their estimated useful lives using the estimated pattern of economic benefit. AbbVie reviews the recoverability of definite-lived intangible assets whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. AbbVie first compares the projected undiscounted cash flows to be generated by the asset to its carrying value. If the undiscounted cash flows of an intangible asset are less than the carrying value, the intangible asset is written down to its fair value. Where cash flows cannot be identified for an individual asset, the review is applied at the lowest level for which cash flows are largely independent of the cash flows of other assets and liabilities. Goodwill and indefinite-lived assets are not amortized, but are subject to an impairment review annually and more frequently when indicators of impairment exist. An impairment of goodwill could occur if the carrying amount of a reporting unit exceeded the fair value of that reporting unit. An impairment of indefinite-lived intangible assets would occur if the fair value of the intangible asset is less than the carrying value. The company tests its goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If the company concludes it is more likely than not that the fair value of the reporting unit is less than its carrying amount, a quantitative impairment test is performed. AbbVie tests indefinite-lived intangible assets for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If the company concludes it is more likely than not that the fair value is less than its carrying amount, a quantitative impairment test is performed. For its quantitative impairment tests, the company uses an estimated future cash flow approach that requires significant judgment with respect to future volume, revenue and expense growth rates, changes in working capital use, the selection of an appropriate discount rate, asset groupings and other assumptions and estimates. The estimates and assumptions used are consistent with the company's business plans and a market participant's views. The use of alternative estimates and assumptions could increase or decrease projected cash flows and the estimated fair value of the related intangible assets. Future changes to these estimates and assumptions could have a material impact on the company's results of operations. Actual results may differ from the company's estimates. Foreign Currency Translation Foreign subsidiary earnings are translated into U.S. dollars using average exchange rates. The net assets of foreign subsidiaries are translated into U.S. dollars using period-end exchange rates. The U.S. dollar affects that arise from translating the net assets of these subsidiaries at changing rates are recognized in other comprehensive income (loss) in the consolidated statements of comprehensive income. The net assets of subsidiaries in highly inflationary economies are remeasured as if the functional currency were the reporting currency. The remeasurement is recognized in net foreign exchange loss in the consolidated statements of earnings. Derivatives All derivative instruments are recognized as either assets or liabilities at fair value on the consolidated balance sheets and are classified as current or long-term based on the scheduled maturity of the instrument. For derivatives formally designated as hedges, the company assesses at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in the fair value or cash flows of the hedged item. The changes in fair value of a derivative designated as a fair value hedge and of the hedged item attributable to the hedged risk are recognized in earnings immediately. The effective portions of changes in the fair value of a derivative designated as a cash flow hedge are reported in AOCI and are subsequently recognized in earnings consistent with the underlying hedged item. If it is determined that a derivative is no longer highly effective as a hedge, the company discontinues hedge accounting prospectively. If a hedged forecasted transaction becomes probable of not occurring, any gains or losses are reclassified from AOCI to earnings. Derivatives that are not designated as hedges are adjusted to fair value through current earnings. The company also uses derivative instruments or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. Realized and unrealized gains and losses from these hedges are included in AOCI. Derivative cash flows, with the exception of net investment hedges, are principally classified in the operating section of the consolidated statements of cash flows, consistent with the underlying hedged item. Cash flows related to net investment hedges are classified in the investing section of the consolidated statements of cash flows.

Supplemental Financial Informat

Supplemental Financial Information	12 Months Ended
	Dec. 31, 2022
Supplemental Financial Information
Supplemental Financial Information	Supplemental Financial Information Interest Expense, Net years ended December 31 (in millions) 2022 2021 2020 Interest expense $ 2,230 $ 2,423 $ 2,454 Interest income (186) (39) (174) Interest expense, net $ 2,044 $ 2,384 $ 2,280 Accounts Payable and Accrued Liabilities as of December 31 (in millions) 2022 2021 Sales rebates $ 10,717 $ 8,254 Dividends payable 2,680 2,543 Accounts payable 2,934 2,882 Current portion of contingent consideration liabilities 1,469 1,249 Salaries, wages and commissions 1,371 1,785 Royalty and license arrangements 412 661 Other 5,819 5,325 Accounts payable and accrued liabilities $ 25,402 $ 22,699 Other Long-Term Liabilities as of December 31 (in millions) 2022 2021 Contingent consideration liabilities $ 14,915 $ 13,638 Liabilities for unrecognized tax benefits 6,502 5,970 Income taxes payable 2,985 3,442 Pension and other post-employment benefits 1,638 3,153 Other 4,615 2,498 Other long-term liabilities $ 30,655 $ 28,701

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share AbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive. The following table summarizes the impact of the two-class method: Years ended December 31, (in millions, except per share data) 2022 2021 2020 Basic EPS Net earnings attributable to AbbVie Inc. $ 11,836 $ 11,542 $ 4,616 Earnings allocated to participating securities 54 74 60 Earnings available to common shareholders $ 11,782 $ 11,468 $ 4,556 Weighted average basic shares of common stock outstanding 1,771 1,770 1,667 Basic earnings per share attributable to AbbVie Inc. $ 6.65 $ 6.48 $ 2.73 Diluted EPS Net earnings attributable to AbbVie Inc. $ 11,836 $ 11,542 $ 4,616 Earnings allocated to participating securities 54 74 60 Earnings available to common shareholders $ 11,782 $ 11,468 $ 4,556 Weighted average shares of common stock outstanding 1,771 1,770 1,667 Effect of dilutive securities 7 7 6 Weighted average diluted shares of common stock outstanding 1,778 1,777 1,673 Diluted earnings per share attributable to AbbVie Inc. $ 6.63 $ 6.45 $ 2.72 Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.

Licensing, Acquisitions, and Ot

Licensing, Acquisitions, and Other Arrangements	12 Months Ended
	Dec. 31, 2022
Licensing, Acquisitions, and Other Arrangements
Licensing, Acquisitions, and Other Arrangements	Licensing, Acquisitions and Other Arrangements Acquisition of DJS Antibodies Ltd In October 2022, AbbVie entered into an agreement to acquire DJS Antibodies Ltd (DJS) including its lead program DJS-002 and proprietary HEPTAD platform. DJS-002 is an LPAR1 antagonist antibody currently in preclinical studies for the treatment of Idiopathic Pulmonary Fibrosis and other fibrotic diseases. HEPTAD platform is a potential novel approach to antibody discovery with specific capabilities targeting transmembrane protein targets. The aggregate purchase price of $287 million was comprised of a $255 million upfront cash payment and $32 million for the acquisition date fair value of contingent consideration liabilities, for which AbbVie may owe up to $95 million in future payments upon achievement of certain development milestones. The transaction was accounted for as a business combination using the acquisition method of accounting. As of the acquisition date, AbbVie acquired $233 million of intangible assets for in-process research and development, $22 million of intangible assets for developed product rights and $60 million of deferred tax liabilities. Other assets and liabilities assumed were insignificant. The acquisition resulted in the recognition of $92 million of goodwill which is not deductible for tax purposes. Acquisition of Soliton, Inc. In December 2021, AbbVie completed its previously announced acquisition of Soliton, Inc. (Soliton). Soliton's RESONIC (Rapid Acoustic Pulse device) has U.S. Food and Drug Administration (FDA) 510(k) clearance for the long-term improvement in the appearance of cellulite up to one year. The transaction was accounted for as a business combination using the acquisition method of accounting. Total consideration transferred allocated to the purchase price consisted of cash consideration of $535 million paid to holders of Soliton common stock, equity-based awards and warrants. As of the transaction date, AbbVie acquired $407 million of intangible assets for developed product rights and assumed deferred tax liabilities totaling $63 million. Other assets and liabilities were insignificant. The acquisition resulted in the recognition of $177 million of goodwill which is not deductible for tax purposes. Acquisition of Luminera In October 2020, AbbVie entered into an agreement with Luminera, a privately held aesthetics company based in Israel, to acquire Luminera's full dermal filler portfolio and R&D pipeline including HArmonyCa, a dermal filler intended for facial soft tissue augmentation. The aggregate accounting purchase price of $186 million was comprised of a $122 million upfront cash payment and $64 million for the acquisition date fair value of contingent consideration liabilities, for which AbbVie may owe up to $90 million in future payments upon achievement of certain commercial milestones. The agreement was accounted for as a business combination using the acquisition method of accounting. As of the acquisition date, AbbVie acquired $127 million of intangible assets for in-process research and development and $33 million of intangible assets for developed product rights. Other assets and liabilities assumed were insignificant. The acquisition resulted in the recognition of $12 million of goodwill which is not deductible for tax purposes. Acquisition of Allergan On May 8, 2020, AbbVie completed its acquisition of all outstanding equity interests in Allergan in a cash and stock transaction. Allergan is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The combination created a diverse entity with leadership positions across immunology, hematologic oncology, aesthetics, neuroscience and eye care. AbbVie's existing product portfolio and pipeline is enhanced with numerous Allergan assets and Allergan's product portfolio benefits from AbbVie's commercial strength, expertise and international infrastructure. Under the terms of the acquisition, each ordinary share of Allergan common stock was converted into the right to receive (i) $120.30 in cash and (ii) 0.8660 of a share of AbbVie common stock. Total consideration for the acquisition of Allergan is summarized as follows: (in millions) Cash consideration paid to Allergan shareholders (a) $ 39,675 Fair value of AbbVie common stock issued to Allergan shareholders (b) 23,979 Fair value of AbbVie equity awards issued to Allergan equity award holders (c) 430 Total consideration $ 64,084 (a) Represents cash consideration transferred of $120.30 per outstanding Allergan ordinary share based on 330 million Allergan ordinary shares outstanding at closing. (b) Represents the acquisition date fair value of 286 million shares of AbbVie common stock issued to Allergan shareholders based on the exchange ratio of 0.8660 AbbVie shares for each outstanding Allergan ordinary share at the May 8, 2020, closing price of $83.96 per share. (c) Represents the pre-acquisition service portion of the fair value of 11 million AbbVie stock options and 8 million RSUs issued to Allergan equity award holders. The acquisition of Allergan has been accounted for as a business combination using the acquisition method of accounting. The acquisition method requires, among other things, that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The valuation of assets acquired and liabilities assumed was finalized during the second quarter of 2021. Measurement period adjustments to the preliminary purchase price allocation during 2021 included (i) an increase to intangible assets of $710 million; (ii) an increase to deferred income tax liabilities of $148 million; (iii) other individually insignificant adjustments for a net increase to identifiable net assets of $2 million; and (iv) a corresponding decrease to goodwill of $564 million. The measurement period adjustments primarily resulted from the completion of the valuation of certain license agreement intangible assets based on facts and circumstances that existed as of the acquisition date and did not result from intervening events subsequent to such date. These adjustments did not have a significant impact on AbbVie's results of operations in 2021 and would not have had a significant impact on prior period results if these adjustments had been made as of the acquisition date. The following table summarizes t he final fair value of assets acquired and liabilities assumed as of the acquisition date: (in millions) Assets acquired and liabilities assumed Cash and equivalents $ 1,537 Short-term investments 1,421 Accounts receivable 2,374 Inventories 2,340 Prepaid expenses and other current assets 1,982 Investments 137 Property and equipment 2,129 Intangible assets Definite-lived intangible assets 68,190 In-process research and development 1,600 Other noncurrent assets 1,395 Short-term borrowings (60) Current portion of long-term debt and finance lease obligations (1,899) Accounts payable and accrued liabilities (5,852) Long-term debt and finance lease obligations (18,937) Deferred income taxes (3,940) Other long-term liabilities (4,765) Total identifiable net assets 47,652 Goodwill 16,432 Total assets acquired and liabilities assumed $ 64,084 The fair value step-up adjustment to inventories of $1.2 billion was amortized to cost of products sold when the inventory was sold to customers and was fully amortized as of December 31, 2021. Intangible assets relate to $68.2 billion of definite-lived intangible assets and $1.6 billion of IPR&D. The acquired definite-lived intangible assets consist of developed product rights and license agreements and are being amortized over a weighted-average estimated useful life of approximately twelve years using the estimated pattern of economic benefit. The estimated fair values of identifiable intangible assets were determined using the "income approach" which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the more significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset or product, the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk, competitive trends impacting the asset and each cash flow stream, as well as other factors. The fair value of long-term debt was determined by quoted market prices as of the acquisition date and the total purchase price adjustment of $1.3 billion is being amortized as a reduction to interest expense, net over the lives of the related debt. Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. Specifically, the goodwill recognized from the acquisition of Allergan represents the value of additional growth platforms and an expanded revenue base as well as anticipated operational synergies and cost savings from the creation of a single combined global organization. The goodwill is not deductible for tax purposes. Following the acquisition date, the operating results of Allergan have been included in the consolidated financial statements. For the period from the acquisition date through December 31, 2020, net revenues attributable to Allergan were $10.3 billion and operating losses attributable to Allergan were $1.1 billion, inclusive of $4.0 billion of intangible asset amortization and $1.2 billion of inventory fair value step-up amortization. Acquisition-related expenses, which were comprised primarily of regulatory, financial advisory and legal fees, totaled $781 million for the year ended December 31, 2020 which were included in SG&A expenses in the consolidated statements of earnings . In the fourth quarter of 2021, AbbVie recovered certain acquisition-related regulatory fees totaling $401 million which was recorded as a reduction to SG&A expenses in the consolidated statement of earnings for the year ended December 31, 2021. Pro Forma Financial Information The following table presents the unaudited pro forma combined results of AbbVie and Allergan for 2020 as if the acquisition of Allergan had occurred on January 1, 2019: years ended December 31 (in millions) 2020 Net revenues $ 50,521 Net earnings 6,746 The unaudited pro forma combined financial information was prepared using the acquisition method of accounting and was based on the historical financial information of AbbVie and Allergan. In order to reflect the occurrence of the acquisition on January 1, 2019 as required, the unaudited pro forma financial information includes adjustments to reflect incremental amortization expense to be incurred based on the final fair values of the identifiable intangible assets acquired; the incremental cost of products sold related to the fair value adjustments associated with acquisition date inventory; the additional interest expense associated with the issuance of debt to finance the acquisition; and the reclassification of acquisition-related costs incurred during the year ended December 31, 2020 to the year ended December 31, 2019. The unaudited pro forma financial information is not necessarily indicative of what the consolidated results of operations would have been had the acquisition been completed on January 1, 2019. In addition, the unaudited pro forma financial information is not a projection of future results of operations of the combined company nor does it reflect the expected realization of any synergies or cost savings associated with the acquisition. Other Licensing & Acquisitions Activity Cash outflows related to other acquisitions and investments totaled $539 million in 2022, $1.4 billion in 2021 and $1.4 billion in 2020. AbbVie recorded acquired IPR&D and milestones expense of $697 million in 2022, $1.1 billion in 2021 and $1.4 billion in 2020. Significant arrangements impacting 2022, 2021 and 2020, some of which require contingent milestone payments, are summarized below. Syndesi Therapeutics SA In February 2022, AbbVie acquired Syndesi Therapeutics SA and its portfolio of novel modulators of the synaptic vesicle protein 2A, including its lead molecule SDI-118 and accounted for the transaction as an asset acquisition. SDI-118 is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. Under the terms of the agreement, AbbVie made an upfront payment of $130 million which was recorded to acquired IPR&D and milestones expense in the consolidated statement of earnings in the first quarter of 2022. The agreement also includes additional future payments of up to $870 million upon the achievement of certain development, regulatory and commercial milestones. Juvise Pharmaceuticals In June 2022, AbbVie and Laboratories Juvise Pharmaceuticals (Juvise) entered into an asset purchase agreement where Juvise acquired worldwide commercial rights of a mature brand Pylera, which is used for the treatment of peptic ulcers with an infection by the bacterium Helicobacter pylori. The transaction was accounted for as the sale of an asset. Upon completion of the transaction, AbbVie received net cash proceeds of $215 million and recognized a pre-tax gain of $172 million which was recorded in other operating income in the consolidated statement of earnings in the second quarter of 2022. Calico Life Sciences LLC In July 2021, AbbVie and Calico Life Sciences LLC (Calico) entered into an extension of their collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. This is the second collaboration extension and builds on the partnership established in 2014 and extended in 2018. Under the terms of the agreement, AbbVie and Calico will each contribute an additional $500 million, and the term is extended for an additional three years. AbbVie’s contribution is payable in two equal installments beginning in 2023. Calico will be responsible for research and early development until 2025 and will advance collaboration projects into Phase 2a through 2030. Following completion of the Phase 2a studies, AbbVie will have the option to exclusively license the collaboration compounds. Upon exercise, AbbVie would be responsible for late-stage development and commercial activities. Collaboration costs and profits will be shared equally by both parties post option exercise. During the third quarter of 2021, AbbVie recorded $500 million as other operating expense in the consolidated statement of earnings related to its commitments under the agreement. TeneoOne and TNB-383B In September 2021, AbbVie acquired TeneoOne, an affiliate of Teneobio, Inc., and TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of relapsed or refractory multiple myeloma (R/R MM). In February 2019, AbbVie and TeneoOne entered a strategic transaction to develop and commercialize TNB-383B, a bispecific antibody that simultaneously targets BCMA and CD3 and is designed to direct the body's own immune system to target and kill BCMA-expressing tumor cells. AbbVie exercised its exclusive right to acquire TeneoOne and TNB-383B based on an interim analysis of an ongoing Phase 1 study and accounted for the transaction as an asset acquisition. Under the terms of the agreement, AbbVie made an exercise payment of $400 million which was recorded to acquired IPR&D and milestones expense in the consolidated statement of earnings in the third quarter of 2021. The agreement also included additional payments of up to $250 million upon the achievement of certain development, regulatory and commercial milestones. REGENXBIO Inc. In September 2021, AbbVie and REGENXBIO Inc. (REGENXBIO) entered into a collaboration to develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases. The collaboration provides AbbVie with an exclusive global license to develop and commercialize RGX-314. REGENXBIO will be responsible for completion of ongoing trials, AbbVie and REGENXBIO will collaborate and share costs of additional trials and AbbVie will lead the clinical development and commercialization of RGX-314 globally. REGENXBIO and AbbVie will share equally in pre-tax profits from net revenues of RGX-314 in the U.S. and AbbVie will pay REGENXBIO tiered royalties on net revenues outside the U.S. Upon closing in the fourth quarter of 2021, AbbVie made an upfront payment of $370 million to exclusively license RGX-314 which was recorded to acquired IPR&D and milestones expense in the consolidated statement of earnings for the year ended December 31, 2022 . The agreement also included additional payments of up to $1.4 billion upon the achievement of certain development, regulatory and commercial milestones. I-Mab Biopharma In September 2020, AbbVie and I-Mab Biopharma (I-Mab) entered into a collaboration agreement for the development and commercialization of lemzoparlimab, an anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. Both companies will collaborate to design and conduct further global clinical trials to evaluate lemzoparlimab. The collaboration provides AbbVie an exclusive global license, excluding greater China, to develop and commercialize lemzoparlimab. The companies will share manufacturing responsibilities with AbbVie being the primary manufacturer for global supply. The agreement also allows for potential collaboration on future CD47-related therapeutic agents, subject to further licenses to explore each other's related programs in their respective territories. The terms of the arrangement include an initial upfront payment of $180 million to exclusively license lemzoparlimab along with a milestone payment of $20 million based on the Phase I results, for a total of $200 million, which was recorded to acquired IPR&D and milestones expense in the consolidated statement of earnings in the fourth quarter of 2020 after regulatory approval of the transaction. In addition, I-Mab will be eligible to receive up to $1.7 billion upon the achievement of certain clinical development, regulatory and commercial milestones, and AbbVie will pay tiered royalties from low-to-mid teen percentages on global net revenues outside of greater China. Genmab A/S In June 2020, AbbVie and Genmab A/S (Genmab) entered into a collaboration agreement to jointly develop and commercialize three of Genmab's early-stage investigational bispecific antibody therapeutics and entered into a discovery research collaboration for future differentiated antibody therapeutics for the treatment of cancer. Under the terms of the agreement, Genmab granted AbbVie an exclusive license to its epcoritamab (DuoBody-CD3xCD20), DuoHexaBody-CD37 and DuoBody-CD3x5T4 programs. For epcoritamab, the companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Genmab will record net revenues in the U.S. and Japan, and the parties will share equally in pre-tax profits from these sales. Genmab will receive tiered royalties on remaining global sales. For the discovery research partnership, Genmab will conduct Phase 1 studies for these programs and AbbVie retains the right to opt-in to program development. During 2020, AbbVie made an upfront payment of $750 million, which was recorded to acquired IPR&D and milestones expense in the consolidated statement of earnings. AbbVie could make additional payments of up to $3.2 billion upon the achievement of certain development, regulatory and commercial milestones for all programs. Other Arrangements

Collaborations

Collaborations	12 Months Ended
	Dec. 31, 2022
Collaborative Arrangements [Abstract]
Collaborations	Collaborations The company has ongoing transactions with other entities through collaboration agreements. The following represent the significant collaboration agreements impacting 2022, 2021 and 2020. Collaboration with Janssen Biotech, Inc. In December 2011, Pharmacyclics, a wholly-owned subsidiary of AbbVie, entered into a worldwide collaboration and license agreement with Janssen Biotech, Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson & Johnson, for the joint development and commercialization of Imbruvica, a novel, orally active, selective covalent inhibitor of Bruton's tyrosine kinase and certain compounds structurally related to Imbruvica, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the United States and outside the United States. The collaboration provides Janssen with an exclusive license to commercialize Imbruvica outside of the United States and co-exclusively with AbbVie in the United States. Both parties are responsible for the development, manufacturing and marketing of any products generated as a result of the collaboration. The collaboration has no set duration or specific expiration date and provides for potential future development, regulatory and approval milestone payments of up to $200 million to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately 60% of collaboration development costs and AbbVie is responsible for the remaining 40% of collaboration development costs. In the United States, both parties have co-exclusive rights to commercialize the products; however, AbbVie is the principal in the end-customer product sales. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. Sales of Imbruvica are included in AbbVie's net revenues. Janssen's share of profits is included in AbbVie's cost of products sold. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share. Outside the United States, Janssen is responsible for and has exclusive rights to commercialize Imbruvica. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. AbbVie's share of profits is included in AbbVie's net revenues. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share. The following table shows the profit and cost sharing relationship between Janssen and AbbVie: years ended December 31 (in millions) 2022 2021 2020 United States - Janssen's share of profits (included in cost of products sold) $ 1,607 $ 2,018 $ 2,012 International - AbbVie's share of profits (included in net revenues) 1,142 1,087 1,009 Global - AbbVie's share of other costs (included in respective line items) 268 304 295 AbbVie’s receivable from Janssen, included in accounts receivable, net, was $295 million at December 31, 2022 and $294 million at December 31, 2021. AbbVie’s payable to Janssen, included in accounts payable and accrued liabilities, was $379 million at December 31, 2022 and $509 million at December 31, 2021. Collaboration with Genentech, Inc. AbbVie and Genentech, Inc. (Genentech), a member of the Roche Group, are parties to a collaboration and license agreement executed in 2007 to jointly research, develop and commercialize human therapeutic products containing BCL-2 inhibitors and certain other compound inhibitors which includes Venclexta, a BCL-2 inhibitor used to treat certain hematological malignancies. AbbVie shares equally with Genentech all pre-tax profits and losses from the development and commercialization of Venclexta in the United States. AbbVie pays royalties on Venclexta net revenues outside the United States. AbbVie manufactures and distributes Venclexta globally and is the principal in the end-customer product sales. Sales of Venclexta are included in AbbVie's net revenues. Genentech's share of United States profits is included in AbbVie's cost of products sold. AbbVie records sales and marketing costs associated with the United States collaboration as part of SG&A expenses and global development costs as part of R&D expenses, net of Genentech’s share. Royalties paid for Venclexta revenues outside the United States are also included in AbbVie’s cost of products sold. The following table shows the profit and cost sharing relationship between Genentech and AbbVie: years ended December 31 (in millions) 2022 2021 2020 Genentech's share of profits, including royalties (included in cost of products sold) $ 778 $ 703 $ 533 AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) 37 40 46 AbbVie's share of development costs (included in R&D) 121 140 129

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill The following table summarizes the changes in the carrying amount of goodwill: (in millions) Balance as of December 31, 2020 $ 33,124 Additions (a) 177 Measurement period adjustments (b) (564) Foreign currency translation adjustments and other (358) Balance as of December 31, 2021 32,379 Additions (c) 92 Foreign currency translation adjustments and other (315) Balance as of December 31, 2022 $ 32,156 (a) Goodwill additions related to the acquisition of Soliton in the fourth quarter of 2021 (see Note 5). (b) Measurement period adjustments recorded in 2021 related to the acquisition of Allergan (see Note 5). (c) Goodwill additions related to the acquisition of DJS in the fourth quarter of 2022 (see Note 5). The company performs its annual goodwill impairment assessment in the third quarter, or earlier if impairment indicators exist. As of December 31, 2022 and 2021, there were no accumulated goodwill impairment losses. Intangible Assets, Net The following table summarizes intangible assets: 2022 2021 as of December 31 (in millions) Gross Accumulated Net Gross Accumulated Net Definite-lived intangible assets Developed product rights $ 87,698 $ (25,003) $ 62,695 $ 88,945 $ (18,463) $ 70,482 License agreements 8,474 (4,642) 3,832 8,487 (3,688) 4,799 Total definite-lived intangible assets 96,172 (29,645) 66,527 97,432 (22,151) 75,281 Indefinite-lived intangible assets 912 — 912 670 — 670 Total intangible assets, net $ 97,084 $ (29,645) $ 67,439 $ 98,102 $ (22,151) $ 75,951 Definite-Lived Intangible Assets In September 2022, the company made a strategic decision to reduce ongoing sales and marketing investment related to Vuity, an on-market product to treat presbyopia. This strategic decision contributed to a significant decrease in the estimated future cash flows for the product and represented a triggering event which required the company to evaluate the underlying definite lived-intangible asset for impairment. The company utilized a discounted cash flow analysis to estimate the fair value of the intangible asset resulting in a full impairment of both the gross and net carrying amount. Based on the revised cash flows, the company recorded a pre-tax impairment charge of $770 million to cost of products sold in the consolidated statement of earnings for the third quarter of 2022. Definite-lived intangible assets are amortized over their estimated useful lives, which range between 1 to 16 years with an average of 12 years for developed product rights and 11 years for license agreements. Amortization expense was $7.7 billion in 2022, $7.7 billion in 2021 and $5.8 billion in 2020 and was included in cost of products sold in the consolidated statements of earnings. The anticipated annual amortization expense for definite-lived intangible assets recorded as of December 31, 2022 is as follows: (in billions) 2023 2024 2025 2026 2027 Anticipated annual amortization expense $ 7.7 $ 7.9 $ 8.0 $ 7.3 $ 5.8 Indefinite-Lived Intangible Assets Indefinite-lived intangible assets represent acquired IPR&D associated with products that have not yet received regulatory approval. Indefinite-lived intangible assets as of December 31, 2022 primarily relate to the acquisitions of Allergan and DJS.

Integration and Restructuring P

Integration and Restructuring Plans	12 Months Ended
	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Integration and Restructuring Plans	Integration and Restructuring Plans Allergan Integration Plan Following the closing of the Allergan acquisition, AbbVie implemented an integration plan designed to reduce costs, integrate and optimize the combined organization and incurred total cumulative charges of $2.3 billion through 2022. These costs consisted of severance and employee benefit costs (cash severance, non-cash severance, including accelerated equity award compensation expense, retention and other termination benefits) and other integration expenses. The following table summarizes the charges (benefits) associated with the Allergan acquisition integration plan: Severance and employee benefits Other integration year ended December 31 (in millions) 2022 2021 2020 2022 2021 2020 Cost of products sold $ (4) $ 5 $ 109 $ 121 $ 127 $ 21 Research and development — — 199 23 102 177 Selling, general and administrative (4) 64 388 403 289 237 Total charges (benefits) $ (8) $ 69 $ 696 $ 547 $ 518 $ 435 The following table summarizes the cash activity in the recorded liability associated with the integration plan: year ended December 31 (in millions) Severance and employee benefits Other integration Charges $ 594 $ 435 Payments and other adjustments (227) (415) Accrued balance as of December 31, 2020 367 20 Charges 65 461 Payments and other adjustments (210) (448) Accrued balance as of December 31, 2021 222 33 Charges (benefits) (8) 385 Payments and other adjustments (116) (409) Accrued balance as of December 31, 2022 $ 98 $ 9 Other Restructuring AbbVie continuously evaluates its operations to identify opportunities to optimize its manufacturing and R&D operations, commercial infrastructure and administrative costs and to respond to changes in its business environment. As a result, AbbVie management periodically approves individual restructuring plans to achieve these objectives. In 2022, 2021 and 2020, no such plans were individually significant. Restructuring charges recorded were $241 million in 2022, $59 million in 2021 and $60 million in 2020 and were primarily related to employee severance and contractual obligations. These charges were recorded in cost of products sold, R&D expense and SG&A expenses in the consolidated statements of earnings based on the classification of the affected employees or operations. The following table summarizes the cash activity in the restructuring reserve for 2022, 2021 and 2020: (in millions) Accrued balance as of December 31, 2019 $ 140 Restructuring charges 58 Payments and other adjustments (108) Accrued balance as of December 31, 2020 90 Restructuring charges 54 Payments and other adjustments (111) Accrued balance as of December 31, 2021 33 Restructuring charges 193 Payments and other adjustments (50) Accrued balance as of December 31, 2022 $ 176

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Leases	Leases AbbVie's lease portfolio primarily consists of real estate properties, vehicles and equipment. The following table summarizes the amounts and location of operating and finance leases on the consolidated balance sheets: as of December 31 (in millions) Balance sheet caption 2022 2021 Assets Operating Other assets $ 737 $ 762 Finance Property and equipment, net 25 33 Total lease assets $ 762 $ 795 Liabilities Operating Current Accounts payable and accrued liabilities $ 166 $ 178 Noncurrent Other long-term liabilities 754 713 Finance Current Current portion of long-term debt and finance lease obligations 17 9 Noncurrent Long-term debt and finance lease obligations 17 25 Total lease liabilities $ 954 $ 925 The following table summarizes the lease costs recognized in the consolidated statements of earnings: years ended December 31 (in millions) 2022 2021 2020 Operating lease cost $ 201 $ 226 $ 192 Short-term lease cost 67 56 59 Variable lease cost 71 71 60 Total lease cost $ 339 $ 353 $ 311 In December 2022, the company entered into an agreement to sublease a portion of its Madison, New Jersey office space through the end of the original lease maturity in 2030. As a result of this agreement, the company recognized an impairment loss on its right-of-use asset of $69 million and wrote-off the related leasehold improvements of $37 million. These losses were recorded to SG&A expense Sublease income and finance lease costs were insignificant in 2022, 2021 and 2020. The following table presents the weighted-average remaining lease term and weighted-average discount rate for operating and finance leases: years ended December 31 2022 2021 2020 Weighted-average remaining lease term (years) Operating 8 7 8 Finance 2 3 3 Weighted-average discount rate Operating 2.6 % 2.4 % 2.5 % Finance 1.5 % 1.1 % 1.4 % The following table presents supplementary cash flow information regarding the company's leases: years ended December 31 (in millions) 2022 2021 2020 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 212 $ 236 $ 185 Right-of-use assets obtained in exchange for new operating lease liabilities 235 66 692 Finance lease cash flows were insignificant in 2022, 2021 and 2020. Right-of-use assets obtained in exchange for new operating lease liabilities as of December 31, 2020 included $453 million of right-of-use assets acquired in the Allergan acquisition. The following table summarizes the future maturities of AbbVie's operating and finance lease liabilities as of December 31, 2022: (in millions) Operating Finance Total (a) 2023 $ 185 $ 17 $ 202 2024 152 7 159 2025 130 5 135 2026 113 6 119 2027 90 — 90 Thereafter 361 — 361 Total lease payments 1,031 35 1,066 Less: Interest 111 1 112 Present value of lease liabilities $ 920 $ 34 $ 954 (a) Lease payments recognized as part of lease liabilities for optional renewal periods are insignificant.
Leases	Leases AbbVie's lease portfolio primarily consists of real estate properties, vehicles and equipment. The following table summarizes the amounts and location of operating and finance leases on the consolidated balance sheets: as of December 31 (in millions) Balance sheet caption 2022 2021 Assets Operating Other assets $ 737 $ 762 Finance Property and equipment, net 25 33 Total lease assets $ 762 $ 795 Liabilities Operating Current Accounts payable and accrued liabilities $ 166 $ 178 Noncurrent Other long-term liabilities 754 713 Finance Current Current portion of long-term debt and finance lease obligations 17 9 Noncurrent Long-term debt and finance lease obligations 17 25 Total lease liabilities $ 954 $ 925 The following table summarizes the lease costs recognized in the consolidated statements of earnings: years ended December 31 (in millions) 2022 2021 2020 Operating lease cost $ 201 $ 226 $ 192 Short-term lease cost 67 56 59 Variable lease cost 71 71 60 Total lease cost $ 339 $ 353 $ 311 In December 2022, the company entered into an agreement to sublease a portion of its Madison, New Jersey office space through the end of the original lease maturity in 2030. As a result of this agreement, the company recognized an impairment loss on its right-of-use asset of $69 million and wrote-off the related leasehold improvements of $37 million. These losses were recorded to SG&A expense Sublease income and finance lease costs were insignificant in 2022, 2021 and 2020. The following table presents the weighted-average remaining lease term and weighted-average discount rate for operating and finance leases: years ended December 31 2022 2021 2020 Weighted-average remaining lease term (years) Operating 8 7 8 Finance 2 3 3 Weighted-average discount rate Operating 2.6 % 2.4 % 2.5 % Finance 1.5 % 1.1 % 1.4 % The following table presents supplementary cash flow information regarding the company's leases: years ended December 31 (in millions) 2022 2021 2020 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 212 $ 236 $ 185 Right-of-use assets obtained in exchange for new operating lease liabilities 235 66 692 Finance lease cash flows were insignificant in 2022, 2021 and 2020. Right-of-use assets obtained in exchange for new operating lease liabilities as of December 31, 2020 included $453 million of right-of-use assets acquired in the Allergan acquisition. The following table summarizes the future maturities of AbbVie's operating and finance lease liabilities as of December 31, 2022: (in millions) Operating Finance Total (a) 2023 $ 185 $ 17 $ 202 2024 152 7 159 2025 130 5 135 2026 113 6 119 2027 90 — 90 Thereafter 361 — 361 Total lease payments 1,031 35 1,066 Less: Interest 111 1 112 Present value of lease liabilities $ 920 $ 34 $ 954 (a) Lease payments recognized as part of lease liabilities for optional renewal periods are insignificant.

Debt, Credit Facilities and Com

Debt, Credit Facilities and Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Debt, Credit Facilities and Commitments and Contingencies
Debt, Credit Facilities and Commitments and Contingencies	Debt, Credit Facilities and Commitments and Contingencies The following table summarizes long-term debt: as of December 31 (dollars in millions) 2022 Effective interest rate (a) 2022 2021 Effective interest rate (a) 2021 2.30-3.45% aggregate notes due 2022 1.92-3.28% $ — 0.99-3.45% $ 12,428 3.75% senior notes due 2023 3.84 % 1,250 3.84 % 1,250 2.85% senior notes due 2023 2.91 % 1,000 2.91 % 1,000 Floating rate term loans due 2023 2.45 % 1,000 0.81 % 1,000 1.50% senior euro notes due 2023 (€500 principal) 0.49 % 532 0.49 % 567 2.80% senior notes due 2023 2.13 % 350 2.13 % 350 2.60% senior notes due 2024 2.69 % 3,750 2.69 % 3,750 1.375% senior euro notes due 2024 (€1,450 principal) 1.46 % 1,543 1.46 % 1,643 3.85% senior notes due 2024 2.07 % 1,032 2.07 % 1,032 1.25% senior euro notes due 2024 (€700 principal) 0.65 % 745 0.65 % 793 3.60% senior notes due 2025 3.66 % 3,750 3.66 % 3,750 3.80% senior notes due 2025 2.09 % 3,021 2.09 % 3,021 Floating rate term loans due 2025 1.39 % — 1.36 % 2,000 Floating rate term loans due 2025 2.82 % 2,000 — — 2.95% senior notes due 2026 3.02 % 4,000 3.02 % 4,000 3.20% senior notes due 2026 3.28 % 2,000 3.28 % 2,000 0.75% senior euro notes due 2027 (€750 principal) 0.86 % 798 0.86 % 850 4.25% senior notes due 2028 4.38 % 1,750 4.38 % 1,750 2.125% senior euro notes due 2028 (€750 principal) 2.18 % 798 2.18 % 850 2.625% senior euro notes due 2028 (€500 principal) 1.20 % 532 1.20 % 567 3.20% senior notes due 2029 3.25 % 5,500 3.25 % 5,500 2.125% senior euro notes due 2029 (€550 principal) 1.19 % 585 1.19 % 623 1.25% senior euro notes due 2031 (€650 principal) 1.30 % 691 1.30 % 737 4.55% senior notes due 2035 3.52 % 1,789 3.52 % 1,789 4.50% senior notes due 2035 4.58 % 2,500 4.58 % 2,500 4.30% senior notes due 2036 4.37 % 1,000 4.37 % 1,000 4.05% senior notes due 2039 4.11 % 4,000 4.11 % 4,000 4.40% senior notes due 2042 4.46 % 2,600 4.46 % 2,600 4.625% senior notes due 2042 4.00 % 457 4.00 % 457 4.85% senior notes due 2044 4.11 % 1,074 4.11 % 1,074 4.70% senior notes due 2045 4.73 % 2,700 4.73 % 2,700 4.75% senior notes due 2045 4.20 % 881 4.20 % 881 4.45% senior notes due 2046 4.50 % 2,000 4.50 % 2,000 4.875% senior notes due 2048 4.94 % 1,750 4.94 % 1,750 4.25% senior notes due 2049 4.29 % 5,750 4.29 % 5,750 Fair value hedges (346) 102 Unamortized bond discounts (116) (130) Unamortized deferred financing costs (222) (251) Unamortized bond premiums (b) 793 954 Other 33 33 Total long-term debt and finance lease obligations 63,270 76,670 Current portion 4,135 12,481 Noncurrent portion $ 59,135 $ 64,189 (a) Excludes the effect of any related interest rate swaps. (b) Represents unamortized purchase price adjustments of Allergan debt. Senior notes and floating rate term loans are redeemable prior to maturity at a redemption price equal to the principal amount plus a make-whole premium and AbbVie may redeem these debt securities at par generally between one and six months prior to maturity. At December 31, 2022, the company was in compliance with its senior note covenants and term loan covenants. Maturities of Long-Term Debt as of and for the years ending December 31 (in millions) 2023 $ 4,132 2024 7,070 2025 8,771 2026 6,000 2027 798 Thereafter 36,357 Total obligations and commitments 63,128 Fair value hedges, unamortized bond premiums/discounts, deferred financing costs and finance lease obligations 142 Total long-term debt and finance lease obligations $ 63,270 Repayment and Issuance of Long-Term Debt In 2022, the company repaid $2.9 billion aggregate principal amount of 3.450% senior notes, $1.7 billion aggregate principal amount of 3.25% senior notes, $1.0 billion aggregate principal amount of 3.2% senior notes. These repayments were ma de by exercising, under the terms of the notes ranging between 60 and 90-day early redemptions at 100% of the principal amount. During the quarter ended December 31, 2022, the company also paid $3.1 billion aggregate principal amount of 2.9% senior notes, $3.0 billion aggregate principal amount of 2.3% senior notes and $750 million aggregate principal amount of floating rate senior notes at maturity. Additionally in 2022, the company refinanced its $2.0 billion floating rate five-year term loan. As part of the refinancing, the company repaid the existing $2.0 billion term loan due May 2025 and borrowed $2.0 billion under a new term loan at a lower floating rate. All other significant terms of the loan, including the maturity date, remained unchanged after the refinancing. Subsequent to December 31, 2022, the company repaid a $1.0 billion floating rate three-year term loan that was scheduled to mature in May 2023. In 2021, the company repaid $1.8 billion aggregate principal amount of 2.3% senior notes, €750 million aggregate principal amount of 0.5% senior Euro notes and $1.2 billion aggregate principal amount of 5.0% senior notes. These repayments were made by exercising, under the terms of the notes, ranging between 30 and 90-day early redemptions at 100% of the principal amounts. The company also repaid $1.3 billion aggregate principal amount of 3.375% senior notes $1.8 billion aggregate principal amount of 2.15% senior notes and $1.5 billion aggregate principal amount of floating rate senior notes at maturity. Additionally in 2021, the company refinanced its $1.0 billion floating rate three-year term loan. As part of the refinancing, the company repaid the existing $1.0 billion term loan due May 2023 and borrowed $1.0 billion under a new term loan at a lower floating rate. All other significant terms of the loan, including the maturity date, remained unchanged after the refinancing. Short-Term Borrowings There were no commercial paper borrowings outstanding as of December 31, 2022 and December 31, 2021. No commercial paper borrowings were issued during 2022 or 2021. There were commercial paper borrowings issued during 2020 and the weighted-average interest rate was 1.8%. AbbVie currently has a $4.0 billion five-year revolving credit facility that matures in August 2024. This credit facility enables the company to borrow funds on an unsecured basis at variable interest rates and contains various covenants, all of which the company was in compliance with as of December 31, 2022. Commitment fees under AbbVie's revolving credit facilities were insignificant in 2022, 2021 and 2020. No amounts were outstanding under the company's credit facilities as of December 31, 2022 and December 31, 2021. Contingencies and Guarantees In connection with the separation, AbbVie has indemnified Abbott for all liabilities resulting from the operation of AbbVie's business other than income tax liabilities with respect to periods prior to the distribution date and other liabilities as agreed to by AbbVie and Abbott. AbbVie has no material exposures to off-balance sheet arrangements and no special-purpose entities. In the ordinary course of business, AbbVie has periodically entered into third-party agreements, such as the assignment of product rights, which have resulted in AbbVie becoming secondarily liable for obligations for which AbbVie had previously been primarily liable. Based upon past experience, the likelihood of payments under these agreements is remote.

Financial Instruments and Fair

Financial Instruments and Fair Value Measures	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value Measures	Financial Instruments and Fair Value Measures Risk Management Policy The company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. AbbVie's hedging policy attempts to manage these risks to an acceptable level based on the company's judgment of the appropriate trade-off between risk, opportunity and costs. The company uses derivative and nonderivative instruments to reduce its exposure to foreign currency exchange rates. AbbVie also periodically enters into interest rate swaps in which the company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount. Derivative instruments are not used for trading purposes or to manage exposure to changes in interest rates for investment securities, and none of the company's outstanding derivative instruments contain credit risk related contingent features; collateral is generally not required. Financial Instruments Various AbbVie foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany transactions denominated in a currency other than the functional currency of the local entity. These contracts, with notional amounts totaling In 2019, the company entered into treasury rate lock agreements with notional amounts totaling $10.0 billion to hedge exposure to variability in future cash flows resulting from changes in interest rates related to the issuance of long-term debt in connection with the acquisition of Allergan. The treasury rate lock agreements were designated as cash flow hedges and recorded at fair value. The agreements were net settled upon issuance of the senior notes in 2019 and the resulting net gain was recognized in other comprehensive income. This gain is reclassified to interest expense, net over the term of the related debt. The company was a party to interest rate swap contracts designated as cash flow hedges that matured in November 2022, for which the notional amount was $750 million at December 31, 2021. The effect of the hedge contracts was to change a floating-rate interest obligation to a fixed rate for that portion of the floating-rate debt. Realized and unrealized gains or losses were included in AOCI and were reclassified to interest expense, net over the lives of the floating-rate debt. The company also enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated trade payables and receivables and intercompany loans. These contracts are not designated as hedges and are recorded at fair value. Resulting gains or losses are reflected in net foreign exchange loss in the consolidated statements of earnings and are generally offset by losses or gains on the foreign currency exposure being managed. These contracts had notional amounts totaling $6.5 billion at December 31, 2022 and $8.2 billion at December 31, 2021. The company also uses foreign currency forward exchange contracts or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. The company had an aggregate principal amount of senior Euro notes designated as net investment hedges of €5.9 billion at December 31, 2022 and December 31, 2021. In addition, the company had foreign currency forward exchange contracts designated as net investment hedges with notional amounts totaling €4.3 billion, SEK2.0 billion, CAD750 million and CHF90 million at December 31, 2022 and €4.3 billion at December 31, 2021. The company uses the spot method of assessing hedge effectiveness for derivative instruments designated as net investment hedges. Realized and unrealized gains and losses from these hedges are included in AOCI and the initial fair value of hedge components excluded from the assessment of effectiveness is recognized in interest expense, net over the life of the hedging instrument. The company is a party to interest rate swap contracts designated as fair value hedges with notional amounts totaling $4.5 billion at December 31, 2022 and December 31, 2021. The effect of the hedge contracts is to change a fixed-rate interest obligation to a floating rate for that portion of the debt. AbbVie records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount. No amounts are excluded from the assessment of effectiveness for cash flow hedges or fair value hedges. The following table summarizes the amounts and location of AbbVie's derivative instruments on the consolidated balance sheets: Fair value - Derivatives in asset position Fair value - as of December 31 (in millions) Balance sheet caption 2022 2021 Balance sheet caption 2022 2021 Foreign currency forward exchange contracts Designated as cash flow hedges Prepaid expenses and other $ 49 $ 51 Accounts payable and accrued liabilities $ 8 $ 2 Designated as cash flow hedges Other assets 1 — Other long-term liabilities — — Designated as net investment hedges Prepaid expenses and other 6 149 Accounts payable and accrued liabilities 36 — Designated as net investment hedges Other assets 74 15 Other long-term liabilities 47 — Not designated as hedges Prepaid expenses and other 33 26 Accounts payable and accrued liabilities 41 13 Interest rate swap contracts Designated as cash flow hedges Prepaid expenses and other — — Accounts payable and accrued liabilities — 7 Designated as fair value hedges Prepaid expenses and other — — Accounts payable and accrued liabilities 17 — Designated as fair value hedges Other assets — 26 Other long-term liabilities 375 15 Total derivatives $ 163 $ 267 $ 524 $ 37 While certain derivatives are subject to netting arrangements with the company's counterparties, the company does not offset derivative assets and liabilities within the consolidated balance sheets. The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income: years ended in December 31 (in millions) 2022 2021 2020 Foreign currency forward exchange contracts Designated as cash flow hedges $ 103 $ 82 $ (71) Designated as net investment hedges 395 341 (95) Interest rate swap contracts designated as cash flow hedges 6 2 (53) Assuming market rates remain constant through contract maturities, the company expects to reclassify pre-tax gains of $86 million into cost of products sold for foreign currency cash flow hedges and pre-tax gains of $24 million into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months. Related to AbbVie’s non-derivative, foreign currency denominated debt designated as net investment hedges, the company recognized in other comprehensive income pre-tax gains of $406 million in 2022, pre-tax gains of $577 million in 2021 and pre-tax losses of $907 million in 2020. The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 13 for the amount of net gains (losses) reclassified out of AOCI. years ended December 31 (in millions) Statement of earnings caption 2022 2021 2020 Foreign currency forward exchange contracts Designated as cash flow hedges Cost of products sold $ 82 $ (87) $ 23 Designated as net investment hedges Interest expense, net 94 26 18 Not designated as hedges Net foreign exchange loss (156) (100) 58 Treasury rate lock agreements designated as cash flow hedges Interest expense, net 23 24 24 Interest rate swap contracts Designated as cash flow hedges Interest expense, net (1) (24) (17) Designated as fair value hedges Interest expense, net (402) (127) 365 Debt designated as hedged item in fair value hedges Interest expense, net 402 127 (365) Fair Value Measures The fair value hierarchy consists of the following three levels: • Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access; • Level 2—Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and • Level 3—Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company's management about the assumptions market participants would use in pricing the asset or liability. The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the consolidated balance sheet as of December 31, 2022: Basis of fair value measurement (in millions) Total Quoted prices in active markets for Significant other observable Significant unobservable inputs Assets Cash and equivalents $ 9,201 $ 4,201 $ 5,000 $ — Money market funds and time deposits 21 — 21 — Debt securities 28 — 28 — Equity securities 91 59 32 — Foreign currency contracts 163 — 163 — Total assets $ 9,504 $ 4,260 $ 5,244 $ — Liabilities Interest rate swap contracts $ 392 $ — $ 392 $ — Foreign currency contracts 132 — 132 — Contingent consideration 16,384 — — 16,384 Total liabilities $ 16,908 $ — $ 524 $ 16,384 The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the consolidated balance sheet as of December 31, 2021: Basis of fair value measurement (in millions) Total Quoted prices in active markets for identical assets Significant other observable Significant unobservable inputs Assets Cash and equivalents $ 9,746 $ 4,451 $ 5,295 $ — Money market funds and time deposits 45 — 45 — Debt securities 46 — 46 — Equity securities 121 100 21 — Interest rate swap contracts 26 — 26 — Foreign currency contracts 241 — 241 — Total assets $ 10,225 $ 4,551 $ 5,674 $ — Liabilities Interest rate swap contracts $ 22 $ — $ 22 $ — Foreign currency contracts 15 — 15 — Contingent consideration 14,887 — — 14,887 Total liabilities $ 14,924 $ — $ 37 $ 14,887 Money market funds and time deposits are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. Equity securities primarily consist of investments for which the fair values were determined by using the published market prices per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using observable market inputs including published interest rate curves and both forward and spot prices for foreign currencies. The fair value measurements of the contingent consideration liabilities were determined based on significant unobservable inputs, including the discount rate, estimated probabilities and timing of achieving specified development, regulatory and commercial milestones and the estimated amount of future sales of the acquired products. The potential contingent consideration payments are estimated by applying a probability-weighted expected payment model for contingent milestone payments and a Monte Carlo simulation model for contingent royalty payments, which are then discounted to present value. Changes to the fair value of the contingent consideration liabilities can result from changes to one or a number of inputs, including discount rates, the probabilities of achieving the milestones, the time required to achieve the milestones and estimated future sales. Significant judgment is employed in determining the appropriateness of certain of these inputs. Changes to the inputs described above could have a material impact on the company's financial position and results of operations in any given period. The fair value of the company's contingent consideration liabilities was calculated using the following significant unobservable inputs: 2022 2021 years ended December 31 (in millions) Range Weighted Average (a) Range Weighted Average (a) Discount rate 4.7% - 5.1% 4.8% 0.2% - 2.6% 1.7 % Probability of payment for unachieved milestones 100% - 100% 100% 89% - 100% 90 % Probability of payment for royalties by indication (b) 56% - 100% 99% 56% - 100% 96 % Projected year of payments 2023 - 2034 2028 2022 - 2034 2027 (a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities. (b) Excluding approved indications, the estimated probability of payment was 56% at December 31, 2022 and ranged from 56% to 89% at December 31, 2021. There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy. The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 inputs: years ended December 31 (in millions) 2022 2021 2020 Beginning balance $ 14,887 $ 12,997 $ 7,340 Additions (a) 32 — 225 Change in fair value recognized in net earnings 2,761 2,679 5,753 Payments (1,296) (789) (321) Ending balance $ 16,384 $ 14,887 $ 12,997 (a) Additions during the year ended December 31, 2022, represent contingent consideration liabilities assumed in the DJS acquisition. Additions during the year ended December 31, 2020, represent contingent consideration liabilities assumed in the Allergan and Luminera acquisitions (see Note 5). The change in fair value recognized in net earnings is recorded in other expense, net in the consolidated statements of earnings and included charges of $2.8 billion in 2022, $2.7 billion in 2021 and $5.8 billion in 2020. In 2022, the change in fair value reflected higher estimated Skyrizi sales driven by stronger market share uptake and the passage of time, partially offset by higher discount rates. In 2021, the change in fair value reflected higher estimated Skyrizi sales driven by stronger market share uptake, favorable clinical trial results and the passage of time, partially offset by higher discount rates. In 2020, the change in fair value reflected higher estimated Skyrizi sales driven by stronger market share uptake, lower discount rates, the passage of time and favorable clinical trial results. Certain financial instruments are carried at historical cost or some basis other than fair value. The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2022 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair values Quoted prices in active markets for identical assets Significant other observable inputs Significant unobservable inputs Liabilities Short-term borrowings $ 1 $ 1 $ — $ 1 $ — Current portion of long-term debt and finance lease obligations, excluding fair value hedges 4,152 4,121 3,930 191 — Long-term debt and finance lease obligations, excluding fair value hedges 59,463 54,073 53,365 708 — Total liabilities $ 63,616 $ 58,195 $ 57,295 $ 900 $ — The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2021 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair values Quoted prices in active markets for identical assets Significant other observable inputs Significant unobservable inputs Liabilities Short-term borrowings $ 14 $ 14 $ — $ 14 $ — Current portion of long-term debt and finance lease obligations, excluding fair value hedges $ 12,455 $ 11,830 $ 11,329 $ 501 $ — Long-term debt and finance lease obligations, excluding fair value hedges 64,113 71,810 70,757 1,053 — Total liabilities $ 76,582 $ 83,654 $ 82,086 $ 1,568 $ — AbbVie also holds investments in equity securities that do not have readily determinable fair values. The company records these investments at cost and remeasures them to fair value based on certain observable price changes or impairment events as they occur. The carrying amount of these investments was $129 million as of December 31, 2022 and $149 million as of December 31, 2021. No significant cumulative upward or downward adjustments have been recorded for these investments as of December 31, 2022. Concentrations of Risk Of total net accounts receivable, three U.S. wholesalers accounted for 82% as of December 31, 2022 and 75% as of December 31, 2021, and substantially all of AbbVie's pharmaceutical product net revenues in the United States were to these three wholesalers. Humira (adalimumab) is AbbVie's single largest product and accounted for approximately 37% of AbbVie's total net revenues in 2022, 37% in 2021 and 43% in 2020.	[1]
[1]Additions during the year ended December 31, 2022, represent contingent consideration liabilities assumed in the DJS acquisition. Additions during the year ended December 31, 2020, represent contingent consideration liabilities assumed in the Allergan and Luminera acquisitions (see Note 5).

Post-Employment Benefits

Post-Employment Benefits	12 Months Ended
	Dec. 31, 2022
Postemployment Benefits [Abstract]
Post-Employment Benefits	Post-Employment Benefits AbbVie sponsors various pension and other post-employment benefit plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. In addition, AbbVie provides medical benefits, primarily to eligible retirees in the United States and Puerto Rico, through other post-retirement benefit plans. Net obligations for these plans have been reflected on the consolidated balance sheets as of December 31, 2022 and 2021. The following table summarizes benefit plan information for the global AbbVie-sponsored defined benefit and other post-employment plans: Defined benefit plans Other post-employment plans as of and for the years ended December 31 (in millions) 2022 2021 2022 2021 Projected benefit obligations Beginning of period $ 12,006 $ 11,792 $ 850 $ 795 Service cost 454 440 51 48 Interest cost 297 237 23 19 Employee contributions 1 2 — — Amendments — — (2) — Actuarial (gain) loss (3,668) (8) (229) 10 Benefits paid (294) (281) (25) (22) Other, primarily foreign currency translation adjustments (208) (176) (1) — End of period 8,588 12,006 667 850 Fair value of plan assets Beginning of period 10,655 9,702 — — Actual return on plan assets (2,031) 1,000 — — Company contributions 357 376 25 22 Employee contributions 1 2 — — Benefits paid (294) (281) (25) (22) Other, primarily foreign currency translation adjustments (216) (144) — — End of period 8,472 10,655 — — Funded status, end of period $ (116) $ (1,351) $ (667) $ (850) Amounts recognized on the consolidated balance sheets Other assets $ 896 $ 991 $ — $ — Accounts payable and accrued liabilities (14) (13) (27) (26) Other long-term liabilities (998) (2,329) (640) (824) Net obligation $ (116) $ (1,351) $ (667) $ (850) Actuarial loss, net $ 2,365 $ 3,504 $ 205 $ 461 Prior service cost (credit) 3 5 (333) (370) Accumulated other comprehensive loss $ 2,368 $ 3,509 $ (128) $ 91 Related to international defined benefit plans the projected benefit obligations in the table above included $2.1 billion at December 31, 2022 and $3.2 billion at December 31, 2021. For plans reflected in the table above, the accumulated benefit obligations were $7.7 billion at December 31, 2022 and $10.5 billion at December 31, 2021. The 2022 actuarial gain of $3.7 billion for qualified pension plans and actuarial gain of $229 million for other post-employment plans were primarily driven by an increase in the discount rate. The 2021 actuarial gain of $8 million for qualified pension plans and actuarial loss of $10 million for other post-employment plans were primarily driven by an increase in the assumed discount rate offset by change in demographic assumptions from 2020. Information For Pension Plans With An Accumulated Benefit Obligation In Excess Of Plan Assets as of December 31 (in millions) 2022 2021 Accumulated benefit obligation $ 1,211 $ 6,395 Fair value of plan assets 746 5,412 Information For Pension Plans With A Projected Benefit Obligation In Excess Of Plan Assets as of December 31 (in millions) 2022 2021 Projected benefit obligation $ 5,592 $ 7,788 Fair value of plan assets 4,580 5,447 AbbVie's U.S. pension plan was modified to close the plan to new entrants effective January 1, 2022. In addition, a change to AbbVie's U.S. retiree health benefit plan was approved in 2020 and communicated to employees and retirees in October 2020. Beginning in 2022, Medicare-eligible retirees and Medicare-eligible dependents choose health care coverage from insurance providers through a private Medicare exchange. AbbVie will continue to provide financial support to Medicare-eligible retirees. This change to the U.S. retiree health benefit plan decreased AbbVie's post-employment benefit obligation and increased AbbVie's unrecognized prior service credit as of December 31, 2020 by $397 million. Amounts Recognized in Other Comprehensive Income The following table summarizes the pre-tax losses (gains) included in other comprehensive income: years ended December 31 (in millions) 2022 2021 2020 Defined benefit plans Actuarial loss (gain) $ (925) $ (345) $ 701 Amortization of prior service cost (2) (2) (2) Amortization of actuarial loss (231) (288) (227) Foreign exchange loss (gain) and other 17 (27) 56 Total loss (gain) $ (1,141) $ (662) $ 528 Other post-employment plans Actuarial loss (gain) $ (229) $ 10 $ 40 Prior service credit (2) — (397) Amortization of prior service credit 38 39 4 Amortization of actuarial loss (26) (32) (26) Total loss (gain) $ (219) $ 17 $ (379) Net Periodic Benefit Cost years ended December 31 (in millions) 2022 2021 2020 Defined benefit plans Service cost $ 454 $ 440 $ 370 Interest cost 297 237 264 Expected return on plan assets (712) (663) (575) Amortization of prior service cost 2 2 2 Amortization of actuarial loss 231 288 227 Net periodic benefit cost $ 272 $ 304 $ 288 Other post-employment plans Service cost $ 51 $ 48 $ 42 Interest cost 23 19 34 Amortization of prior service credit (38) (39) (4) Amortization of actuarial loss 26 32 26 Net periodic benefit cost $ 62 $ 60 $ 98 The components of net periodic benefit cost other than service cost are included in other expense, net in the consolidated statements of earnings. Weighted-Average Assumptions Used in Determining Benefit Obligations at the Measurement Date as of December 31 2022 2021 Defined benefit plans Discount rate 5.0 % 2.8 % Rate of compensation increases 5.5 % 5.2 % Cash balance interest crediting rate 2.7 % 2.7 % Other post-employment plans Discount rate 5.3 % 3.1 % The assumptions used in calculating the December 31, 2022 measurement date benefit obligations will be used in the calculation of net periodic benefit cost in 2023. Weighted-Average Assumptions Used in Determining Net Periodic Benefit Cost years ended December 31 2022 2021 2020 Defined benefit plans Discount rate for determining service cost 3.0 % 2.6 % 3.1 % Discount rate for determining interest cost 2.6 % 2.2 % 3.0 % Expected long-term rate of return on plan assets 7.1 % 7.1 % 7.1 % Expected rate of change in compensation 5.2 % 4.6 % 4.6 % Cash balance interest crediting rate 2.7 % 2.8 % 2.8 % Other post-employment plans Discount rate for determining service cost 3.3 % 3.0 % 3.7 % Discount rate for determining interest cost 2.7 % 2.2 % 3.2 % For the December 31, 2022 post-retirement health care obligations remeasurement, the company assumed a 6.2% pre-65 (2.0% post-65) annual rate of increase in the per capita cost of covered health care benefits. The pre-65 rate was assumed to decrease gradually to 4.5% (1.8% post-65) in 2030 and remain at that level thereafter. For purposes of measuring the 2022 post-retirement health care costs, the company assumed a 5.9% pre-65 (2.1% post-65) annual rate of increase in the per capita cost of covered health care benefits. The pre-65 rate was assumed to decrease gradually to 4.5% (1.8% post-65) for 2029 and remain at that level thereafter. Defined Benefit Pension Plan Assets Basis of fair value measurement as of December 31 (in millions) 2022 Quoted prices in active markets for identical assets Significant other observable inputs Significant unobservable inputs Equities U.S. large cap (a) $ 949 $ 949 $ — $ — U.S. mid cap (b) 157 157 — — International (c) 327 327 — — Fixed income securities U.S. government securities (d) 237 69 168 — Corporate debt instruments (d) 680 144 536 — Non-U.S. government securities (d) 548 402 146 — Other (d) 84 81 3 — Absolute return funds (e) 91 4 87 — Real assets 9 9 — — Other (f) 278 277 1 — Total $ 3,360 $ 2,419 $ 941 $ — Total assets measured at NAV 5,112 Fair value of plan assets $ 8,472 Basis of fair value measurement as of December 31 (in millions) 2021 Quoted prices in active markets for identical assets Significant other observable inputs Significant unobservable inputs Equities U.S. large cap (a) $ 1,428 $ 1,428 $ — $ — U.S. mid cap (b) 198 198 — — International (c) 458 458 — — Fixed income securities U.S. government securities (d) 228 95 133 — Corporate debt instruments (d) 945 179 766 — Non-U.S. government securities (d) 602 445 157 — Other (d) 273 268 5 — Absolute return funds (e) 100 5 95 — Real assets 10 10 — — Other (f) 261 216 45 — Total $ 4,503 $ 3,302 $ 1,201 $ — Total assets measured at NAV 6,152 Fair value of plan assets $ 10,655 (a) A mix of index funds and actively managed equity accounts that are benchmarked to various large cap indices. (b) A mix of index funds and actively managed equity accounts that are benchmarked to various mid cap indices. (c) A mix of index funds and actively managed equity accounts that are benchmarked to various non-U.S. equity indices in both developed and emerging markets. (d) Securities held by actively managed accounts, index funds and mutual funds. (e) Primarily funds having global mandates with the flexibility to allocate capital broadly across a wide range of asset classes and strategies, including but not limited to equities, fixed income, commodities, financial futures, currencies and other securities, with objectives to outperform agreed upon benchmarks of specific return and volatility targets. (f) Investments in cash and cash equivalents. Equities and registered investment companies having quoted prices are valued at the published market prices. Fixed income securities that are valued using significant other observable inputs are quoted at prices obtained from independent financial service industry-recognized vendors. Investments held in pooled investment funds, common collective trusts or limited partnerships are valued at the net asset value (NAV) practical expedient to estimate fair value. The NAV is provided by the fund administrator and is based on the value of the underlying assets owned by the fund minus its liabilities. The investment mix of equity securities, fixed income and other asset allocation strategies is based upon achieving a desired return, balancing higher return, more volatile equity securities and lower return, less volatile fixed income securities. Investment allocations are established for each plan and are generally made across a range of markets, industry sectors, capitalization sizes and in the case of fixed income securities, maturities and credit quality. The 2022 target investment allocation for the AbbVie Pension Plan was 62.5% in equity securities, 22.5% in fixed income securities and 15% in asset allocation strategies and other holdings. There are no known significant concentrations of risk in the plan assets of the AbbVie Pension Plan or of any other plans. The expected return on plan assets assumption for each plan is based on management's expectations of long-term average rates of return to be achieved by the underlying investment portfolio. In establishing this assumption, management considers historical and expected returns for the asset classes in which the plans are invested, as well as current economic and capital market conditions. Expected Benefit Payments The following table summarizes total benefit payments expected to be paid to plan participants including payments funded from both plan and company assets: years ending December 31 (in millions) Defined Other 2023 $ 310 $ 28 2024 333 31 2025 355 34 2026 378 37 2027 404 39 2028 to 2032 2,427 244 Defined Contribution Plan AbbVie maintains defined contribution savings plans for the benefit of its eligible employees. The expense recognized for these plans was $474 million in 2022, $267 million in 2021 and $191 million in 2020. AbbVie provides certain other post-employment benefits, primarily salary continuation arrangements, to qualifying employees and accrues for the related cost over the service lives of the employees.

Equity

Equity	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Equity	Equity Stock-Based Compensation In May 2021, stockholders of the company approved the AbbVie Amended and Restated 2013 Incentive Stock Program (the Amended Plan), which amends and restates the AbbVie 2013 Incentive Stock Program (2013 ISP). AbbVie grants stock-based awards to eligible employees pursuant to the Amended Plan, which provides for several different forms of benefits, including non-qualified stock options, RSUs and various performance-based awards. Under the Amended Plan, a total of 144 million shares of AbbVie common stock have been reserved for issuance as awards to AbbVie employees. AbbVie measures compensation expense for stock-based awards based on the grant date fair value of the awards and the estimated number of awards that are expected to vest. Forfeitures are estimated based on historical experience at the time of grant and are revised in subsequent periods if actual forfeitures differ from those estimates. Compensation cost for stock-based awards is amortized over the service period, which could be shorter than the vesting period if an employee is retirement eligible. Retirement eligible employees generally are those who are age 55 or older and have at least 10 years of service. Stock-based compensation expense is principally related to awards issued pursuant to the 2013 ISP and the Amended Plan and is summarized as follows: years ended December 31 (in millions) 2022 2021 2020 Cost of products sold $ 38 $ 46 $ 47 Research and development 232 226 247 Selling, general and administrative 401 420 459 Pre-tax compensation expense 671 692 753 Tax benefit 122 126 131 After-tax compensation expense $ 549 $ 566 $ 622 Realized excess tax benefits associated with stock-based compensation totaled $116 million in 2022, $50 million in 2021 and $34 million in 2020. Stock Options Stock options awarded to employees typically have a contractual term of 10 years and generally vest in one-third increments over a three-year period. The exercise price is equal to at least 100% of the market value on the date of grant. The fair value is determined using the Black-Scholes model. The weighted-average grant-date fair values of stock options granted were $22.83 in 2022, $16.28 in 2021 and $12.14 in 2020. In connection with the Allergan acquisition, during the second quarter of 2020, AbbVie issued 11.2 million stock options to holders of Allergan options as a result of the conversion of such options. These options were fair-valued using a lattice valuation model. Refer to Note 5 for additional information regarding the Allergan acquisition. The following table summarizes AbbVie stock option activity in 2022: (options in thousands, aggregate intrinsic value in millions) Options Weighted- average Weighted-average remaining Aggregate intrinsic value Outstanding at December 31, 2021 12,374 $ 81.98 4.7 $ 661 Granted 863 144.54 Exercised (3,764) 70.85 Lapsed and forfeited (153) 107.65 Outstanding at December 31, 2022 9,320 $ 91.84 4.8 $ 650 Exercisable at December 31, 2022 7,120 $ 84.54 3.7 $ 549 The total intrinsic value of options exercised was $295 million in 2022, $239 million in 2021 and $186 million in 2020. The total fair value of options vested during 2022 was $21 million. As of December 31, 2022, $6 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next two years. RSUs and Performance Shares RSUs awarded to employees other than senior executives and other key employees generally vest in ratable increments over a three The majority of the equity awards AbbVie grants to its senior executives and other key employees are performance-based. Equity awards granted to senior executives and other key employees consist of a combination of performance-vested RSUs and performance shares as well as non-qualified stock options described above. The performance-vested RSUs have the potential to vest in one-third increments during a three-year performance period and may be earned based on AbbVie’s return on invested capital (ROIC) performance relative to a defined peer group of pharmaceutical, biotech and life science companies. The recipient may receive one share of AbbVie common stock for each vested award. The performance shares have the potential to vest over a three-year performance period and may be earned based on AbbVie’s EPS achievement and AbbVie’s total stockholder return (TSR) (a market condition) relative to a defined peer group of pharmaceutical, biotech and life sciences companies. Dividend equivalents on performance-vested RSUs and performance shares accrue during the performance period and are payable at vesting only to the extent that shares are earned. The weighted-average grant-date fair value of RSUs and performance shares generally is determined based on the number of shares/units granted and the quoted price of AbbVie’s common stock on the date of grant. The weighted-average grant-date fair values of performance shares with a TSR market condition are determined using the Monte Carlo simulation model. The following table summarizes AbbVie RSU and performance share activity for 2022: (share units in thousands) Share units Weighted-average grant date fair value Outstanding at December 31, 2021 14,890 $ 94.93 Granted 5,943 138.73 Vested (6,958) 89.31 Forfeited (844) 111.45 Outstanding at December 31, 2022 13,031 $ 116.84 The fair market value of RSUs and performance shares (as applicable) vested was $1.0 billion in 2022, $718 million in 2021 and $618 million in 2020. In connection with the Allergan acquisition, during the second quarter of 2020, AbbVie issued 8.2 million RSUs to holders of Allergan equity awards based on a conversion factor described in the transaction agreement. Refer to Note 5 for additional information regarding the Allergan acquisition. As of December 31, 2022, $578 million of unrecognized compensation cost related to RSUs and performance shares is expected to be recognized as expense over approximately the next two years. Cash Dividends Cash dividends declared per common share totaled $5.71 in 2022, $5.31 in 2021 and $4.84 in 2020. The following table summarizes quarterly cash dividends declared during 2022, 2021 and 2020: 2022 2021 2020 Date Declared Payment Date Dividend Per Share Date Declared Payment Date Dividend Per Share Date Declared Payment Date Dividend Per Share 10/28/22 02/15/23 $1.48 10/29/21 02/15/22 $1.41 10/30/20 02/16/21 $1.30 09/09/22 11/15/22 $1.41 09/10/21 11/15/21 $1.30 09/11/20 11/16/20 $1.18 06/23/22 08/15/22 $1.41 06/17/21 08/16/21 $1.30 06/17/20 08/14/20 $1.18 02/17/22 05/16/22 $1.41 02/18/21 05/14/21 $1.30 02/20/20 05/15/20 $1.18 Stock Repurchase Program The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management’s discretion. The program has no time limit and can be discontinued at any time. Shares repurchased under these programs are recorded at acquisition cost, including related expenses and are available for general corporate purposes. AbbVie repurchased 8 million shares for $1.1 billion in 2022, 6 million shares for $670 million in 2021 and 8 million shares for $757 million in 2020. AbbVie's remaining stock repurchase authorization was $1.4 billion as of December 31, 2022. On February 16, 2023, AbbVie's board of directors authorized a $5.0 billion increase to the existing stock repurchase authorization. Accumulated Other Comprehensive Loss The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for 2022, 2021 and 2020: (in millions) (brackets denote losses) Foreign currency translation adjustments Net investment hedging activities Pension Cash flow hedging activities Total Balance as of December 31, 2019 $ (928) $ 9 $ (2,965) $ 288 $ (3,596) Other comprehensive income (loss) before reclassifications 1,511 (785) (300) (108) 318 Net losses (gains) reclassified from accumulated other comprehensive loss — (14) 198 (23) 161 Net current-period other comprehensive income (loss) 1,511 (799) (102) (131) 479 Balance as of December 31, 2020 583 (790) (3,067) 157 (3,117) Other comprehensive income (loss) before reclassifications (1,153) 720 298 76 (59) Net losses (gains) reclassified from accumulated other comprehensive loss — (21) 223 75 277 Net current-period other comprehensive income (loss) (1,153) 699 521 151 218 Balance as of December 31, 2021 (570) (91) (2,546) 308 (2,899) Other comprehensive income (loss) before reclassifications (943) 629 915 91 692 Net losses (gains) reclassified from accumulated other comprehensive loss — (74) 173 (91) 8 Net current-period other comprehensive income (loss) (943) 555 1,088 — 700 Balance as of December 31, 2022 $ (1,513) $ 464 $ (1,458) $ 308 $ (2,199) Other comprehensive income for 2022 included pension and post-employment benefit plan gains of $1.1 billion primarily due actuarial gains driven by higher discount rates partially offset by losses on plan assets. Other comprehensive income for 2022 also included foreign currency translation adjustments totaling losses of $943 million principally due to the impact of the weakening of the Euro on the translation of the company’s Euro-denominated assets and the offsetting impact of net investment hedging activities totaling gains of $555 million. Other comprehensive income for 2021 included foreign currency translation adjustments totaling losses of $1.2 billion principally due to the impact of the weakening of the Euro on the translation of the company's Euro-denominated assets and the offsetting impact of net investment hedging activities totaling gains of $699 million. Other comprehensive income for 2020 included foreign currency translation adjustments totaling gains of $1.5 billion principally due to the impact of the strengthening of the Euro on the translation of the company's Euro-denominated assets and the offsetting impact of net investment hedging activities totaling losses of $799 million. The table below presents the impact on AbbVie's consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss: years ended December 31 (in millions) (brackets denote gains) 2022 2021 2020 Net investment hedging activities Gains on derivative amount excluded from effectiveness testing (a) $ (94) $ (26) $ (18) Tax expense 20 5 4 Total reclassifications, net of tax $ (74) $ (21) $ (14) Pension and post-employment benefits Amortization of actuarial losses and other (b) $ 221 $ 283 $ 251 Tax benefit (48) (60) (53) Total reclassifications, net of tax $ 173 $ 223 $ 198 Cash flow hedging activities Losses (gains) on foreign currency forward exchange contracts (c) $ (82) $ 87 $ (23) Gains on treasury rate lock agreements (a) (23) (24) (24) Losses on interest rate swap contracts (a) 1 24 17 Tax expense (benefit) 13 (12) 7 Total reclassifications, net of tax $ (91) $ 75 $ (23) (a) Amounts are included in interest expense, net (see Note 11). (b) Amounts are included in the computation of net periodic benefit cost (see Note 12). (c) Amounts are included in cost of products sold (see Note 11). Other In addition to common stock, AbbVie's authorized capital includes 200 million shares of preferred stock, par value $0.01. As of December 31, 2022, no shares of preferred stock were issued or outstanding.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Earnings Before Income Tax Expense years ended December 31 (in millions) 2022 2021 2020 Domestic $ (4,608) $ (1,644) $ (4,467) Foreign 18,085 14,633 7,865 Total earnings before income tax expense $ 13,477 $ 12,989 $ 3,398 Income Tax Expense years ended December 31 (in millions) 2022 2021 2020 Current Domestic $ 2,647 $ 1,987 $ 907 Foreign 916 351 194 Total current taxes $ 3,563 $ 2,338 $ 1,101 Deferred Domestic $ (1,512) $ (839) $ (58) Foreign (419) (59) (2,267) Total deferred taxes $ (1,931) $ (898) $ (2,325) Total income tax expense (benefit) $ 1,632 $ 1,440 $ (1,224) Effective Tax Rate Reconciliation years ended December 31 2022 2021 2020 Statutory tax rate 21.0 % 21.0 % 21.0 % Effect of foreign operations (4.4) (5.4) 2.4 U.S. tax credits (2.8) (2.8) (10.6) Impacts related to U.S. tax reform — — (1.1) Non-deductible expenses 0.6 0.3 7.2 Tax law changes and related restructuring (2.4) (2.0) (48.5) Tax audits and settlements 0.9 (0.4) (5.1) All other, net (0.8) 0.4 (1.3) Effective tax rate 12.1 % 11.1 % (36.0) % The effective income tax rate fluctuates year to year due to the allocation of the company's taxable earnings among jurisdictions, as well as certain discrete factors and events in each year, including changes in tax law, acquisitions and collaborations. The effective income tax rates in 2022, 2021 and 2020 differed from the statutory tax rate principally due to the impact of foreign operations which reflects the impact of lower income tax rates in locations outside the United States, tax incentives in Puerto Rico and other foreign tax jurisdictions, business development activities, changes in enacted tax rates and laws and related restructuring, tax audits and settlements and changes in fair value of contingent consideration. The effective tax rates for these periods also reflected the benefit from U.S. tax credits principally related to research and development credits, the orphan drug tax credit and Puerto Rico excise tax credits. The Puerto Rico tax credits relate to excise tax on certain products manufactured in Puerto Rico. The tax is levied on gross inventory purchases from entities in Puerto Rico and is included in cost of products sold in the consolidated statements of earnings. The majority of the tax is creditable for U.S. income tax purposes. In 2022, Puerto Rico enacted Act 52-2002 (the Puerto Rico Act) allowing for a transition from a Puerto Rico excise tax levied on gross inventory purchases to an income-based tax beginning in 2023. The company completed the transition requirements of the Puerto Rico Act in 2022, resulting in the remeasurement of certain deferred tax assets and liabilities based on income tax rates at which they are expected to reverse in the future. The net tax benefit from the remeasurement of deferred taxes related to the Puerto Rico Act was $323 million. The 2020 effective income tax rate included the recognition of a net tax benefit of $1.7 billion related to changes in tax laws and related restructuring, including certain intra-group transfers of intellectual property and deferred tax remeasurement. The Tax Cuts and Jobs Act (the Act) was signed into law in December 2017, resulting in significant changes to the U.S. corporate tax system, including a one-time transition tax on a mandatory deemed repatriation of earnings of certain foreign subsidiaries that were previously untaxed. The Act also created a minimum tax on certain foreign sourced earnings. The company’s accounting policy for the minimum tax on foreign sourced earnings is to report the tax effects on the basis that the minimum tax will be recognized in tax expense in the year it is incurred as a period expense. Deferred Tax Assets and Liabilities as of December 31 (in millions) 2022 2021 Deferred tax assets Compensation and employee benefits $ 497 $ 937 Accruals and reserves 1,023 667 Chargebacks and rebates 991 837 Advance payments 547 809 Net operating losses and other carryforwards 10,391 10,095 Other 1,710 1,234 Total deferred tax assets 15,159 14,579 Valuation allowances (9,627) (9,391) Total net deferred tax assets 5,532 5,188 Deferred tax liabilities Excess of book basis over tax basis of intangible assets (3,590) (4,711) Excess of book basis over tax basis in investments (340) (308) Other (772) (904) Total deferred tax liabilities (4,702) (5,923) Net deferred tax assets (liabilities) $ 830 $ (735) The increase in net deferred tax assets is primarily related to capitalization of R&D expense and increases in accruals and reserves, offset by a decrease in advance payments. The decrease in deferred tax liabilities is primarily related to amortization of intangible assets. In connection with the Allergan acquisition, the company recorded adjustments within the measurement period in 2021 related to foreign net operating losses and other credit carryforwards that are not expected to be realized. The adjustments reflected an increase of $8.2 billion to deferred tax assets and an offsetting increase to valuation allowances, resulting in no net impact to deferred tax assets. The company had valuation allowances of $9.6 billion as of December 31, 2022 and $9.4 billion as of December 31, 2021. These were principally related to foreign and state net operating losses and other credit carryforwards that are not expected to be realized. As of December 31, 2022, the company had U.S. federal, state and foreign credit carryforwards of $355 million as well as U.S. federal, state and foreign net operating loss carryforwards of $33.2 billion, which will expire at various times through 2042. The remaining U.S. federal and foreign loss carryforwards of $6.0 billion have no expiration. The Act significantly changed the timing and manner in which earnings of foreign subsidiaries are subject to U.S. tax. Therefore, unremitted foreign earnings subject to the Act’s transition tax are not considered indefinitely reinvested. Post-2017 earnings subject to the U.S. minimum tax on foreign sourced earnings or eligible for the 100 percent foreign dividends received deduction are also not considered indefinitely reinvested earnings. However, the company generally considers instances of outside basis differences in foreign subsidiaries that would incur additional U.S. tax upon reversal (e.g., capital gain distribution) to be permanent in duration. The unrecognized tax liability is not practicable to determine. Unrecognized Tax Benefits years ended December 31 (in millions) 2022 2021 2020 Beginning balance $ 5,489 $ 5,264 $ 2,661 Increase due to acquisition — — 2,674 Increase due to current year tax positions 88 208 91 Increase due to prior year tax positions 243 137 59 Decrease due to prior year tax positions (33) (62) (7) Settlements (7) (24) (141) Lapse of statutes of limitations (110) (34) (73) Ending balance $ 5,670 $ 5,489 $ 5,264 If recognized, the net amount of potential tax benefits that would impact the company's effective tax rate is $5.5 billion in 2022 and $5.2 billion in 2021. The "Increase due to current year tax positions" and "Increase due to prior year tax positions" in the table above include amounts related to federal, state and international tax items. "Increase due to acquisition" in the table above includes amounts related to federal, state and international tax items recorded in acquisition accounting related to the Allergan acquisition. AbbVie recognizes interest and penalties related to income tax matters in income tax expense in the consolidated statements of earnings. AbbVie recognized gross income tax expense of $339 million in 2022, $161 million in 2021 and $142 million in 2020, for interest and penalties related to income tax matters. AbbVie had an accrual for the payment of gross interest and penalties of $1.1 billion at December 31, 2022, $803 million at December 31, 2021 and $642 million at December 31, 2020. The company is routinely audited by the tax authorities in significant jurisdictions and a number of audits are currently underway. It is reasonably possible during the next 12 months that uncertain tax positions may be settled, which could result in a decrease in the gross amount of unrecognized tax benefits. Due to the potential for resolution of federal, state and foreign examinations and the expiration of various statutes of limitation, the company's gross unrecognized tax benefits balance may change within the next 12 months up to $162 million. All significant federal, state, local and international matters have been concluded for years through 2009. The company believes adequate provision has been made for all income tax uncertainties.

Legal Proceedings and Contingen

Legal Proceedings and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings and Contingencies	Legal Proceedings and Contingencies AbbVie is subject to contingencies, such as various claims, legal proceedings and investigations regarding product liability, intellectual property, commercial, securities and other matters that arise in the normal course of business. The most significant matters are described below. Loss contingency provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount within a probable range is recorded. For litigation matters discussed below for which a loss is probable or reasonably possible, the company is unable to estimate the possible loss or range of loss, if any, beyond the amounts accrued. Initiation of new legal proceedings or a change in the status of existing proceedings may result in a change in the estimated loss accrued by AbbVie. While it is not feasible to predict the outcome of all proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on AbbVie’s consolidated financial position, results of operations or cash flows. Subject to certain exceptions specified in the separation agreement by and between Abbott Laboratories (Abbott) and AbbVie, AbbVie assumed the liability for, and control of, all pending and threatened legal matters related to its business, including liabilities for any claims or legal proceedings related to products that had been part of its business, but were discontinued prior to the distribution, as well as assumed or retained liabilities, and will indemnify Abbott for any liability arising out of or resulting from such assumed legal matters. Antitrust Litigation Lawsuits are pending against AbbVie and others generally alleging that the 2005 patent litigation settlement involving Niaspan entered into between Kos Pharmaceuticals, Inc. (a company acquired by Abbott in 2006 and presently a subsidiary of AbbVie) and a generic company violates federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys' fees. The lawsuits pending in federal court consist of four individual plaintiff lawsuits and two consolidated purported class actions: one brought by Niaspan direct purchasers and one brought by Niaspan end-payors. The cases are pending in the United States District Court for the Eastern District of Pennsylvania for coordinated or consolidated pre-trial proceedings under the MDL Rules as In re: Niaspan Antitrust Litigation , MDL No. 2460. In August 2019, the court certified a class of direct purchasers of Niaspan. In June 2020 and August 2021, the court denied the end-payors' motion to certify a class. In October 2016, the Orange County, California District Attorney’s Office filed a lawsuit on behalf of the State of California regarding the Niaspan patent litigation settlement in Orange County Superior Court, asserting a claim under the unfair competition provision of the California Business and Professions Code seeking injunctive relief, restitution, civil penalties and attorneys’ fees. In August 2019, direct purchasers of AndroGel filed a lawsuit, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al., against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, alleging that 2006 patent litigation settlements and related agreements by Solvay Pharmaceuticals, Inc. (a company Abbott acquired in February 2010 and now known as AbbVie Products LLC) with three generic companies violated federal antitrust law, and also alleging that 2011 patent litigation by Abbott with two generic companies regarding AndroGel was sham litigation and the settlements of those litigations violated federal antitrust law. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys’ fees. In November 2022, the State of Oregon filed a lawsuit in the Multnomah County, Oregon Circuit Court making similar allegations regarding the 2011 patent litigation with one of the generic companies. Lawsuits are pending against Forest Laboratories, LLC, an AbbVie subsidiary, and others generally alleging that 2009 and 2010 patent litigation settlements involving Namenda entered into between Forest and generic companies and other conduct by Forest involving Namenda, violated state antitrust, unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys’ fees. The lawsuits, purported class actions filed by indirect purchasers of Namenda, are consolidated as In re: Namenda Indirect Purchaser Antitrust Litigation in the United States District Court for the Southern District of New York. In November 2022, the parties reached an agreement to settle this matter that has received preliminary court approval. Lawsuits are pending against Forest Laboratories, LLC and others generally alleging that 2012 and 2013 patent litigation settlements involving Bystolic with six generic manufacturers violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys’ fees. The lawsuits, purported class actions filed on behalf of direct and indirect purchasers of Bystolic, are consolidated as In re: Bystolic Antitrust Litigation in the United States District Court for the Southern District of New York. Government Proceedings Lawsuits are pending against Allergan and several other manufacturers generally alleging that they improperly promoted and sold prescription opioid products. Approximately 3,000 matters are pending against Allergan. Most of the federal court cases are consolidated for pre-trial purposes in the United States District Court for the Northern District of Ohio under the MDL rules as In re: National Prescription Opiate Litigation, MDL No. 2804. Approximately 270 matters are pending in various state courts. The plaintiffs in these cases, which include states, counties, cities, other municipal entities, Native American tribes, union trust funds and other third-party payors, private hospitals and personal injury claimants, generally seek compensatory and punitive damages. In November 2022, Allergan finalized the terms of a settlement with state and local government entities and Native American tribes. That settlement is subject to certain conditions, including Allergan's determination that a sufficient number of government entities elect to participate in the settlement. AbbVie recorded a charge of $2.1 billion to selling, general and administrative expense in the consolidated statement of earnings in the second quarter of 2022 related to this potential settlement. Shareholder and Securities Litigation In June 2016, a lawsuit, Elliott Associates, L.P., et al. v. AbbVie Inc., was filed by five investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connection with its proposed transaction with Shire. Similar lawsuits were filed between July 2017 and October 2019 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. In September 2021, the Illinois court granted AbbVie's motion for summary judgment on all pending claims in all pending cases, dismissing them with prejudice. In November 2022, the Illinois appellate court affirmed summary judgment in AbbVie's favor and, in December 2022, that court denied plaintiffs' petition for rehearing. In October 2018, a federal securities lawsuit, Holwill v. AbbVie Inc., et al., was filed in the United States District Court for the Northern District of Illinois against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for Humira sales growth in financial filings between 2013 and 2018 were misleading because they omitted alleged misconduct in connection with Humira patient and reimbursement support services and other services and items of value that allegedly induced Humira prescriptions. In September 2021, the court granted plaintiffs' motion to certify a class. In May 2022, a shareholder derivative lawsuit, Ranney v. Gonzalez, et al., was filed in Delaware Chancery Court, alleging that certain AbbVie directors and officers breached their fiduciary duties based on related allegations. In December 2022, after AbbVie and the director/officer defendants filed a motion to dismiss, the plaintiff voluntarily dismissed the lawsuit with prejudice. Lawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's textured breast implants. The lawsuits, which were filed by Allergan shareholders, have been consolidated in the United States District Court for the Southern District of New York as In re: Allergan plc Securities Litigation. The plaintiffs generally seek compensatory damages and attorneys’ fees. In September 2019, the court partially granted Allergan's motion to dismiss. In September 2021, the court granted plaintiffs' motion to certify a class. In December 2022, the court granted Allergan's motion for summary judgment on the remaining claims, dismissing them with prejudice. Plaintiffs are appealing the court's motion to dismiss and summary judgment rulings. In April 2022, a federal securities lawsuit, Nakata v. AbbVie Inc., was filed in the United States District Court for the Northern District of Illinois against AbbVie and certain officers alleging misstatements regarding the potential effect that safety information about another company’s product would have on the Food and Drug Administration’s approval and labeling for AbbVie’s Rinvoq. In May and July 2022, two shareholder derivative lawsuits, Treppel Family Trust v. Gonzalez et al., and Katcher v. Gonzalez, et al., were filed in the same court, alleging that certain AbbVie directors and officers breached fiduciary and other legal duties based on related allegations. Product Liability and General Litigation In 2018, a qui tam lawsuit, U.S. ex rel. Silbersher v. Allergan Inc., et al., was filed in the United States District Court for the Northern District of California against several Allergan entities and others, alleging that their conduct before the U.S. Patent Office resulted in false claims for payment being made to federal and state healthcare payors for Namenda XR and Namzaric. The plaintiff-relator seeks damages and attorneys' fees under the federal False Claims Act and state law analogues. The federal government and state governments declined to intervene in the lawsuit. In August 2022, the United States Court of Appeals reversed the district court’s denial of Allergan’s motion to dismiss. The case has been remanded to the district court for further proceedings consistent with that ruling. Intellectual Property Litigation Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib tablets (a drug Pharmacyclics sells under the trademark Imbruvica). Cases were filed in the United States District Court for the District of Delaware in March 2019 against Alvogen Pine Brook LLC and Natco Pharma Ltd. In August 2021, the court issued a decision holding all asserted patents infringed and valid. The judgment precludes Defendants from obtaining regulatory approval and launching until the last patent expires in 2036. On August 30, 2021, Defendants appealed. On November 15, 2022, the Court of Appeals for the Federal Circuit affirmed the judgment. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of Imbruvica, is the co-plaintiff in these suits. AbbVie Inc. is seeking to enforce patent rights relating to venetoclax (a drug sold under the trademark Venclexta). Litigation was filed in the United States District Court for the District of Delaware in July 2020 against Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc.: and Alembic Pharmaceuticals Ltd., Alembic Pharmaceuticals, Inc., and Alembic Global Holdings SA. AbbVie alleges defendants’ proposed generic venetoclax products infringe certain patents and seeks declaratory and injunctive relief. Genentech, Inc., which is in a global collaboration with AbbVie concerning the development and marketing of Venclexta, is the co-plaintiff in this suit.

Segment and Geographic Area Inf

Segment and Geographic Area Information	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Segment and Geographic Area Information	Segment and Geographic Area InformationAbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods. Substantially all of AbbVie's net revenues in the United States are to three wholesalers. Outside the United States, products are sold primarily to health care providers or through distributors, depending on the market served. The following tables detail AbbVie's worldwide net revenues: years ended December 31 (in millions) 2022 2021 2020 Immunology Humira United States $ 18,619 $ 17,330 $ 16,112 International 2,618 3,364 3,720 Total $ 21,237 $ 20,694 $ 19,832 Skyrizi United States $ 4,484 $ 2,486 $ 1,385 International 681 453 205 Total $ 5,165 $ 2,939 $ 1,590 Rinvoq United States $ 1,794 $ 1,271 $ 653 International 728 380 78 Total $ 2,522 $ 1,651 $ 731 Hematologic Oncology Imbruvica United States $ 3,426 $ 4,321 $ 4,305 Collaboration revenues 1,142 1,087 1,009 Total $ 4,568 $ 5,408 $ 5,314 Venclexta United States $ 1,009 $ 934 $ 804 International 1,000 886 533 Total $ 2,009 $ 1,820 $ 1,337 Aesthetics Botox Cosmetic (a) United States $ 1,654 $ 1,424 $ 687 International 961 808 425 Total $ 2,615 $ 2,232 $ 1,112 Juvederm Collection (a) United States $ 548 $ 658 $ 318 International 880 877 400 Total $ 1,428 $ 1,535 $ 718 Other Aesthetics (a) United States $ 1,122 $ 1,268 $ 666 International 168 198 94 Total $ 1,290 $ 1,466 $ 760 Neuroscience Botox Therapeutic (a) United States $ 2,255 $ 2,012 $ 1,155 International 464 439 232 Total $ 2,719 $ 2,451 $ 1,387 Vraylar (a) United States $ 2,037 $ 1,728 $ 951 International 1 — — Total $ 2,038 $ 1,728 $ 951 Duodopa United States $ 95 $ 102 $ 103 International 363 409 391 Total $ 458 $ 511 $ 494 Ubrelvy (a) United States $ 680 $ 552 $ 125 Qulipta United States $ 158 $ — $ — Other Neuroscience (a) United States $ 456 $ 667 $ 528 International 19 18 11 Total $ 475 $ 685 $ 539 years ended December 31 (in millions) 2022 2021 2020 Eye Care Lumigan/Ganfort (a) United States $ 242 $ 273 $ 165 International 272 306 213 Total $ 514 $ 579 $ 378 Alphagan/Combigan (a) United States $ 202 $ 373 $ 223 International 144 156 103 Total $ 346 $ 529 $ 326 Restasis (a) United States $ 621 $ 1,234 $ 755 International 45 56 32 Total $ 666 $ 1,290 $ 787 Other Eye Care (a) United States $ 538 $ 523 $ 305 International 637 646 388 Total $ 1,175 $ 1,169 $ 693 Other Key Products Mavyret United States $ 755 $ 754 $ 785 International 786 956 1,045 Total $ 1,541 $ 1,710 $ 1,830 Creon United States $ 1,278 $ 1,191 $ 1,114 Linzess/Constella (a) United States $ 1,003 $ 1,006 $ 649 International 32 32 18 Total $ 1,035 $ 1,038 $ 667 All other $ 4,137 $ 5,019 $ 5,119 Total net revenues $ 58,054 $ 56,197 $ 45,804 (a) Net revenues include Allergan product revenues after the acquisition closing date of May 8, 2020. Net revenues to external customers by geographic area, based on product shipment destination, were as follows: years ended December 31 (in millions) 2022 2021 2020 United States $ 45,713 $ 43,510 $ 34,879 Germany 1,340 1,223 1,049 Canada 1,159 1,397 1,159 Japan 956 1,090 1,198 China 912 857 471 France 787 936 797 Australia 508 533 527 Spain 506 519 453 United Kingdom 462 497 509 Italy 444 506 379 Brazil 430 368 406 All other countries 4,837 4,761 3,977 Total net revenues $ 58,054 $ 56,197 $ 45,804 Long-lived assets, primarily net property and equipment, by geographic area were as follows: as of December 31 (in millions) 2022 2021 United States and Puerto Rico $ 3,243 $ 3,369 Europe 1,369 1,400 All other 323 341 Total long-lived assets $ 4,935 $ 5,110

Fourth Quarter Financial Result

Fourth Quarter Financial Results (unaudited)	12 Months Ended
	Dec. 31, 2022
Quarterly Financial Information Disclosure [Abstract]
Fourth Quarter Financial Results (unaudited)	Fourth Quarter Financial Results (unaudited) quarter ended December 31 (in millions except per share data) 2022 Net revenues $ 15,121 Gross margin 10,951 Net earnings attributable to AbbVie Inc. 2,473 Basic earnings per share attributable to AbbVie Inc. $ 1.39 Diluted earnings per share attributable to AbbVie Inc. $ 1.38 Cash dividends declared per common share $ 1.48

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and necessarily include amounts based on estimates and assumptions by management. Actual results could differ from those amounts. Significant estimates include amounts for rebates, pension and other post-employment benefits, income taxes, litigation, valuation of goodwill and intangible assets, contingent consideration liabilities, financial instruments and inventory and accounts receivable exposures.
Basis of Consolidation	Basis of Consolidation The consolidated financial statements include the accounts of AbbVie and all of its subsidiaries in which a controlling interest is maintained. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, where AbbVie is determined to be the primary beneficiary. Investments in companies over which AbbVie has a significant influence but not a controlling interest are accounted for using the equity method with AbbVie's share of earnings or losses reported in other expense, net in the consolidated statements of earnings. Intercompany balances and transactions are eliminated.
Revenue Recognition	Revenue Recognition AbbVie recognizes revenue when control of promised goods or services is transferred to the company’s customers, in an amount that reflects the consideration AbbVie expects to be entitled to in exchange for those goods or services. Sales, value add and other taxes collected concurrent with revenue-producing activities are excluded from revenue. AbbVie generates revenue primarily from product sales. For the majority of sales, the company transfers control, invoices the customer and recognizes revenue upon shipment to the customer. The company recognizes shipping and handling costs as an expense in cost of products sold when the company transfers control to the customer. Payment terms vary depending on the type and location of the customer, are based on customary commercial terms and are generally less than one year. AbbVie does not adjust revenue for the effects of a significant financing component for contracts where AbbVie expects the period between the transfer of the good or service and collection to be one year or less. Cash discounts, rebates and chargebacks, sales incentives, product returns and certain other adjustments are accounted for as variable consideration. Provisions for variable consideration are based on current pricing, executed contracts, government pricing legislation and historical data and are provided for in the period the related revenues are recorded. Rebate amounts are typically based upon the volume of purchases using contractual or statutory prices, which may vary by product and by payer. For each type of rebate, factors used in the calculation of the accrual include the identification of the products subject to the rebate, the applicable price terms and the estimated lag time between sale and payment of the rebate, which can be significant. In addition to revenue from contracts with customers, the company also recognizes certain collaboration revenues. See Note 6 for additional information related to the collaborations with Janssen Biotech, Inc. and Genentech, Inc. Additionally, see Note 16 for disaggregation of revenue by product and geography.
Research and Development Expenses	Research and Development ExpensesInternal R&D costs are expensed as incurred. Clinical trial costs incurred by third parties are expensed as the contracted work is performed.
Acquired In-Process Research and Development	Acquired IPR&D and Milestones Expenses In an asset acquisition, payments incurred prior to regulatory approval to acquire rights to in-process R&D projects are expensed as acquired IPR&D and milestones expense in the consolidated statements of earnings unless the project has an alternative future use. These costs include upfront and development milestone payments related to R&D collaborations, licensing arrangements, or other asset acquisitions that provide rights to develop, manufacture and/or sell pharmaceutical products. Where contingent development milestone payments are due to third parties, prior to regulatory approval, the payment obligations are expensed when the milestone results are achieved. Regulatory and commercial milestone payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized to cost of products sold over the remaining useful life of the related product.
Business Combinations	Business Combinations AbbVie utilizes the acquisition method of accounting for business combinations. This method requires, among other things, that results of operations of acquired companies are included in AbbVie's results of operations beginning on the acquisition date and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Any excess of the fair value of consideration transferred over the fair value of the net assets acquired is recognized as goodwill. Contingent consideration liabilities are recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent consideration liabilities are recognized in other expense, net in the consolidated statements of earnings. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other business acquisition costs are expensed when incurred.
Collaborations and Other Arrangements	Collaborations and Other Arrangements The company enters into collaborative agreements with third parties to develop and commercialize drug candidates. Collaborative activities may include joint research and development and commercialization of new products. AbbVie generally receives certain licensing rights under these arrangements. These collaborations often require upfront payments and may include additional milestone, research and development cost sharing, royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development and commercialization. Upfront payments associated with collaborative arrangements and subsequent payments made to the partner for the achievement of development milestones prior to regulatory approval are expensed to acquired IPR&D and milestones expense in the consolidated statements of earnings. Regulatory and commercial milestone payments made to the partner subsequent to regulatory approval are capitalized as intangible assets and amortized to cost of products sold over the estimated useful life of the related asset. Royalties are expensed to cost of products sold in the consolidated statements of earnings when incurred.
Advertising	AdvertisingCosts associated with advertising are expensed as incurred and are included in selling, general and administrative (SG&A) expense in the consolidated statements of earnings.
Pension and Other Post-Employment Benefits	Pension and Other Post-Employment Benefits AbbVie records annual expenses relating to its defined benefit pension and other post-employment benefit plans based on calculations which utilize various actuarial assumptions including discount rates, rates of return on assets, compensation increases, turnover rates and health care cost trend rates. AbbVie reviews its actuarial assumptions on an annual basis and makes modifications to the assumptions based on current rates and trends. Actuarial gains and losses are deferred in accumulated other comprehensive income (loss) (AOCI), net of tax and are amortized over the remaining service attribution periods of the employees under the corridor method. Differences between the expected long-term return on plan assets and the actual annual return are generally amortized to net periodic benefit cost over a five-year period.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Provisions for federal, state and foreign income taxes are calculated on reported pre-tax earnings based on current tax laws. Deferred taxes are provided using enacted tax rates on the future tax consequences of temporary differences, which are the differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases and the tax benefits of carryforwards. A valuation allowance is established or maintained when, based on currently available information, it is more likely than not that all or a portion of a deferred tax asset will not be realized.
Cash and Equivalents	Cash and Equivalents Cash and equivalents include money market funds and time deposits with original maturities of three months or less.
Investments	Investments Investments consist primarily of equity securities, held-to-maturity debt securities, marketable debt securities and time deposits. Investments in equity securities that have readily determinable fair values are recorded at fair value. Investments in equity securities that do not have readily determinable fair values are recorded at cost and are remeasured to fair value based on certain observable price changes or impairment events as they occur. Held-to-maturity debt securities are recorded at cost. Gains or losses on investments are included in other expense, net in the consolidated statements of earnings. Investments in marketable debt securities are classified as available-for-sale and are recorded at fair value with any unrealized holding gains or losses, net of tax, included in AOCI on the consolidated balance sheets until realized, at which time the gains or losses are recognized in earnings. AbbVie periodically assesses its marketable debt securities for impairment and credit losses. When a decline in fair value of marketable debt security is due to credit related factors, an allowance for credit losses is recorded with a corresponding charge to other expense, net in the consolidated statements of earnings. When AbbVie determines that a non-credit related impairment has occurred, the amortized cost basis of the investment, net of allowance for credit losses, is written down with a charge to other expense, net in the consolidated statements of earnings and an available-for-sale investment's unrealized loss is reclassified from AOCI to other expense, net in the consolidated statements of earnings. Realized gains and losses on sales of investments are computed using the first-in, first-out method adjusted for any impairments and credit losses that were recorded in net earnings.
Accounts Receivable	Accounts Receivable Accounts receivable are stated at amortized cost less allowance for credit losses. The allowance for credit losses reflects the best estimate of future losses over the contractual life of outstanding accounts receivable and is determined on the basis of historical experience, specific allowances for known troubled accounts, other currently available information including customer financial condition and both current and forecasted economic conditions.
Inventories	InventoriesInventories are valued at the lower of cost (first-in, first-out basis) or market. Cost includes material and conversion costs.
Property and Equipment	Depreciation for property and equipment is recorded on a straight-line basis over the estimated useful lives of the assets. The estimated useful life for buildings ranges from 10 to 50 years. Buildings include leasehold improvements which are amortized over the lesser of the remainder of the lease term or the useful life of the leasehold improvement. The estimated useful life for equipment ranges from 2 to 25 years. Equipment includes certain computer software and software development costs incurred in connection with developing or obtaining software for internal use and is amortized over 3 to 10 years.
Leases	Leases Short-term leases with a term of 12 months or less are not recorded on the balance sheet. For leases commencing or modified in 2019 or later, AbbVie does not separate lease components from non-lease components. The company records lease liabilities based on the present value of lease payments over the lease term. AbbVie generally uses an incremental borrowing rate to discount its lease liabilities, as the rate implicit in the lease is typically not readily determinable. Certain lease agreements include renewal options that are under the company's control. AbbVie includes optional renewal periods in the lease term only when it is reasonably certain that AbbVie will exercise its option. Variable lease payments include payments to lessors for taxes, maintenance, insurance and other operating costs as well as payments that are adjusted based on an index or rate. The company's lease agreements do not contain any significant residual value guarantees or restrictive covenants.
Short-Term Leases	Short-term leases with a term of 12 months or less are not recorded on the balance sheet.
Litigation and Contingencies	Litigation and Contingencies Loss contingency provisions are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information. When a best estimate cannot be made, the minimum loss contingency amount in a probable range is recorded. Legal fees are expensed as incurred. AbbVie accrues for product liability claims on an undiscounted basis. The liabilities are evaluated quarterly and adjusted if necessary as additional information becomes available. Receivables for insurance recoveries for product liability claims, if any, are recorded as assets on an undiscounted basis when it is probable that a recovery will be realized.
Goodwill and Intangible Assets	Goodwill and Intangible Assets Intangible assets acquired in a business combination are recorded at fair value using a discounted cash flow model. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, risk, the cost of capital and terminal values of market participants. Definite-lived intangibles are amortized over their estimated useful lives using the estimated pattern of economic benefit. AbbVie reviews the recoverability of definite-lived intangible assets whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. AbbVie first compares the projected undiscounted cash flows to be generated by the asset to its carrying value. If the undiscounted cash flows of an intangible asset are less than the carrying value, the intangible asset is written down to its fair value. Where cash flows cannot be identified for an individual asset, the review is applied at the lowest level for which cash flows are largely independent of the cash flows of other assets and liabilities. Goodwill and indefinite-lived assets are not amortized, but are subject to an impairment review annually and more frequently when indicators of impairment exist. An impairment of goodwill could occur if the carrying amount of a reporting unit exceeded the fair value of that reporting unit. An impairment of indefinite-lived intangible assets would occur if the fair value of the intangible asset is less than the carrying value. The company tests its goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If the company concludes it is more likely than not that the fair value of the reporting unit is less than its carrying amount, a quantitative impairment test is performed. AbbVie tests indefinite-lived intangible assets for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If the company concludes it is more likely than not that the fair value is less than its carrying amount, a quantitative impairment test is performed. For its quantitative impairment tests, the company uses an estimated future cash flow approach that requires significant judgment with respect to future volume, revenue and expense growth rates, changes in working capital use, the selection of an appropriate discount rate, asset groupings and other assumptions and estimates. The estimates and assumptions used are consistent with the company's business plans and a market participant's views. The use of alternative estimates and assumptions could increase or decrease projected cash flows and the estimated fair value of the related intangible assets. Future changes to these estimates and assumptions could have a material impact on the company's results of operations. Actual results may differ from the company's estimates.
Foreign Currency Translation	Foreign Currency TranslationForeign subsidiary earnings are translated into U.S. dollars using average exchange rates. The net assets of foreign subsidiaries are translated into U.S. dollars using period-end exchange rates. The U.S. dollar affects that arise from translating the net assets of these subsidiaries at changing rates are recognized in other comprehensive income (loss) in the consolidated statements of comprehensive income. The net assets of subsidiaries in highly inflationary economies are remeasured as if the functional currency were the reporting currency. The remeasurement is recognized in net foreign exchange loss in the consolidated statements of earnings.
Derivatives	Derivatives All derivative instruments are recognized as either assets or liabilities at fair value on the consolidated balance sheets and are classified as current or long-term based on the scheduled maturity of the instrument. For derivatives formally designated as hedges, the company assesses at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in the fair value or cash flows of the hedged item. The changes in fair value of a derivative designated as a fair value hedge and of the hedged item attributable to the hedged risk are recognized in earnings immediately. The effective portions of changes in the fair value of a derivative designated as a cash flow hedge are reported in AOCI and are subsequently recognized in earnings consistent with the underlying hedged item. If it is determined that a derivative is no longer highly effective as a hedge, the company discontinues hedge accounting prospectively. If a hedged forecasted transaction becomes probable of not occurring, any gains or losses are reclassified from AOCI to earnings. Derivatives that are not designated as hedges are adjusted to fair value through current earnings. The company also uses derivative instruments or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. Realized and unrealized gains and losses from these hedges are included in AOCI. Derivative cash flows, with the exception of net investment hedges, are principally classified in the operating section of the consolidated statements of cash flows, consistent with the underlying hedged item. Cash flows related to net investment hedges are classified in the investing section of the consolidated statements of cash flows.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Schedule of inventories	Inventories are valued at the lower of cost (first-in, first-out basis) or market. Cost includes material and conversion costs. Inventories consisted of the following: as of December 31 (in millions) 2022 2021 Finished goods $ 1,162 $ 932 Work-in-process 1,417 1,193 Raw materials 1,000 1,003 Inventories $ 3,579 $ 3,128
Schedule of property and equipment	Property and Equipment as of December 31 (in millions) 2022 2021 Land $ 286 $ 287 Buildings 2,737 2,791 Equipment 7,107 6,850 Construction in progress 856 799 Property and equipment, gross 10,986 10,727 Less accumulated depreciation (6,051) (5,617) Property and equipment, net $ 4,935 $ 5,110

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	12 Months Ended
	Dec. 31, 2022
Supplemental Financial Information
Schedule of interest expense, net	Interest Expense, Net years ended December 31 (in millions) 2022 2021 2020 Interest expense $ 2,230 $ 2,423 $ 2,454 Interest income (186) (39) (174) Interest expense, net $ 2,044 $ 2,384 $ 2,280
Schedule of accounts payable and accrued liabilities	Accounts Payable and Accrued Liabilities as of December 31 (in millions) 2022 2021 Sales rebates $ 10,717 $ 8,254 Dividends payable 2,680 2,543 Accounts payable 2,934 2,882 Current portion of contingent consideration liabilities 1,469 1,249 Salaries, wages and commissions 1,371 1,785 Royalty and license arrangements 412 661 Other 5,819 5,325 Accounts payable and accrued liabilities $ 25,402 $ 22,699
Schedule of other long-term liabilities	Other Long-Term Liabilities as of December 31 (in millions) 2022 2021 Contingent consideration liabilities $ 14,915 $ 13,638 Liabilities for unrecognized tax benefits 6,502 5,970 Income taxes payable 2,985 3,442 Pension and other post-employment benefits 1,638 3,153 Other 4,615 2,498 Other long-term liabilities $ 30,655 $ 28,701

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Schedule of basic and diluted earnings per share, impact of two-class method	The following table summarizes the impact of the two-class method: Years ended December 31, (in millions, except per share data) 2022 2021 2020 Basic EPS Net earnings attributable to AbbVie Inc. $ 11,836 $ 11,542 $ 4,616 Earnings allocated to participating securities 54 74 60 Earnings available to common shareholders $ 11,782 $ 11,468 $ 4,556 Weighted average basic shares of common stock outstanding 1,771 1,770 1,667 Basic earnings per share attributable to AbbVie Inc. $ 6.65 $ 6.48 $ 2.73 Diluted EPS Net earnings attributable to AbbVie Inc. $ 11,836 $ 11,542 $ 4,616 Earnings allocated to participating securities 54 74 60 Earnings available to common shareholders $ 11,782 $ 11,468 $ 4,556 Weighted average shares of common stock outstanding 1,771 1,770 1,667 Effect of dilutive securities 7 7 6 Weighted average diluted shares of common stock outstanding 1,778 1,777 1,673 Diluted earnings per share attributable to AbbVie Inc. $ 6.63 $ 6.45 $ 2.72

Licensing, Acquisitions, and _2

Licensing, Acquisitions, and Other Arrangements (Tables)	12 Months Ended
	Dec. 31, 2022
Licensing, Acquisitions, and Other Arrangements
Schedule of consideration for the acquisition of Allergan	Total consideration for the acquisition of Allergan is summarized as follows: (in millions) Cash consideration paid to Allergan shareholders (a) $ 39,675 Fair value of AbbVie common stock issued to Allergan shareholders (b) 23,979 Fair value of AbbVie equity awards issued to Allergan equity award holders (c) 430 Total consideration $ 64,084 (a) Represents cash consideration transferred of $120.30 per outstanding Allergan ordinary share based on 330 million Allergan ordinary shares outstanding at closing. (b) Represents the acquisition date fair value of 286 million shares of AbbVie common stock issued to Allergan shareholders based on the exchange ratio of 0.8660 AbbVie shares for each outstanding Allergan ordinary share at the May 8, 2020, closing price of $83.96 per share. (c) Represents the pre-acquisition service portion of the fair value of 11 million AbbVie stock options and 8 million RSUs issued to Allergan equity award holders.
Schedule of fair value of assets acquired and liabilities assumed	The following table summarizes t he final fair value of assets acquired and liabilities assumed as of the acquisition date: (in millions) Assets acquired and liabilities assumed Cash and equivalents $ 1,537 Short-term investments 1,421 Accounts receivable 2,374 Inventories 2,340 Prepaid expenses and other current assets 1,982 Investments 137 Property and equipment 2,129 Intangible assets Definite-lived intangible assets 68,190 In-process research and development 1,600 Other noncurrent assets 1,395 Short-term borrowings (60) Current portion of long-term debt and finance lease obligations (1,899) Accounts payable and accrued liabilities (5,852) Long-term debt and finance lease obligations (18,937) Deferred income taxes (3,940) Other long-term liabilities (4,765) Total identifiable net assets 47,652 Goodwill 16,432 Total assets acquired and liabilities assumed $ 64,084
Schedule of unaudited pro forma combined results	The following table presents the unaudited pro forma combined results of AbbVie and Allergan for 2020 as if the acquisition of Allergan had occurred on January 1, 2019: years ended December 31 (in millions) 2020 Net revenues $ 50,521 Net earnings 6,746

Collaborations (Tables)

Collaborations (Tables)	12 Months Ended
	Dec. 31, 2022
Janssen Biotech, Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Schedule of profit and cost sharing relationship	The following table shows the profit and cost sharing relationship between Janssen and AbbVie: years ended December 31 (in millions) 2022 2021 2020 United States - Janssen's share of profits (included in cost of products sold) $ 1,607 $ 2,018 $ 2,012 International - AbbVie's share of profits (included in net revenues) 1,142 1,087 1,009 Global - AbbVie's share of other costs (included in respective line items) 268 304 295
Genentech, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Schedule of profit and cost sharing relationship	The following table shows the profit and cost sharing relationship between Genentech and AbbVie: years ended December 31 (in millions) 2022 2021 2020 Genentech's share of profits, including royalties (included in cost of products sold) $ 778 $ 703 $ 533 AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) 37 40 46 AbbVie's share of development costs (included in R&D) 121 140 129

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of changes in the carrying amount of goodwill	The following table summarizes the changes in the carrying amount of goodwill: (in millions) Balance as of December 31, 2020 $ 33,124 Additions (a) 177 Measurement period adjustments (b) (564) Foreign currency translation adjustments and other (358) Balance as of December 31, 2021 32,379 Additions (c) 92 Foreign currency translation adjustments and other (315) Balance as of December 31, 2022 $ 32,156 (a) Goodwill additions related to the acquisition of Soliton in the fourth quarter of 2021 (see Note 5). (b) Measurement period adjustments recorded in 2021 related to the acquisition of Allergan (see Note 5). (c) Goodwill additions related to the acquisition of DJS in the fourth quarter of 2022 (see Note 5).
Schedule of definite-lived intangible assets	The following table summarizes intangible assets: 2022 2021 as of December 31 (in millions) Gross Accumulated Net Gross Accumulated Net Definite-lived intangible assets Developed product rights $ 87,698 $ (25,003) $ 62,695 $ 88,945 $ (18,463) $ 70,482 License agreements 8,474 (4,642) 3,832 8,487 (3,688) 4,799 Total definite-lived intangible assets 96,172 (29,645) 66,527 97,432 (22,151) 75,281 Indefinite-lived intangible assets 912 — 912 670 — 670 Total intangible assets, net $ 97,084 $ (29,645) $ 67,439 $ 98,102 $ (22,151) $ 75,951
Schedule of indefinite-lived intangible assets	The following table summarizes intangible assets: 2022 2021 as of December 31 (in millions) Gross Accumulated Net Gross Accumulated Net Definite-lived intangible assets Developed product rights $ 87,698 $ (25,003) $ 62,695 $ 88,945 $ (18,463) $ 70,482 License agreements 8,474 (4,642) 3,832 8,487 (3,688) 4,799 Total definite-lived intangible assets 96,172 (29,645) 66,527 97,432 (22,151) 75,281 Indefinite-lived intangible assets 912 — 912 670 — 670 Total intangible assets, net $ 97,084 $ (29,645) $ 67,439 $ 98,102 $ (22,151) $ 75,951
Schedule of anticipated annual amortization expense	The anticipated annual amortization expense for definite-lived intangible assets recorded as of December 31, 2022 is as follows: (in billions) 2023 2024 2025 2026 2027 Anticipated annual amortization expense $ 7.7 $ 7.9 $ 8.0 $ 7.3 $ 5.8

Integration and Restructuring_2

Integration and Restructuring Plans (Tables)	12 Months Ended
	Dec. 31, 2022
Allergan integration plan
Restructuring charges
Summary of charges associated with integration plan	The following table summarizes the charges (benefits) associated with the Allergan acquisition integration plan: Severance and employee benefits Other integration year ended December 31 (in millions) 2022 2021 2020 2022 2021 2020 Cost of products sold $ (4) $ 5 $ 109 $ 121 $ 127 $ 21 Research and development — — 199 23 102 177 Selling, general and administrative (4) 64 388 403 289 237 Total charges (benefits) $ (8) $ 69 $ 696 $ 547 $ 518 $ 435
Summary of cash activity in the restructuring reserve	The following table summarizes the cash activity in the recorded liability associated with the integration plan: year ended December 31 (in millions) Severance and employee benefits Other integration Charges $ 594 $ 435 Payments and other adjustments (227) (415) Accrued balance as of December 31, 2020 367 20 Charges 65 461 Payments and other adjustments (210) (448) Accrued balance as of December 31, 2021 222 33 Charges (benefits) (8) 385 Payments and other adjustments (116) (409) Accrued balance as of December 31, 2022 $ 98 $ 9
Other restructuring
Restructuring charges
Summary of cash activity in the restructuring reserve	The following table summarizes the cash activity in the restructuring reserve for 2022, 2021 and 2020: (in millions) Accrued balance as of December 31, 2019 $ 140 Restructuring charges 58 Payments and other adjustments (108) Accrued balance as of December 31, 2020 90 Restructuring charges 54 Payments and other adjustments (111) Accrued balance as of December 31, 2021 33 Restructuring charges 193 Payments and other adjustments (50) Accrued balance as of December 31, 2022 $ 176

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Summary of amounts and location of operating and finance leases on the consolidated balance sheets	The following table summarizes the amounts and location of operating and finance leases on the consolidated balance sheets: as of December 31 (in millions) Balance sheet caption 2022 2021 Assets Operating Other assets $ 737 $ 762 Finance Property and equipment, net 25 33 Total lease assets $ 762 $ 795 Liabilities Operating Current Accounts payable and accrued liabilities $ 166 $ 178 Noncurrent Other long-term liabilities 754 713 Finance Current Current portion of long-term debt and finance lease obligations 17 9 Noncurrent Long-term debt and finance lease obligations 17 25 Total lease liabilities $ 954 $ 925
Summary of lease costs recognized in the condensed consolidated statements of earnings	The following table summarizes the lease costs recognized in the consolidated statements of earnings: years ended December 31 (in millions) 2022 2021 2020 Operating lease cost $ 201 $ 226 $ 192 Short-term lease cost 67 56 59 Variable lease cost 71 71 60 Total lease cost $ 339 $ 353 $ 311
Schedule of weighted-average remaining lease term and weighted-average discount rate for operating and finance leases	The following table presents the weighted-average remaining lease term and weighted-average discount rate for operating and finance leases: years ended December 31 2022 2021 2020 Weighted-average remaining lease term (years) Operating 8 7 8 Finance 2 3 3 Weighted-average discount rate Operating 2.6 % 2.4 % 2.5 % Finance 1.5 % 1.1 % 1.4 %
Schedule of supplementary cash flow information regarding the company's leases	The following table presents supplementary cash flow information regarding the company's leases: years ended December 31 (in millions) 2022 2021 2020 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 212 $ 236 $ 185 Right-of-use assets obtained in exchange for new operating lease liabilities 235 66 692
Summary of future maturities of AbbVie's operating lease liabilities	The following table summarizes the future maturities of AbbVie's operating and finance lease liabilities as of December 31, 2022: (in millions) Operating Finance Total (a) 2023 $ 185 $ 17 $ 202 2024 152 7 159 2025 130 5 135 2026 113 6 119 2027 90 — 90 Thereafter 361 — 361 Total lease payments 1,031 35 1,066 Less: Interest 111 1 112 Present value of lease liabilities $ 920 $ 34 $ 954 (a) Lease payments recognized as part of lease liabilities for optional renewal periods are insignificant.
Summary of future maturities of AbbVie's finance lease liabilities	The following table summarizes the future maturities of AbbVie's operating and finance lease liabilities as of December 31, 2022: (in millions) Operating Finance Total (a) 2023 $ 185 $ 17 $ 202 2024 152 7 159 2025 130 5 135 2026 113 6 119 2027 90 — 90 Thereafter 361 — 361 Total lease payments 1,031 35 1,066 Less: Interest 111 1 112 Present value of lease liabilities $ 920 $ 34 $ 954 (a) Lease payments recognized as part of lease liabilities for optional renewal periods are insignificant.

Debt, Credit Facilities and C_2

Debt, Credit Facilities and Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2022
Debt, Credit Facilities and Commitments and Contingencies
Summary of long-term debt	The following table summarizes long-term debt: as of December 31 (dollars in millions) 2022 Effective interest rate (a) 2022 2021 Effective interest rate (a) 2021 2.30-3.45% aggregate notes due 2022 1.92-3.28% $ — 0.99-3.45% $ 12,428 3.75% senior notes due 2023 3.84 % 1,250 3.84 % 1,250 2.85% senior notes due 2023 2.91 % 1,000 2.91 % 1,000 Floating rate term loans due 2023 2.45 % 1,000 0.81 % 1,000 1.50% senior euro notes due 2023 (€500 principal) 0.49 % 532 0.49 % 567 2.80% senior notes due 2023 2.13 % 350 2.13 % 350 2.60% senior notes due 2024 2.69 % 3,750 2.69 % 3,750 1.375% senior euro notes due 2024 (€1,450 principal) 1.46 % 1,543 1.46 % 1,643 3.85% senior notes due 2024 2.07 % 1,032 2.07 % 1,032 1.25% senior euro notes due 2024 (€700 principal) 0.65 % 745 0.65 % 793 3.60% senior notes due 2025 3.66 % 3,750 3.66 % 3,750 3.80% senior notes due 2025 2.09 % 3,021 2.09 % 3,021 Floating rate term loans due 2025 1.39 % — 1.36 % 2,000 Floating rate term loans due 2025 2.82 % 2,000 — — 2.95% senior notes due 2026 3.02 % 4,000 3.02 % 4,000 3.20% senior notes due 2026 3.28 % 2,000 3.28 % 2,000 0.75% senior euro notes due 2027 (€750 principal) 0.86 % 798 0.86 % 850 4.25% senior notes due 2028 4.38 % 1,750 4.38 % 1,750 2.125% senior euro notes due 2028 (€750 principal) 2.18 % 798 2.18 % 850 2.625% senior euro notes due 2028 (€500 principal) 1.20 % 532 1.20 % 567 3.20% senior notes due 2029 3.25 % 5,500 3.25 % 5,500 2.125% senior euro notes due 2029 (€550 principal) 1.19 % 585 1.19 % 623 1.25% senior euro notes due 2031 (€650 principal) 1.30 % 691 1.30 % 737 4.55% senior notes due 2035 3.52 % 1,789 3.52 % 1,789 4.50% senior notes due 2035 4.58 % 2,500 4.58 % 2,500 4.30% senior notes due 2036 4.37 % 1,000 4.37 % 1,000 4.05% senior notes due 2039 4.11 % 4,000 4.11 % 4,000 4.40% senior notes due 2042 4.46 % 2,600 4.46 % 2,600 4.625% senior notes due 2042 4.00 % 457 4.00 % 457 4.85% senior notes due 2044 4.11 % 1,074 4.11 % 1,074 4.70% senior notes due 2045 4.73 % 2,700 4.73 % 2,700 4.75% senior notes due 2045 4.20 % 881 4.20 % 881 4.45% senior notes due 2046 4.50 % 2,000 4.50 % 2,000 4.875% senior notes due 2048 4.94 % 1,750 4.94 % 1,750 4.25% senior notes due 2049 4.29 % 5,750 4.29 % 5,750 Fair value hedges (346) 102 Unamortized bond discounts (116) (130) Unamortized deferred financing costs (222) (251) Unamortized bond premiums (b) 793 954 Other 33 33 Total long-term debt and finance lease obligations 63,270 76,670 Current portion 4,135 12,481 Noncurrent portion $ 59,135 $ 64,189 (a) Excludes the effect of any related interest rate swaps. (b) Represents unamortized purchase price adjustments of Allergan debt.
Summary of maturities of long-term debt	as of and for the years ending December 31 (in millions) 2023 $ 4,132 2024 7,070 2025 8,771 2026 6,000 2027 798 Thereafter 36,357 Total obligations and commitments 63,128 Fair value hedges, unamortized bond premiums/discounts, deferred financing costs and finance lease obligations 142 Total long-term debt and finance lease obligations $ 63,270

Financial Instruments and Fai_2

Financial Instruments and Fair Value Measures (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Summary of amounts and location of derivatives on the consolidated balance sheets	The following table summarizes the amounts and location of AbbVie's derivative instruments on the consolidated balance sheets: Fair value - Derivatives in asset position Fair value - as of December 31 (in millions) Balance sheet caption 2022 2021 Balance sheet caption 2022 2021 Foreign currency forward exchange contracts Designated as cash flow hedges Prepaid expenses and other $ 49 $ 51 Accounts payable and accrued liabilities $ 8 $ 2 Designated as cash flow hedges Other assets 1 — Other long-term liabilities — — Designated as net investment hedges Prepaid expenses and other 6 149 Accounts payable and accrued liabilities 36 — Designated as net investment hedges Other assets 74 15 Other long-term liabilities 47 — Not designated as hedges Prepaid expenses and other 33 26 Accounts payable and accrued liabilities 41 13 Interest rate swap contracts Designated as cash flow hedges Prepaid expenses and other — — Accounts payable and accrued liabilities — 7 Designated as fair value hedges Prepaid expenses and other — — Accounts payable and accrued liabilities 17 — Designated as fair value hedges Other assets — 26 Other long-term liabilities 375 15 Total derivatives $ 163 $ 267 $ 524 $ 37
Schedule of pre-tax amounts of derivatives recognized in other comprehensive income (loss)	The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income: years ended in December 31 (in millions) 2022 2021 2020 Foreign currency forward exchange contracts Designated as cash flow hedges $ 103 $ 82 $ (71) Designated as net investment hedges 395 341 (95) Interest rate swap contracts designated as cash flow hedges 6 2 (53)
Summary of pre-tax amounts and location of derivatives recognized in the consolidated statement of earnings	The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 13 for the amount of net gains (losses) reclassified out of AOCI. years ended December 31 (in millions) Statement of earnings caption 2022 2021 2020 Foreign currency forward exchange contracts Designated as cash flow hedges Cost of products sold $ 82 $ (87) $ 23 Designated as net investment hedges Interest expense, net 94 26 18 Not designated as hedges Net foreign exchange loss (156) (100) 58 Treasury rate lock agreements designated as cash flow hedges Interest expense, net 23 24 24 Interest rate swap contracts Designated as cash flow hedges Interest expense, net (1) (24) (17) Designated as fair value hedges Interest expense, net (402) (127) 365 Debt designated as hedged item in fair value hedges Interest expense, net 402 127 (365)
Summary of bases used to measure assets and liabilities carried at fair value on a recurring basis	The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the consolidated balance sheet as of December 31, 2022: Basis of fair value measurement (in millions) Total Quoted prices in active markets for Significant other observable Significant unobservable inputs Assets Cash and equivalents $ 9,201 $ 4,201 $ 5,000 $ — Money market funds and time deposits 21 — 21 — Debt securities 28 — 28 — Equity securities 91 59 32 — Foreign currency contracts 163 — 163 — Total assets $ 9,504 $ 4,260 $ 5,244 $ — Liabilities Interest rate swap contracts $ 392 $ — $ 392 $ — Foreign currency contracts 132 — 132 — Contingent consideration 16,384 — — 16,384 Total liabilities $ 16,908 $ — $ 524 $ 16,384 The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the consolidated balance sheet as of December 31, 2021: Basis of fair value measurement (in millions) Total Quoted prices in active markets for identical assets Significant other observable Significant unobservable inputs Assets Cash and equivalents $ 9,746 $ 4,451 $ 5,295 $ — Money market funds and time deposits 45 — 45 — Debt securities 46 — 46 — Equity securities 121 100 21 — Interest rate swap contracts 26 — 26 — Foreign currency contracts 241 — 241 — Total assets $ 10,225 $ 4,551 $ 5,674 $ — Liabilities Interest rate swap contracts $ 22 $ — $ 22 $ — Foreign currency contracts 15 — 15 — Contingent consideration 14,887 — — 14,887 Total liabilities $ 14,924 $ — $ 37 $ 14,887
Summary of significant level 3 unobservable inputs	The fair value of the company's contingent consideration liabilities was calculated using the following significant unobservable inputs: 2022 2021 years ended December 31 (in millions) Range Weighted Average (a) Range Weighted Average (a) Discount rate 4.7% - 5.1% 4.8% 0.2% - 2.6% 1.7 % Probability of payment for unachieved milestones 100% - 100% 100% 89% - 100% 90 % Probability of payment for royalties by indication (b) 56% - 100% 99% 56% - 100% 96 % Projected year of payments 2023 - 2034 2028 2022 - 2034 2027 (a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities. (b) Excluding approved indications, the estimated probability of payment was 56% at December 31, 2022 and ranged from 56% to 89% at December 31, 2021.	[1],[2]
Summary of changes in fair value of Level 3 inputs	The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 inputs: years ended December 31 (in millions) 2022 2021 2020 Beginning balance $ 14,887 $ 12,997 $ 7,340 Additions (a) 32 — 225 Change in fair value recognized in net earnings 2,761 2,679 5,753 Payments (1,296) (789) (321) Ending balance $ 16,384 $ 14,887 $ 12,997 (a) Additions during the year ended December 31, 2022, represent contingent consideration liabilities assumed in the DJS acquisition. Additions during the year ended December 31, 2020, represent contingent consideration liabilities assumed in the Allergan and Luminera acquisitions (see Note 5).
Schedule of book values, approximate fair values and bases used to measure certain financial instruments	The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2022 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair values Quoted prices in active markets for identical assets Significant other observable inputs Significant unobservable inputs Liabilities Short-term borrowings $ 1 $ 1 $ — $ 1 $ — Current portion of long-term debt and finance lease obligations, excluding fair value hedges 4,152 4,121 3,930 191 — Long-term debt and finance lease obligations, excluding fair value hedges 59,463 54,073 53,365 708 — Total liabilities $ 63,616 $ 58,195 $ 57,295 $ 900 $ — The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2021 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair values Quoted prices in active markets for identical assets Significant other observable inputs Significant unobservable inputs Liabilities Short-term borrowings $ 14 $ 14 $ — $ 14 $ — Current portion of long-term debt and finance lease obligations, excluding fair value hedges $ 12,455 $ 11,830 $ 11,329 $ 501 $ — Long-term debt and finance lease obligations, excluding fair value hedges 64,113 71,810 70,757 1,053 — Total liabilities $ 76,582 $ 83,654 $ 82,086 $ 1,568 $ —
[1]Excluding approved indications, the estimated probability of payment was 56% at December 31, 2022 and ranged from 56% to 89% at December 31, 2021.[2]Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.

Post-Employment Benefits (Table

Post-Employment Benefits (Tables)	12 Months Ended
	Dec. 31, 2022
Postemployment Benefits [Abstract]
Schedule of benefit plan information	The following table summarizes benefit plan information for the global AbbVie-sponsored defined benefit and other post-employment plans: Defined benefit plans Other post-employment plans as of and for the years ended December 31 (in millions) 2022 2021 2022 2021 Projected benefit obligations Beginning of period $ 12,006 $ 11,792 $ 850 $ 795 Service cost 454 440 51 48 Interest cost 297 237 23 19 Employee contributions 1 2 — — Amendments — — (2) — Actuarial (gain) loss (3,668) (8) (229) 10 Benefits paid (294) (281) (25) (22) Other, primarily foreign currency translation adjustments (208) (176) (1) — End of period 8,588 12,006 667 850 Fair value of plan assets Beginning of period 10,655 9,702 — — Actual return on plan assets (2,031) 1,000 — — Company contributions 357 376 25 22 Employee contributions 1 2 — — Benefits paid (294) (281) (25) (22) Other, primarily foreign currency translation adjustments (216) (144) — — End of period 8,472 10,655 — — Funded status, end of period $ (116) $ (1,351) $ (667) $ (850) Amounts recognized on the consolidated balance sheets Other assets $ 896 $ 991 $ — $ — Accounts payable and accrued liabilities (14) (13) (27) (26) Other long-term liabilities (998) (2,329) (640) (824) Net obligation $ (116) $ (1,351) $ (667) $ (850) Actuarial loss, net $ 2,365 $ 3,504 $ 205 $ 461 Prior service cost (credit) 3 5 (333) (370) Accumulated other comprehensive loss $ 2,368 $ 3,509 $ (128) $ 91
Information For Pension Plans With An Accumulated Benefit Obligation In Excess Of Plan Assets	Information For Pension Plans With An Accumulated Benefit Obligation In Excess Of Plan Assets as of December 31 (in millions) 2022 2021 Accumulated benefit obligation $ 1,211 $ 6,395 Fair value of plan assets 746 5,412
Information For Pension Plans With A Projected Benefit Obligation In Excess Of Plan Assets	Information For Pension Plans With A Projected Benefit Obligation In Excess Of Plan Assets as of December 31 (in millions) 2022 2021 Projected benefit obligation $ 5,592 $ 7,788 Fair value of plan assets 4,580 5,447
Summary of pretax gains and losses included in other comprehensive income (loss)	The following table summarizes the pre-tax losses (gains) included in other comprehensive income: years ended December 31 (in millions) 2022 2021 2020 Defined benefit plans Actuarial loss (gain) $ (925) $ (345) $ 701 Amortization of prior service cost (2) (2) (2) Amortization of actuarial loss (231) (288) (227) Foreign exchange loss (gain) and other 17 (27) 56 Total loss (gain) $ (1,141) $ (662) $ 528 Other post-employment plans Actuarial loss (gain) $ (229) $ 10 $ 40 Prior service credit (2) — (397) Amortization of prior service credit 38 39 4 Amortization of actuarial loss (26) (32) (26) Total loss (gain) $ (219) $ 17 $ (379)
Summary of net periodic benefit cost relating to the company's defined benefit and other post-employment plans	Net Periodic Benefit Cost years ended December 31 (in millions) 2022 2021 2020 Defined benefit plans Service cost $ 454 $ 440 $ 370 Interest cost 297 237 264 Expected return on plan assets (712) (663) (575) Amortization of prior service cost 2 2 2 Amortization of actuarial loss 231 288 227 Net periodic benefit cost $ 272 $ 304 $ 288 Other post-employment plans Service cost $ 51 $ 48 $ 42 Interest cost 23 19 34 Amortization of prior service credit (38) (39) (4) Amortization of actuarial loss 26 32 26 Net periodic benefit cost $ 62 $ 60 $ 98
Schedule of weighted-average assumptions used in determining benefit obligations at the measurement date	Weighted-Average Assumptions Used in Determining Benefit Obligations at the Measurement Date as of December 31 2022 2021 Defined benefit plans Discount rate 5.0 % 2.8 % Rate of compensation increases 5.5 % 5.2 % Cash balance interest crediting rate 2.7 % 2.7 % Other post-employment plans Discount rate 5.3 % 3.1 %
Schedule of weighted-average assumptions used in determining net periodic benefit cost	Weighted-Average Assumptions Used in Determining Net Periodic Benefit Cost years ended December 31 2022 2021 2020 Defined benefit plans Discount rate for determining service cost 3.0 % 2.6 % 3.1 % Discount rate for determining interest cost 2.6 % 2.2 % 3.0 % Expected long-term rate of return on plan assets 7.1 % 7.1 % 7.1 % Expected rate of change in compensation 5.2 % 4.6 % 4.6 % Cash balance interest crediting rate 2.7 % 2.8 % 2.8 % Other post-employment plans Discount rate for determining service cost 3.3 % 3.0 % 3.7 % Discount rate for determining interest cost 2.7 % 2.2 % 3.2 %
Schedule of defined benefit pension plan assets	Defined Benefit Pension Plan Assets Basis of fair value measurement as of December 31 (in millions) 2022 Quoted prices in active markets for identical assets Significant other observable inputs Significant unobservable inputs Equities U.S. large cap (a) $ 949 $ 949 $ — $ — U.S. mid cap (b) 157 157 — — International (c) 327 327 — — Fixed income securities U.S. government securities (d) 237 69 168 — Corporate debt instruments (d) 680 144 536 — Non-U.S. government securities (d) 548 402 146 — Other (d) 84 81 3 — Absolute return funds (e) 91 4 87 — Real assets 9 9 — — Other (f) 278 277 1 — Total $ 3,360 $ 2,419 $ 941 $ — Total assets measured at NAV 5,112 Fair value of plan assets $ 8,472 Basis of fair value measurement as of December 31 (in millions) 2021 Quoted prices in active markets for identical assets Significant other observable inputs Significant unobservable inputs Equities U.S. large cap (a) $ 1,428 $ 1,428 $ — $ — U.S. mid cap (b) 198 198 — — International (c) 458 458 — — Fixed income securities U.S. government securities (d) 228 95 133 — Corporate debt instruments (d) 945 179 766 — Non-U.S. government securities (d) 602 445 157 — Other (d) 273 268 5 — Absolute return funds (e) 100 5 95 — Real assets 10 10 — — Other (f) 261 216 45 — Total $ 4,503 $ 3,302 $ 1,201 $ — Total assets measured at NAV 6,152 Fair value of plan assets $ 10,655 (a) A mix of index funds and actively managed equity accounts that are benchmarked to various large cap indices. (b) A mix of index funds and actively managed equity accounts that are benchmarked to various mid cap indices. (c) A mix of index funds and actively managed equity accounts that are benchmarked to various non-U.S. equity indices in both developed and emerging markets. (d) Securities held by actively managed accounts, index funds and mutual funds. (e) Primarily funds having global mandates with the flexibility to allocate capital broadly across a wide range of asset classes and strategies, including but not limited to equities, fixed income, commodities, financial futures, currencies and other securities, with objectives to outperform agreed upon benchmarks of specific return and volatility targets. (f) Investments in cash and cash equivalents.
Schedule of expected benefit payments	Expected Benefit Payments The following table summarizes total benefit payments expected to be paid to plan participants including payments funded from both plan and company assets: years ending December 31 (in millions) Defined Other 2023 $ 310 $ 28 2024 333 31 2025 355 34 2026 378 37 2027 404 39 2028 to 2032 2,427 244

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Schedule of share-based compensation expense	Stock-based compensation expense is principally related to awards issued pursuant to the 2013 ISP and the Amended Plan and is summarized as follows: years ended December 31 (in millions) 2022 2021 2020 Cost of products sold $ 38 $ 46 $ 47 Research and development 232 226 247 Selling, general and administrative 401 420 459 Pre-tax compensation expense 671 692 753 Tax benefit 122 126 131 After-tax compensation expense $ 549 $ 566 $ 622
Summary of AbbVie stock option activity	The following table summarizes AbbVie stock option activity in 2022: (options in thousands, aggregate intrinsic value in millions) Options Weighted- average Weighted-average remaining Aggregate intrinsic value Outstanding at December 31, 2021 12,374 $ 81.98 4.7 $ 661 Granted 863 144.54 Exercised (3,764) 70.85 Lapsed and forfeited (153) 107.65 Outstanding at December 31, 2022 9,320 $ 91.84 4.8 $ 650 Exercisable at December 31, 2022 7,120 $ 84.54 3.7 $ 549
Summary of AbbVie RSA and RSU activity	The following table summarizes AbbVie RSU and performance share activity for 2022: (share units in thousands) Share units Weighted-average grant date fair value Outstanding at December 31, 2021 14,890 $ 94.93 Granted 5,943 138.73 Vested (6,958) 89.31 Forfeited (844) 111.45 Outstanding at December 31, 2022 13,031 $ 116.84
Summary of quarterly cash dividends	The following table summarizes quarterly cash dividends declared during 2022, 2021 and 2020: 2022 2021 2020 Date Declared Payment Date Dividend Per Share Date Declared Payment Date Dividend Per Share Date Declared Payment Date Dividend Per Share 10/28/22 02/15/23 $1.48 10/29/21 02/15/22 $1.41 10/30/20 02/16/21 $1.30 09/09/22 11/15/22 $1.41 09/10/21 11/15/21 $1.30 09/11/20 11/16/20 $1.18 06/23/22 08/15/22 $1.41 06/17/21 08/16/21 $1.30 06/17/20 08/14/20 $1.18 02/17/22 05/16/22 $1.41 02/18/21 05/14/21 $1.30 02/20/20 05/15/20 $1.18
Summary of changes in each component of accumulated other comprehensive loss, net of tax	The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for 2022, 2021 and 2020: (in millions) (brackets denote losses) Foreign currency translation adjustments Net investment hedging activities Pension Cash flow hedging activities Total Balance as of December 31, 2019 $ (928) $ 9 $ (2,965) $ 288 $ (3,596) Other comprehensive income (loss) before reclassifications 1,511 (785) (300) (108) 318 Net losses (gains) reclassified from accumulated other comprehensive loss — (14) 198 (23) 161 Net current-period other comprehensive income (loss) 1,511 (799) (102) (131) 479 Balance as of December 31, 2020 583 (790) (3,067) 157 (3,117) Other comprehensive income (loss) before reclassifications (1,153) 720 298 76 (59) Net losses (gains) reclassified from accumulated other comprehensive loss — (21) 223 75 277 Net current-period other comprehensive income (loss) (1,153) 699 521 151 218 Balance as of December 31, 2021 (570) (91) (2,546) 308 (2,899) Other comprehensive income (loss) before reclassifications (943) 629 915 91 692 Net losses (gains) reclassified from accumulated other comprehensive loss — (74) 173 (91) 8 Net current-period other comprehensive income (loss) (943) 555 1,088 — 700 Balance as of December 31, 2022 $ (1,513) $ 464 $ (1,458) $ 308 $ (2,199)
Schedule of the impact of significant amounts reclassified out of each component of accumulated other comprehensive loss	The table below presents the impact on AbbVie's consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss: years ended December 31 (in millions) (brackets denote gains) 2022 2021 2020 Net investment hedging activities Gains on derivative amount excluded from effectiveness testing (a) $ (94) $ (26) $ (18) Tax expense 20 5 4 Total reclassifications, net of tax $ (74) $ (21) $ (14) Pension and post-employment benefits Amortization of actuarial losses and other (b) $ 221 $ 283 $ 251 Tax benefit (48) (60) (53) Total reclassifications, net of tax $ 173 $ 223 $ 198 Cash flow hedging activities Losses (gains) on foreign currency forward exchange contracts (c) $ (82) $ 87 $ (23) Gains on treasury rate lock agreements (a) (23) (24) (24) Losses on interest rate swap contracts (a) 1 24 17 Tax expense (benefit) 13 (12) 7 Total reclassifications, net of tax $ (91) $ 75 $ (23) (a) Amounts are included in interest expense, net (see Note 11). (b) Amounts are included in the computation of net periodic benefit cost (see Note 12). (c) Amounts are included in cost of products sold (see Note 11).

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of earnings before income tax expense	Earnings Before Income Tax Expense years ended December 31 (in millions) 2022 2021 2020 Domestic $ (4,608) $ (1,644) $ (4,467) Foreign 18,085 14,633 7,865 Total earnings before income tax expense $ 13,477 $ 12,989 $ 3,398
Schedule of income tax expense	Income Tax Expense years ended December 31 (in millions) 2022 2021 2020 Current Domestic $ 2,647 $ 1,987 $ 907 Foreign 916 351 194 Total current taxes $ 3,563 $ 2,338 $ 1,101 Deferred Domestic $ (1,512) $ (839) $ (58) Foreign (419) (59) (2,267) Total deferred taxes $ (1,931) $ (898) $ (2,325) Total income tax expense (benefit) $ 1,632 $ 1,440 $ (1,224)
Summary of effective tax rate reconciliation	Effective Tax Rate Reconciliation years ended December 31 2022 2021 2020 Statutory tax rate 21.0 % 21.0 % 21.0 % Effect of foreign operations (4.4) (5.4) 2.4 U.S. tax credits (2.8) (2.8) (10.6) Impacts related to U.S. tax reform — — (1.1) Non-deductible expenses 0.6 0.3 7.2 Tax law changes and related restructuring (2.4) (2.0) (48.5) Tax audits and settlements 0.9 (0.4) (5.1) All other, net (0.8) 0.4 (1.3) Effective tax rate 12.1 % 11.1 % (36.0) %
Schedule of deferred tax assets and liabilities	Deferred Tax Assets and Liabilities as of December 31 (in millions) 2022 2021 Deferred tax assets Compensation and employee benefits $ 497 $ 937 Accruals and reserves 1,023 667 Chargebacks and rebates 991 837 Advance payments 547 809 Net operating losses and other carryforwards 10,391 10,095 Other 1,710 1,234 Total deferred tax assets 15,159 14,579 Valuation allowances (9,627) (9,391) Total net deferred tax assets 5,532 5,188 Deferred tax liabilities Excess of book basis over tax basis of intangible assets (3,590) (4,711) Excess of book basis over tax basis in investments (340) (308) Other (772) (904) Total deferred tax liabilities (4,702) (5,923) Net deferred tax assets (liabilities) $ 830 $ (735)
Schedule of unrecognized tax benefits	Unrecognized Tax Benefits years ended December 31 (in millions) 2022 2021 2020 Beginning balance $ 5,489 $ 5,264 $ 2,661 Increase due to acquisition — — 2,674 Increase due to current year tax positions 88 208 91 Increase due to prior year tax positions 243 137 59 Decrease due to prior year tax positions (33) (62) (7) Settlements (7) (24) (141) Lapse of statutes of limitations (110) (34) (73) Ending balance $ 5,670 $ 5,489 $ 5,264

Segment and Geographic Area I_2

Segment and Geographic Area Information (Tables)	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Schedule of net revenues by product	The following tables detail AbbVie's worldwide net revenues: years ended December 31 (in millions) 2022 2021 2020 Immunology Humira United States $ 18,619 $ 17,330 $ 16,112 International 2,618 3,364 3,720 Total $ 21,237 $ 20,694 $ 19,832 Skyrizi United States $ 4,484 $ 2,486 $ 1,385 International 681 453 205 Total $ 5,165 $ 2,939 $ 1,590 Rinvoq United States $ 1,794 $ 1,271 $ 653 International 728 380 78 Total $ 2,522 $ 1,651 $ 731 Hematologic Oncology Imbruvica United States $ 3,426 $ 4,321 $ 4,305 Collaboration revenues 1,142 1,087 1,009 Total $ 4,568 $ 5,408 $ 5,314 Venclexta United States $ 1,009 $ 934 $ 804 International 1,000 886 533 Total $ 2,009 $ 1,820 $ 1,337 Aesthetics Botox Cosmetic (a) United States $ 1,654 $ 1,424 $ 687 International 961 808 425 Total $ 2,615 $ 2,232 $ 1,112 Juvederm Collection (a) United States $ 548 $ 658 $ 318 International 880 877 400 Total $ 1,428 $ 1,535 $ 718 Other Aesthetics (a) United States $ 1,122 $ 1,268 $ 666 International 168 198 94 Total $ 1,290 $ 1,466 $ 760 Neuroscience Botox Therapeutic (a) United States $ 2,255 $ 2,012 $ 1,155 International 464 439 232 Total $ 2,719 $ 2,451 $ 1,387 Vraylar (a) United States $ 2,037 $ 1,728 $ 951 International 1 — — Total $ 2,038 $ 1,728 $ 951 Duodopa United States $ 95 $ 102 $ 103 International 363 409 391 Total $ 458 $ 511 $ 494 Ubrelvy (a) United States $ 680 $ 552 $ 125 Qulipta United States $ 158 $ — $ — Other Neuroscience (a) United States $ 456 $ 667 $ 528 International 19 18 11 Total $ 475 $ 685 $ 539 years ended December 31 (in millions) 2022 2021 2020 Eye Care Lumigan/Ganfort (a) United States $ 242 $ 273 $ 165 International 272 306 213 Total $ 514 $ 579 $ 378 Alphagan/Combigan (a) United States $ 202 $ 373 $ 223 International 144 156 103 Total $ 346 $ 529 $ 326 Restasis (a) United States $ 621 $ 1,234 $ 755 International 45 56 32 Total $ 666 $ 1,290 $ 787 Other Eye Care (a) United States $ 538 $ 523 $ 305 International 637 646 388 Total $ 1,175 $ 1,169 $ 693 Other Key Products Mavyret United States $ 755 $ 754 $ 785 International 786 956 1,045 Total $ 1,541 $ 1,710 $ 1,830 Creon United States $ 1,278 $ 1,191 $ 1,114 Linzess/Constella (a) United States $ 1,003 $ 1,006 $ 649 International 32 32 18 Total $ 1,035 $ 1,038 $ 667 All other $ 4,137 $ 5,019 $ 5,119 Total net revenues $ 58,054 $ 56,197 $ 45,804 (a) Net revenues include Allergan product revenues after the acquisition closing date of May 8, 2020.
Schedule of net revenues to external customers by geographic area	Net revenues to external customers by geographic area, based on product shipment destination, were as follows: years ended December 31 (in millions) 2022 2021 2020 United States $ 45,713 $ 43,510 $ 34,879 Germany 1,340 1,223 1,049 Canada 1,159 1,397 1,159 Japan 956 1,090 1,198 China 912 857 471 France 787 936 797 Australia 508 533 527 Spain 506 519 453 United Kingdom 462 497 509 Italy 444 506 379 Brazil 430 368 406 All other countries 4,837 4,761 3,977 Total net revenues $ 58,054 $ 56,197 $ 45,804
Schedule of long-lived assets by geographic area	Long-lived assets, primarily net property and equipment, by geographic area were as follows: as of December 31 (in millions) 2022 2021 United States and Puerto Rico $ 3,243 $ 3,369 Europe 1,369 1,400 All other 323 341 Total long-lived assets $ 4,935 $ 5,110

Fourth Quarter Financial Resu_2

Fourth Quarter Financial Results (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2022
Quarterly Financial Information Disclosure [Abstract]
Schedule of fourth quarter financial results	quarter ended December 31 (in millions except per share data) 2022 Net revenues $ 15,121 Gross margin 10,951 Net earnings attributable to AbbVie Inc. 2,473 Basic earnings per share attributable to AbbVie Inc. $ 1.39 Diluted earnings per share attributable to AbbVie Inc. $ 1.38 Cash dividends declared per common share $ 1.48

Background and Basis of Prese_2

Background and Basis of Presentation (Details)	Jan. 01, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Percentage of outstanding common stock distributed to Abbott shareholders	100%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Reclassification of development milestones expense from research and development expense		$ 162	$ 178
Reclassification of development milestone expense to IPR&D and milestones expense		162	178
Advertising expenses	$ 2,000	$ 2,100	$ 1,800
Amortization period of differences between the expected and actual return on plan assets	5 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Inventories (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Finished goods	$ 1,162	$ 932
Work-in-process	1,417	1,193
Raw materials	1,000	1,003
Inventories	$ 3,579	$ 3,128

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Property and Equipment
Property and equipment, gross	$ 10,986	$ 10,727
Less accumulated depreciation	(6,051)	(5,617)
Property and equipment, net	4,935	5,110
Depreciation expense	778	803	$ 666
Land
Property and Equipment
Property and equipment, gross	286	287
Buildings
Property and Equipment
Property and equipment, gross	$ 2,737	2,791
Buildings | Minimum
Property and Equipment
Estimated useful lives	10 years
Buildings | Maximum
Property and Equipment
Estimated useful lives	50 years
Equipment
Property and Equipment
Property and equipment, gross	$ 7,107	6,850
Equipment | Minimum
Property and Equipment
Estimated useful lives	2 years
Amortization period of software costs included in equipment	3 years
Equipment | Maximum
Property and Equipment
Estimated useful lives	25 years
Amortization period of software costs included in equipment	10 years
Construction in progress
Property and Equipment
Property and equipment, gross	$ 856	$ 799

Supplemental Financial Inform_3

Supplemental Financial Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Interest Expense, Net
Interest expense	$ 2,230	$ 2,423	$ 2,454
Interest income	(186)	(39)	(174)
Interest expense, net	2,044	2,384	$ 2,280
Accounts Payable and Accrued Liabilities
Sales rebates	10,717	8,254
Dividends payable	2,680	2,543
Accounts payable	2,934	2,882
Current portion of contingent consideration liabilities	1,469	1,249
Salaries, wages and commissions	1,371	1,785
Royalty and license arrangements	412	661
Other	5,819	5,325
Accounts payable and accrued liabilities	25,402	22,699
Other Long-Term Liabilities
Contingent consideration liabilities	14,915	13,638
Liabilities for unrecognized tax benefits	6,502	5,970
Income taxes payable	2,985	3,442
Pension and other post-employment benefits	1,638	3,153
Other	4,615	2,498
Other long-term liabilities	$ 30,655	$ 28,701

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Basic EPS
Net earnings attributable to AbbVie Inc.	$ 2,473	$ 11,836	$ 11,542	$ 4,616
Earnings allocated to participating securities		54	74	60
Earnings available to common shareholders		$ 11,782	$ 11,468	$ 4,556
Weighted-average basic shares outstanding (in shares)		1,771	1,770	1,667
Basic earnings per share (in dollars per share)	$ 1.39	$ 6.65	$ 6.48	$ 2.73
Diluted EPS
Net earnings attributable to AbbVie Inc.	$ 2,473	$ 11,836	$ 11,542	$ 4,616
Earnings allocated to participating securities		54	74	60
Earnings available to common shareholders		$ 11,782	$ 11,468	$ 4,556
Weighted-average basic shares outstanding (in shares)		1,771	1,770	1,667
Effect of dilutive securities (in shares)		7	7	6
Weighted-average diluted shares outstanding (in shares)		1,778	1,777	1,673
Diluted earnings per share (in dollars per share)	$ 1.38	$ 6.63	$ 6.45	$ 2.72

Licensing, Acquisitions, and _3

Licensing, Acquisitions, and Other Arrangement- Acquisitions of DJS (Details) - USD ($) $ in Millions	1 Months Ended
	Oct. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Goodwill		$ 32,156	$ 32,379	$ 33,124
DJS Antibodies LTD
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Total consideration	$ 287
Upfront cash payment	255
Contingent consideration	32
Maximum future payments upon achievement of certain milestones	95
Intangible assets - Developed product rights	233
Intangible assets - In-process research and development	22
Deferred tax liabilities	60
Goodwill	$ 92

Licensing, Acquisitions, and _4

Licensing, Acquisitions, and Other Arrangements - Acquisition of Soliton, Inc. (Details) - USD ($) $ in Millions	1 Months Ended
	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2020
Business Acquisition
Goodwill	$ 32,379	$ 32,156	$ 33,124
Solition, Inc.
Business Acquisition
Total consideration	535
Intangible assets - Developed product rights	407
Deferred tax liabilities	63
Goodwill	$ 177

Licensing, Acquisition, and Oth

Licensing, Acquisition, and Other Arrangements - Acquisition of Luminera (Details) - USD ($) $ in Millions	1 Months Ended
	Oct. 31, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition
Goodwill		$ 32,156	$ 32,379	$ 33,124
Luminera
Business Acquisition
Total consideration	$ 186
Upfront cash payment	122
Contingent consideration	64
Maximum future payments upon achievement of certain milestones	90
Intangible assets - Developed product rights	127
Intangible assets - In-process research and development	33
Goodwill	$ 12

Licensing, Acquisitions, and _5

Licensing, Acquisitions, and Other Arrangements - Acquisition of Allergan (Details) - USD ($) $ / shares in Units, $ in Millions			6 Months Ended	8 Months Ended	12 Months Ended
		May 08, 2020	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition
Closing price of AbbVie common stock (in dollars per share)	[1]	$ 83.96
Goodwill measurement period adjustments	[2]					$ 564
Amortization of intangible assets					$ 7,689	7,718	$ 5,805
Fair Value of Assets Acquired and Liabilities Assumed
Goodwill				$ 33,124	$ 32,156	32,379	33,124
Allergan plc
Business Acquisition
Cash per share received by Allergan shareholders (in dollars per share)	[3]	$ 120.30
Amount of AbbVie stock per share received by Allergan shareholders (in shares)	[1]	0.8660
Allergan ordinary shares outstanding at closing (in shares)	[3]	330,000,000
Shares of AbbVie's common stock issued to Allergan shareholders (in shares)	[1]	286,000,000
Stock options issued to Allergan's equity award holders (in shares)	[4]	11,200,000
RSUs issued to Allergan equity award holders	[4]	8,200,000
Other net measurement period adjustments to identifiable net assets			$ 2
Goodwill measurement period adjustments			564
Fair value step-up adjustment to inventories		$ 1,200
Weighted average useful life of acquired intangible assets				12 years
Fair value of purchase price adjustment to long-term debt		1,300
Net revenues attributable to Allergan from acquisition date				$ 10,300
Operating losses attributable to Allergan from acquisition date				1,100
Amortization of intangible assets				4,000
Inventory fair value step-up amortization				$ 1,200
Consideration Transferred
Cash consideration paid	[3]	39,675
Fair value of AbbVie common stock issued to Allergan shareholders	[1]	23,979
Fair value of AbbVie equity stock issued to Allergan equity award holders	[4]	430
Total consideration		64,084
Fair Value of Assets Acquired and Liabilities Assumed
Cash and equivalents		1,537
Short-term investments		1,421
Accounts receivable		2,374
Inventories		2,340
Prepaid expenses and other current assets		1,982
Investments		137
Property and equipment		2,129
Intangible assets - Developed product rights		68,190
Intangible assets - In-process research and development		1,600
Other noncurrent assets		1,395
Short-term borrowings		(60)
Current portion of long-term debt and finance lease obligations		(1,899)
Accounts payable and accrued liabilities		(5,852)
Long-term debt and finance lease obligations		(18,937)
Deferred income taxes		(3,940)
Other long-term liabilities		(4,765)
Total identifiable net assets		47,652
Goodwill		16,432
Total assets acquired and liabilities assumed		$ 64,084
Pro Forma Information
Net revenues							50,521
Net earnings							6,746
Allergan plc | Developed product rights intangible assets
Business Acquisition
Intangible assets measurement period adjustments			710
Allergan plc | IPR&D intangible assets
Business Acquisition
Deferred income tax measurement period adjustment			$ (148)
Allergan plc | Selling, general and administrative
Business Acquisition
Acquisition-related expenses						$ (401)	$ 781
[1]Represents the acquisition date fair value of 286 million shares of AbbVie common stock issued to Allergan shareholders based on the exchange ratio of 0.8660 AbbVie shares for each outstanding Allergan ordinary share at the May 8, 2020, closing price of $83.96 per share.[2]Measurement period adjustments recorded in 2021 related to the acquisition of Allergan (see Note 5).[3]Represents cash consideration transferred of $120.30 per outstanding Allergan ordinary share based on 330 million Allergan ordinary shares outstanding at closing.[4]Represents the pre-acquisition service portion of the fair value of 11 million AbbVie stock options and 8 million RSUs issued to Allergan equity award holders.

Licensing, Acquisitions, and _6

Licensing, Acquisitions, and Other Arrangements - Other Licensing & Acquisitions Activity (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended					12 Months Ended
	Sep. 30, 2020	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Feb. 28, 2022	Jun. 30, 2020
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Cash outflows related to other acquisitions and investments							$ 539	$ 1,377	$ 1,350
Acquired IPR&D and milestones							697	1,124	1,376
Gain (Loss) on Disposition of Other Assets							172	68	0
Other operating expense, net							56	432	0
Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Research and Development Milestone Expenses							252	162	178
Syndesi Therapeutics SA
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Acquired IPR&D and milestones			$ 130
Syndesi Therapeutics SA | Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Potential additional milestone payments										$ 870
Juvise Pharmaceuticals
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Proceeds from Sale of Other Assets		$ 215
TeneoOne | Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Acquired IPR&D and milestones					$ 400
TeneoOne | Maximum | Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Potential additional milestone payments					250
REGENXBIO Inc. | Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Acquired IPR&D and milestones				$ 370
REGENXBIO Inc. | Maximum | Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Potential additional milestone payments					1,400
I-Mab Biopharma | Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Acquired IPR&D and milestones						$ 200
I-Mab Biopharma | Maximum | Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Potential additional milestone payments	$ 1,700
Genmab A/S | Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Acquired IPR&D and milestones									750
Genmab A/S | Maximum | Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Potential additional milestone payments											$ 3,200
Other individually insignificant arrangements | Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Acquired IPR&D and milestones							315	$ 192	$ 248
Other individually insignificant arrangements | Maximum | Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Potential additional milestone payments							$ 7,500
Calico Life Sciences LLC | Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Additional contribution to collaboration					500
Additional contribution to collaboration by partner					500
Other operating expense, net					$ (500)
Other operating income | Juvise Pharmaceuticals
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Gain (Loss) on Disposition of Other Assets		$ 172
Acquired IPR&D and milestones | I-Mab Biopharma | Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Upfront payment	180
Milestone payment	$ 20

Collaborations (Details)

Collaborations (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangements and Non-collaborative Arrangement Transactions
AbbVie's receivable from Janssen	$ 11,254	$ 9,977
AbbVie's payable to Janssen	$ 25,402	22,699
Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Share of collaboration development costs responsible by the entity (as a percent)	40%
Janssen Biotech, Inc | Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Milestone payments	$ 200
Share of collaboration development costs responsible by Janssen (as a percent)	60%
Global - AbbVie's share of other costs (included in respective line items)	$ 268	304	$ 295
AbbVie's receivable from Janssen	295	294
AbbVie's payable to Janssen	379	509
Janssen Biotech, Inc | Collaborative arrangement | United States
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold)	1,607	2,018	2,012
Janssen Biotech, Inc | Collaborative arrangement | International
Collaborative Arrangements and Non-collaborative Arrangement Transactions
International - AbbVie's share of profits (included in net revenues)	1,142	1,087	1,009
Genentech, Inc. | Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold)	778	703	533
AbbVie's share of development costs (included in R&D)	121	140	129
Genentech, Inc. | Collaborative arrangement | United States
Collaborative Arrangements and Non-collaborative Arrangement Transactions
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A)	$ 37	$ 40	$ 46

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill (Details) - USD ($)		12 Months Ended
		Dec. 31, 2022		Dec. 31, 2021
Changes in the carrying amount of goodwill
Balance at the beginning of the period		$ 32,379,000,000		$ 33,124,000,000
Additions		92,000,000	[1]	177,000,000	[2]
Goodwill measurement period adjustments	[3]			(564,000,000)
Foreign currency translation adjustments and other		(315,000,000)		(358,000,000)
Balance at the end of the period		32,156,000,000		32,379,000,000
Accumulated goodwill impairment losses
Accumulated goodwill impairment losses		$ 0		$ 0
[1]Goodwill additions related to the acquisition of DJS in the fourth quarter of 2022 (see Note 5).[2]Goodwill additions related to the acquisition of Soliton in the fourth quarter of 2021 (see Note 5).[3]Measurement period adjustments recorded in 2021 related to the acquisition of Allergan (see Note 5).

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Summary of Intangible Assets (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Definite-lived intangible assets
Gross carrying amount	$ 96,172	$ 97,432
Accumulated amortization	(29,645)	(22,151)
Net carrying amount	66,527	75,281
Indefinite-lived intangible assets	912	670
Total intangible assets gross carrying amount	97,084	98,102
Total intangible assets, net	67,439	75,951
Developed product rights
Definite-lived intangible assets
Gross carrying amount	87,698	88,945
Accumulated amortization	(25,003)	(18,463)
Net carrying amount	62,695	70,482
License agreements
Definite-lived intangible assets
Gross carrying amount	8,474	8,487
Accumulated amortization	(4,642)	(3,688)
Net carrying amount	$ 3,832	$ 4,799

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Definite-Lived Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Definite-lived intangible assets
Impairment of intangible assets	$ 770	$ 770	$ 50	$ 0
Amortization of intangible assets		7,689	$ 7,718	$ 5,805
Anticipated annual amortization expense
2023		7,700
2024		7,900
2025		8,000
2026		7,300
2027		$ 5,800
Minimum
Definite-lived intangible assets
Amortization period		1 year
Maximum
Definite-lived intangible assets
Amortization period		16 years
Weighted Average | Developed product rights
Definite-lived intangible assets
Amortization period		12 years
Weighted Average | License agreements
Definite-lived intangible assets
Amortization period		11 years

Integration and Restructuring_3

Integration and Restructuring Plans (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Restructuring charges
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of products sold, Research and development, Selling, general and administrative	Cost of products sold, Research and development, Selling, general and administrative	Cost of products sold, Research and development, Selling, general and administrative
Allergan integration plan
Restructuring charges
Restructuring and Related Cost, Cost Incurred to Date	$ 2,300
Allergan integration plan | Employee Severance
Restructuring charges
Charges associated with integration or restructuring plans	(8)	$ 69	$ 696
Restructuring reserve rollforward
Accrued balance beginning of the period	222	367
Integration and restructuring charges	(8)	65	594
Payments and other adjustments	(116)	(210)	(227)
Accrued balance end of the period	98	222	367
Allergan integration plan | Employee Severance | Cost of products sold
Restructuring charges
Charges associated with integration or restructuring plans	(4)	5	109
Allergan integration plan | Employee Severance | Research and development
Restructuring charges
Charges associated with integration or restructuring plans	0	0	199
Allergan integration plan | Employee Severance | Selling, general and administrative
Restructuring charges
Charges associated with integration or restructuring plans	(4)	64	388
Allergan integration plan | Other restructuring
Restructuring charges
Charges associated with integration or restructuring plans	547	518	435
Restructuring reserve rollforward
Accrued balance beginning of the period	33	20
Integration and restructuring charges	385	461	435
Payments and other adjustments	(409)	(448)	(415)
Accrued balance end of the period	9	33	20
Allergan integration plan | Other restructuring | Cost of products sold
Restructuring charges
Charges associated with integration or restructuring plans	121	127	21
Allergan integration plan | Other restructuring | Research and development
Restructuring charges
Charges associated with integration or restructuring plans	23	102	177
Allergan integration plan | Other restructuring | Selling, general and administrative
Restructuring charges
Charges associated with integration or restructuring plans	403	289	237
Other restructuring
Restructuring reserve rollforward
Accrued balance beginning of the period	33	90	140
Integration and restructuring charges	193	54	58
Payments and other adjustments	(50)	(111)	(108)
Accrued balance end of the period	176	33	90
Other restructuring | Employee Severance
Restructuring charges
Charges associated with integration or restructuring plans	$ 241	$ 59	$ 60

Leases - Balance Sheet Disclosu

Leases - Balance Sheet Disclosure (Details) - USD ($) $ in Millions	Dec. 31, 2022		Dec. 31, 2021
Assets
Operating lease assets	$ 737		$ 762
Finance lease assets	25		33
Total lease assets	$ 762		$ 795
Operating Lease assets balance sheet caption	Other assets		Other assets
Finance lease assets balance sheet caption	Property and equipment, net		Property and equipment, net
Liabilities
Current operating lease liabilities	$ 166		$ 178
Noncurrent operating lease liabilities	754		713
Current finance lease liabilities	17		9
Noncurrent finance lease liabilities	17		25
Total lease liabilities	$ 954	[1]	$ 925
Current operating lease liabilities balance sheet caption	Accounts payable and accrued liabilities		Accounts payable and accrued liabilities
Noncurrent operating lease liabilities balance sheet caption	Other long-term liabilities		Other long-term liabilities
Current finance lease liabilities balance sheet caption	Current portion of long-term debt and finance lease obligations		Current portion of long-term debt and finance lease obligations
Noncurrent finance lease liabilities balance sheet caption	Long-term debt and finance lease obligations		Long-term debt and finance lease obligations
[1]Lease payments recognized as part of lease liabilities for optional renewal periods are insignificant.

Leases - Cost (Details)

Leases - Cost (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating lease cost		$ 201	$ 226	$ 192
Short-term lease cost		67	56	59
Variable lease cost		71	71	60
Total lease cost		$ 339	$ 353	$ 311
Operating Lease, Impairment Loss	$ 69
Property and Equipment
Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]		Selling, general and administrative
Leasehold Improvements
Property and Equipment
Impairment, Long-Lived Asset, Held-for-Use	$ 37

Leases - Weighted-Average Remai

Leases - Weighted-Average Remaining Lease Term and Discount Rate (Details)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Weighted-average remaining lease term for operating leases	8 years	7 years	8 years
Weighted-average remaining lease term for finance leases	2 years	3 years	3 years
Weighted-average discount rate for operating leases	2.60%	2.40%	2.50%
Weighted-average discount rate for finance leases	1.50%	1.10%	1.40%

Leases - Cash Flow Disclosure (

Leases - Cash Flow Disclosure (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition
Operating cash flows from operating leases	$ 212	$ 236	$ 185
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 235	$ 66	692
Allergan plc
Business Acquisition
Right-of-use assets obtained in exchange for new operating lease liabilities			$ 453

Leases - Maturities of Lease Li

Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Millions		Dec. 31, 2022		Dec. 31, 2021
Operating leases
2023		$ 185
2024		152
2025		130
2026		113
2027		90
Thereafter		361
Total lease payments		1,031
Less: Interest		111
Present value of lease liabilities		920
Finance leases
2023		17
2024		7
2025		5
2026		6
2027		0
Thereafter		0
Total lease payments		35
Less: Interest		1
Present value of lease liabilities		34
Total
2023	[1]	202
2024	[1]	159
2025	[1]	135
2026	[1]	119
2027	[1]	90
Thereafter	[1]	361
Total lease payments	[1]	1,066
Less: Interest	[1]	112
Present value of lease liabilities		$ 954	[1]	$ 925
[1]Lease payments recognized as part of lease liabilities for optional renewal periods are insignificant.

Debt, Credit Facilities and C_3

Debt, Credit Facilities and Commitments and Contingencies - Summary of Long-Term Debt (Details) $ in Millions		Dec. 31, 2022 USD ($)	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 USD ($)
Long-term debt
Fair value hedges		$ 346		$ (102)
Unamortized bond discounts		116		130
Unamortized deferred financing costs		(222)		(251)
Unamortized bond premiums	[1]	793		954
Total long-term debt and finance lease obligations		63,270		76,670
Current portion		4,135		12,481
Noncurrent portion		59,135		64,189
Aggregate notes due 2022
Long-term debt
Long-term debt and lease obligations, gross		$ 0		$ 12,428
Aggregate notes due 2022 | Minimum
Long-term debt
Weighted-average effective interest rate	[2]	1.92%	1.92%	0.99%
Stated interest rate (as a percent)		2.30%	2.30%
Aggregate notes due 2022 | Maximum
Long-term debt
Weighted-average effective interest rate	[2]	3.28%	3.28%	3.45%
Stated interest rate (as a percent)		3.45%	3.45%
Other
Long-term debt
Long-term debt and lease obligations, gross		$ 33		$ 33
Senior notes
Long-term debt
Weighted-average effective interest rate	[2]	2.91%	2.91%	2.91%
Long-term debt and lease obligations, gross		$ 1,000		$ 1,000
Senior notes | 3.75% notes due 2023
Long-term debt
Weighted-average effective interest rate	[2]	3.84%	3.84%	3.84%
Long-term debt and lease obligations, gross		$ 1,250		$ 1,250
Stated interest rate (as a percent)		3.75%	3.75%
Senior notes | 2.85% notes due 2023
Long-term debt
Stated interest rate (as a percent)		2.85%	2.85%
Senior notes | 1.50% notes due 2023 (€500 principal)
Long-term debt
Weighted-average effective interest rate	[2]	0.49%	0.49%	0.49%
Long-term debt and lease obligations, gross		$ 532		$ 567
Stated interest rate (as a percent)		1.50%	1.50%
Aggregate principal amount of debt | €			€ 500,000,000
Senior notes | 2.80% notes due 2023
Long-term debt
Weighted-average effective interest rate	[2]	2.13%	2.13%	2.13%
Long-term debt and lease obligations, gross		$ 350		$ 350
Stated interest rate (as a percent)		2.80%	2.80%
Senior notes | 2.60% notes due 2024
Long-term debt
Weighted-average effective interest rate	[2]	2.69%	2.69%	2.69%
Long-term debt and lease obligations, gross		$ 3,750		$ 3,750
Stated interest rate (as a percent)		2.60%	2.60%
Senior notes | 1.375% notes due 2024 (€1,450 principal)
Long-term debt
Weighted-average effective interest rate	[2]	1.46%	1.46%	1.46%
Long-term debt and lease obligations, gross		$ 1,543		$ 1,643
Stated interest rate (as a percent)		1.375%	1.375%
Aggregate principal amount of debt | €			€ 1,450,000,000
Senior notes | 3.85% notes due 2024
Long-term debt
Weighted-average effective interest rate	[2]	2.07%	2.07%	2.07%
Long-term debt and lease obligations, gross		$ 1,032		$ 1,032
Stated interest rate (as a percent)		3.85%	3.85%
Senior notes | 1.25% notes due 2024 (€700 principal)
Long-term debt
Weighted-average effective interest rate	[2]	0.65%	0.65%	0.65%
Long-term debt and lease obligations, gross		$ 745		$ 793
Stated interest rate (as a percent)		1.25%	1.25%
Aggregate principal amount of debt | €			€ 700,000,000
Senior notes | 3.60% notes due 2025
Long-term debt
Weighted-average effective interest rate	[2]	3.66%	3.66%	3.66%
Long-term debt and lease obligations, gross		$ 3,750		$ 3,750
Stated interest rate (as a percent)		3.60%	3.60%
Senior notes | 3.80% notes due 2025
Long-term debt
Weighted-average effective interest rate	[2]	2.09%	2.09%	2.09%
Long-term debt and lease obligations, gross		$ 3,021		$ 3,021
Stated interest rate (as a percent)		3.80%	3.80%
Senior notes | 2.95% notes due 2026
Long-term debt
Weighted-average effective interest rate	[2]	3.02%	3.02%	3.02%
Long-term debt and lease obligations, gross		$ 4,000		$ 4,000
Stated interest rate (as a percent)		2.95%	2.95%
Senior notes | 3.20% notes due 2026
Long-term debt
Weighted-average effective interest rate	[2]	3.28%	3.28%	3.28%
Long-term debt and lease obligations, gross		$ 2,000		$ 2,000
Stated interest rate (as a percent)		3.20%	3.20%
Senior notes | 0.75% notes due 2027 (€750 principal)
Long-term debt
Weighted-average effective interest rate	[2]	0.86%	0.86%	0.86%
Long-term debt and lease obligations, gross		$ 798		$ 850
Stated interest rate (as a percent)		0.75%	0.75%
Aggregate principal amount of debt | €			€ 750,000,000
Senior notes | 4.25% notes due 2028
Long-term debt
Weighted-average effective interest rate	[2]	4.38%	4.38%	4.38%
Long-term debt and lease obligations, gross		$ 1,750		$ 1,750
Stated interest rate (as a percent)		4.25%	4.25%
Senior notes | 2.125% notes due 2028 (€750 principal)
Long-term debt
Weighted-average effective interest rate	[2]	2.18%	2.18%	2.18%
Long-term debt and lease obligations, gross		$ 798		$ 850
Stated interest rate (as a percent)		2.125%	2.125%
Aggregate principal amount of debt | €			€ 750,000,000
Senior notes | 2.625% notes due 2028 (€500 principal)
Long-term debt
Weighted-average effective interest rate	[2]	1.20%	1.20%	1.20%
Long-term debt and lease obligations, gross		$ 532		$ 567
Stated interest rate (as a percent)		2.625%	2.625%
Aggregate principal amount of debt | €			€ 500,000,000
Senior notes | 3.20% notes due 2029
Long-term debt
Weighted-average effective interest rate	[2]	3.25%	3.25%	3.25%
Long-term debt and lease obligations, gross		$ 5,500		$ 5,500
Stated interest rate (as a percent)		3.20%	3.20%
Senior notes | 2.125% notes due 2029 (€550 principal)
Long-term debt
Weighted-average effective interest rate	[2]	1.19%	1.19%	1.19%
Long-term debt and lease obligations, gross		$ 585		$ 623
Stated interest rate (as a percent)		2.125%	2.125%
Aggregate principal amount of debt | €			€ 550,000,000
Senior notes | 1.25% notes due 2031 (€650 principal)
Long-term debt
Weighted-average effective interest rate	[2]	1.30%	1.30%	1.30%
Long-term debt and lease obligations, gross		$ 691		$ 737
Stated interest rate (as a percent)		1.25%	1.25%
Aggregate principal amount of debt | €			€ 650,000,000
Senior notes | 4.55% notes due 2035
Long-term debt
Weighted-average effective interest rate	[2]	3.52%	3.52%	3.52%
Long-term debt and lease obligations, gross		$ 1,789		$ 1,789
Stated interest rate (as a percent)		4.55%	4.55%
Senior notes | 4.50% notes due 2035
Long-term debt
Weighted-average effective interest rate	[2]	4.58%	4.58%	4.58%
Long-term debt and lease obligations, gross		$ 2,500		$ 2,500
Stated interest rate (as a percent)		4.50%	4.50%
Senior notes | 4.30% notes due 2036
Long-term debt
Weighted-average effective interest rate	[2]	4.37%	4.37%	4.37%
Long-term debt and lease obligations, gross		$ 1,000		$ 1,000
Stated interest rate (as a percent)		4.30%	4.30%
Senior notes | 4.05% notes due 2039
Long-term debt
Weighted-average effective interest rate	[2]	4.11%	4.11%	4.11%
Long-term debt and lease obligations, gross		$ 4,000		$ 4,000
Stated interest rate (as a percent)		4.05%	4.05%
Senior notes | 4.40% notes due 2042
Long-term debt
Weighted-average effective interest rate	[2]	4.46%	4.46%	4.46%
Long-term debt and lease obligations, gross		$ 2,600		$ 2,600
Stated interest rate (as a percent)		4.40%	4.40%
Senior notes | 4.625% notes due 2042
Long-term debt
Weighted-average effective interest rate	[2]	4%	4%	4%
Long-term debt and lease obligations, gross		$ 457		$ 457
Stated interest rate (as a percent)		4.625%	4.625%
Senior notes | 4.85% notes due 2044
Long-term debt
Weighted-average effective interest rate	[2]	4.11%	4.11%	4.11%
Long-term debt and lease obligations, gross		$ 1,074		$ 1,074
Stated interest rate (as a percent)		4.85%	4.85%
Senior notes | 4.70% notes due 2045
Long-term debt
Weighted-average effective interest rate	[2]	4.73%	4.73%	4.73%
Long-term debt and lease obligations, gross		$ 2,700		$ 2,700
Stated interest rate (as a percent)		4.70%	4.70%
Senior notes | 4.75% notes due 2045
Long-term debt
Weighted-average effective interest rate	[2]	4.20%	4.20%	4.20%
Long-term debt and lease obligations, gross		$ 881		$ 881
Stated interest rate (as a percent)		4.75%	4.75%
Senior notes | 4.45% notes due 2046
Long-term debt
Weighted-average effective interest rate	[2]	4.50%	4.50%	4.50%
Long-term debt and lease obligations, gross		$ 2,000		$ 2,000
Stated interest rate (as a percent)		4.45%	4.45%
Senior notes | 4.875% notes due 2048
Long-term debt
Weighted-average effective interest rate	[2]	4.94%	4.94%	4.94%
Long-term debt and lease obligations, gross		$ 1,750		$ 1,750
Stated interest rate (as a percent)		4.875%	4.875%
Senior notes | 4.25% notes due 2049
Long-term debt
Weighted-average effective interest rate	[2]	4.29%	4.29%	4.29%
Long-term debt and lease obligations, gross		$ 5,750		$ 5,750
Stated interest rate (as a percent)		4.25%	4.25%
Term loan facilities | Floating rate term loans due 2023
Long-term debt
Weighted-average effective interest rate	[2]	2.45%	2.45%	0.81%
Long-term debt and lease obligations, gross		$ 1,000		$ 1,000
Term loan facilities | Floating rate term loans due 2025
Long-term debt
Weighted-average effective interest rate	[2]	1.39%	1.39%	1.36%
Long-term debt and lease obligations, gross		$ 0		$ 2,000
Term loan facilities | Floating rate term loans due 2025
Long-term debt
Weighted-average effective interest rate	[2]	2.82%	2.82%	0%
Long-term debt and lease obligations, gross		$ 2,000		$ 0
[1]Represents unamortized purchase price adjustments of Allergan debt.[2]Excludes the effect of any related interest rate swaps.

Debt, Credit Facilities and C_4

Debt, Credit Facilities and Commitments and Contingencies - Summary of Maturities of Long-Term Debt (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Long-term Debt, Fiscal Year Maturity [Abstract]
2023	$ 4,132
2024	7,070
2025	8,771
2026	6,000
2027	798
Thereafter	36,357
Long-term debt obligations, gross	63,128
Fair value hedges, unamortized bond premiums and discounts, deferred financing costs and finance lease obligations	142
Aggregate principal amount outstanding	$ 63,270	$ 76,670

Debt, Credit Facilities and C_5

Debt, Credit Facilities and Commitments and Contingencies - Long-Term Debt - Additional Information (Details) € in Millions, $ in Millions	2 Months Ended	12 Months Ended
	Feb. 17, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€)
Long-term debt
Aggregate principal amount outstanding		$ 63,270	$ 76,670
Long-term debt obligations, gross		63,128
Senior notes | Senior Notes 3.450 Percent Due 2022
Long-term debt
Repayments of long-term debt		$ (2,900)
Stated interest rate (as a percent)		3.45%
Senior notes | Senior Notes 3.25 Percent Due 2022
Long-term debt
Repayments of long-term debt		$ (1,700)
Stated interest rate (as a percent)		3.25%
Senior notes | 3.20% notes due 2022
Long-term debt
Repayments of long-term debt		$ (1,000)
Stated interest rate (as a percent)		3.20%
Senior notes | 2.90% notes due 2022
Long-term debt
Repayments of long-term debt		$ (3,100)
Stated interest rate (as a percent)		2.90%
Senior notes | Senior Notes 2.3 Percent Due 2022
Long-term debt
Repayments of long-term debt		$ (3,000)
Stated interest rate (as a percent)		2.30%
Senior notes | Floating rate notes due 2022
Long-term debt
Repayments of long-term debt		$ (750)
Senior notes | 2.30% Senior Notes due 2021
Long-term debt
Repayments of long-term debt			$ 1,800
Stated interest rate (as a percent)			2.30%
Senior notes | 0.500% Senior Euro Notes Due 2021
Long-term debt
Repayments of long-term debt | €				€ 750
Stated interest rate (as a percent)			0.50%
Senior notes | Senior Notes Due 2021 At 5.000 Percent
Long-term debt
Repayments of long-term debt			$ (1,200)
Stated interest rate (as a percent)			5%
Senior notes | Senior Notes Due in 2021 At 3.375 Percent
Long-term debt
Repayments of long-term debt			$ 1,300
Stated interest rate (as a percent)			3.375%
Senior notes | Senior Notes Due in 2021 At 2.15 Percent
Long-term debt
Repayments of long-term debt			$ 1,800
Stated interest rate (as a percent)			2.15%
Senior notes | Senior Notes Due in May 2021 At Floating Rates
Long-term debt
Repayments of long-term debt			$ 1,500
Term loan facilities | Floating rate term loans due 2025
Long-term debt
Repayments of long-term debt		2,000
Long-term debt obligations, gross		2,000
Term loan facilities | Floating rate term loans due 2025
Long-term debt
Long-term debt obligations, gross		$ 2,000
Term loan facilities | Floating rate notes due 2023
Long-term debt
Long-term debt obligations, gross			1,000
Term loan facilities | Floating rate notes due 2023 | Subsequent event
Long-term debt
Repayments of long-term debt	$ 1,000
Term loan facilities | Floating rate term loans due 2023
Long-term debt
Repayments of long-term debt			1,000
Long-term debt obligations, gross			$ 1,000

Debt, Credit Facilities and C_6

Debt, Credit Facilities and Commitments and Contingencies - Short-Term Borrowings (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Short-term borrowings
Short-term borrowings	$ 1	$ 14
Weighted-average interest rate on commercial paper (as a percent)			1.80%
Revolving credit facility, maximum borrowing capacity	$ 4,000
Revolving credit facility
Short-term borrowings
Revolving credit facility term	5 years
Revolving credit facility outstanding	$ 0	0
Commercial Paper
Short-term borrowings
Short-term borrowings	$ 0	$ 0

Financial Instruments and Fai_3

Financial Instruments and Fair Value Measures - Financial Instruments (Details) SFr in Millions, $ in Millions, € in Billions, kr in Billions	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2022 EUR (€) derivative	Dec. 31, 2022 USD ($) derivative	Dec. 31, 2022 SEK (kr) derivative	Dec. 31, 2022 CAD ($) derivative	Dec. 31, 2022 CHF (SFr) derivative	Dec. 31, 2021 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2019 USD ($)
Derivative instruments, notional amount and fair value
Number of outstanding derivative instruments containing credit risk contingent features | derivative			0	0	0	0	0
Amount excluded from the assessment of effectiveness for cash flow hedges	$ 0	$ 0
Amount excluded from the assessment of effectiveness for fair value hedges	$ 0	$ 0
Fair value - Derivatives in asset position				$ 163,000,000					$ 267,000,000
Fair value - Derivatives in liability position				524,000,000					37,000,000
Designated as hedging instrument | Net investment hedges | Senior notes
Derivative instruments, notional amount and fair value
Aggregate principal amount of senior Euro notes | €			€ 5.9					€ 5.9
Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments				1,700,000,000					1,100,000,000
Duration of forward exchange contracts	18 months
Approximate length of time over which accumulated gains and losses will be recognized in cost of products sold	6 months
Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position				49,000,000					51,000,000
Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position				8,000,000					2,000,000
Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | Other assets
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position				1,000,000					0
Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | Other long-term liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position				0					0
Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments			€ 4.3		kr 2	$ 750	SFr 90	€ 4.3
Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position				6,000,000					149,000,000
Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position				36,000,000					0
Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Other assets
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position				74,000,000					15,000,000
Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Other long-term liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position				47,000,000					0
Designated as hedging instrument | Treasury rate lock agreements | Cash flow hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments										$ 10,000,000,000
Designated as hedging instrument | Interest rate swap contracts | Cash flow hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments									750,000,000
Designated as hedging instrument | Interest rate swap contracts | Cash flow hedges | Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position				0					0
Designated as hedging instrument | Interest rate swap contracts | Cash flow hedges | Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position				0					7,000,000
Designated as hedging instrument | Interest rate swap contracts | Fair value hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments				4,500,000,000					4,500,000,000
Designated as hedging instrument | Interest rate swap contracts | Fair value hedges | Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position				0					0
Designated as hedging instrument | Interest rate swap contracts | Fair value hedges | Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position				17,000,000					0
Designated as hedging instrument | Interest rate swap contracts | Fair value hedges | Other assets
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position				0					26,000,000
Designated as hedging instrument | Interest rate swap contracts | Fair value hedges | Other long-term liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position				375,000,000					15,000,000
Not designated as hedging instrument | Foreign currency forward exchange contracts
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments				6,500,000,000					8,200,000,000
Not designated as hedging instrument | Foreign currency forward exchange contracts | Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position				33,000,000					26,000,000
Not designated as hedging instrument | Foreign currency forward exchange contracts | Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position				$ 41,000,000					$ 13,000,000

Financial Instruments and Fai_4

Financial Instruments and Fair Value Measures - Amount of Gain/(Loss) Recognized For Derivative Instruments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cost of products sold
Gain (loss) on derivatives
Pre-tax losses to be transferred into cost of products sold for foreign currency cash flow hedges during the next 12 months	$ 86
Interest expense, net
Gain (loss) on derivatives
Pre-tax gains to be transferred into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months	24
Designated as hedging instrument | Senior notes
Gain (loss) on derivatives
Pre-tax gains (losses) from net investment hedges recognized in other comprehensive income	406	$ 577	$ (907)
Designated as hedging instrument | Interest expense, net | Senior notes | Fair value hedges
Gain (loss) on derivatives
Debt designated as hedged item in fair value hedges gains (losses) recognized in the consolidated statements of earnings	402	127	(365)
Foreign currency forward exchange contracts | Designated as hedging instrument
Gain (loss) on derivatives
Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income	103	82	(71)
Pre-tax gains (losses) from net investment hedges recognized in other comprehensive income	395	341	(95)
Foreign currency forward exchange contracts | Designated as hedging instrument | Cash flow hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidated statements of earnings	$ 82	$ (87)	$ 23
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of products sold	Cost of products sold	Cost of products sold
Foreign currency forward exchange contracts | Designated as hedging instrument | Net investment hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidated statements of earnings	$ 94	$ 26	$ 18
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Gain on derivative amount excluded from effectiveness testing	Gain on derivative amount excluded from effectiveness testing	Gain on derivative amount excluded from effectiveness testing
Foreign currency forward exchange contracts | Not designated as hedging instrument
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidated statements of earnings	$ (156)	$ (100)	$ 58
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Foreign Currency Transaction Gain (Loss), before Tax	Foreign Currency Transaction Gain (Loss), before Tax	Foreign Currency Transaction Gain (Loss), before Tax
Interest rate swap contracts | Designated as hedging instrument
Gain (loss) on derivatives
Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income	$ 6	$ 2	$ (53)
Interest rate swap contracts | Designated as hedging instrument | Cash flow hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidated statements of earnings	$ (1)	$ (24)	$ (17)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Gain on derivative amount excluded from effectiveness testing	Gain on derivative amount excluded from effectiveness testing	Gain on derivative amount excluded from effectiveness testing
Interest rate swap contracts | Designated as hedging instrument | Fair value hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidated statements of earnings	$ (402)	$ (127)	$ 365
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Gain on derivative amount excluded from effectiveness testing	Gain on derivative amount excluded from effectiveness testing	Gain on derivative amount excluded from effectiveness testing
Treasury rate lock agreements | Designated as hedging instrument | Cash flow hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidated statements of earnings	$ 23	$ 24	$ 24
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Gain on derivative amount excluded from effectiveness testing	Gain on derivative amount excluded from effectiveness testing	Gain on derivative amount excluded from effectiveness testing

Financial Instruments and Fai_5

Financial Instruments and Fair Value Measures - Fair Value Measures (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Assets
Foreign currency contracts	$ 163	$ 267
Liabilities
Foreign currency contracts	524	37
Change in fair value recognized in net earnings	(2,761)	(2,679)	$ (5,753)
Recurring
Assets
Cash and equivalents	9,201	9,746
Debt securities	28	46
Equity securities	91	121
Interest rate swap contracts		26
Total assets	9,504	10,225
Liabilities
Interest rate swap contracts	392	22
Contingent consideration	16,384	14,887
Total liabilities	16,908	14,924
Recurring | Money market funds and time deposits
Assets
Money market funds and time deposits	21	45
Recurring | Foreign currency contracts
Assets
Foreign currency contracts	163	241
Liabilities
Foreign currency contracts	132	15
Recurring | Quoted prices in active markets for identical assets (Level 1)
Assets
Cash and equivalents	4,201	4,451
Debt securities	0	0
Equity securities	59	100
Interest rate swap contracts		0
Total assets	4,260	4,551
Liabilities
Interest rate swap contracts	0	0
Contingent consideration	0	0
Total liabilities	0	0
Recurring | Quoted prices in active markets for identical assets (Level 1) | Money market funds and time deposits
Assets
Money market funds and time deposits	0	0
Recurring | Quoted prices in active markets for identical assets (Level 1) | Foreign currency contracts
Assets
Foreign currency contracts	0	0
Liabilities
Foreign currency contracts	0	0
Recurring | Significant other observable inputs (Level 2)
Assets
Cash and equivalents	5,000	5,295
Debt securities	28	46
Equity securities	32	21
Interest rate swap contracts		26
Total assets	5,244	5,674
Liabilities
Interest rate swap contracts	392	22
Contingent consideration	0	0
Total liabilities	524	37
Recurring | Significant other observable inputs (Level 2) | Money market funds and time deposits
Assets
Money market funds and time deposits	21	45
Recurring | Significant other observable inputs (Level 2) | Foreign currency contracts
Assets
Foreign currency contracts	163	241
Liabilities
Foreign currency contracts	132	15
Recurring | Significant unobservable inputs (Level 3)
Assets
Cash and equivalents	0	0
Debt securities	0	0
Equity securities	0	0
Interest rate swap contracts		0
Total assets	0	0
Liabilities
Interest rate swap contracts	0	0
Contingent consideration	16,384	14,887
Total liabilities	16,384	14,887
Recurring | Significant unobservable inputs (Level 3) | Money market funds and time deposits
Assets
Money market funds and time deposits	0	0
Recurring | Significant unobservable inputs (Level 3) | Foreign currency contracts
Assets
Foreign currency contracts	0	0
Liabilities
Foreign currency contracts	$ 0	$ 0

Financial Instruments and Fai_6

Financial Instruments and Fair Value Measures - Significant Level 3 Unobservable Inputs (Details)		Dec. 31, 2022	Dec. 31, 2021
Probability of payment for royalties excluding approved indications
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration		0.56
Minimum | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration		0.047	0.002
Minimum | Probability of payment for unachieved milestones
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration		1	0.89
Minimum | Probability of payment for royalties by indication
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	[1]	0.56	0.56
Minimum | Projected year of payments
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration		2,023	2,022
Minimum | Probability of payment for royalties excluding approved indications
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration			0.56
Maximum | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration		0.051	0.026
Maximum | Probability of payment for unachieved milestones
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration		1	1
Maximum | Probability of payment for royalties by indication
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	[1]	1	1
Maximum | Projected year of payments
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration		2,034	2,034
Maximum | Probability of payment for royalties excluding approved indications
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration			0.89
Weighted Average | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	[2]	0.048	0.017
Weighted Average | Probability of payment for unachieved milestones
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	[2]	1	0.90
Weighted Average | Probability of payment for royalties by indication
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	[1],[2]	0.99	0.96
Weighted Average | Projected year of payments
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	[2]	2,028	2,027
[1]Excluding approved indications, the estimated probability of payment was 56% at December 31, 2022 and ranged from 56% to 89% at December 31, 2021.[2]Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.

Financial Instruments and Fai_7

Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022		Dec. 31, 2021	Dec. 31, 2020
Transfers of assets between the fair value measurement levels
Transfers of assets into Level 3 of the fair value hierarchy	$ 0
Transfers of assets out of Level 3 of the fair value hierarchy	0
Transfers of liabilities between the fair value measurement levels
Transfers of liabilities into Level 3 of the fair value hierarchy	0
Transfers of liabilities out of Level 3 of the fair value hierarchy	0
Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3)
Beginning balance	14,887,000,000		$ 12,997,000,000	$ 7,340,000,000
Additions	$ 32,000,000	[1]	$ 0	$ 225,000,000	[1]
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Nonoperating Income (Expense)		Other Nonoperating Income (Expense)	Other Nonoperating Income (Expense)
Change in fair value recognized in net earnings	$ (2,761,000,000)		$ (2,679,000,000)	$ (5,753,000,000)
Payments	(1,296,000,000)		(789,000,000)	(321,000,000)
Ending balance	$ 16,384,000,000		$ 14,887,000,000	$ 12,997,000,000
[1]Additions during the year ended December 31, 2022, represent contingent consideration liabilities assumed in the DJS acquisition. Additions during the year ended December 31, 2020, represent contingent consideration liabilities assumed in the Allergan and Luminera acquisitions (see Note 5).

Financial Instruments and Fai_8

Financial Instruments and Fair Value Measures - Bases Used to Measure The Approximate Fair Value of Financial Instruments (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Liabilities
Carrying amount of investments in equity securities that do not have readily determinable fair values	$ 129	$ 149
Book value
Liabilities
Short-term borrowings	1	14
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	4,152	12,455
Long-term debt and finance lease obligations, excluding fair value hedges	59,463	64,113
Total liabilities	63,616	76,582
Estimate of Fair Value Measurement
Liabilities
Short-term borrowings	1	14
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	4,121	11,830
Long-term debt and finance lease obligations, excluding fair value hedges	54,073	71,810
Total liabilities	58,195	83,654
Estimate of Fair Value Measurement | Quoted prices in active markets for identical assets (Level 1)
Liabilities
Short-term borrowings	0	0
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	3,930	11,329
Long-term debt and finance lease obligations, excluding fair value hedges	53,365	70,757
Total liabilities	57,295	82,086
Estimate of Fair Value Measurement | Significant other observable inputs (Level 2)
Liabilities
Short-term borrowings	1	14
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	191	501
Long-term debt and finance lease obligations, excluding fair value hedges	708	1,053
Total liabilities	900	1,568
Estimate of Fair Value Measurement | Significant unobservable inputs (Level 3)
Liabilities
Short-term borrowings	0	0
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	0	0
Long-term debt and finance lease obligations, excluding fair value hedges	0	0
Total liabilities	$ 0	$ 0

Financial Instruments and Fai_9

Financial Instruments and Fair Value Measures - Concentrations of Risk (Details) - wholesaler	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Concentration of Risk
Number of principal customers	3
Net revenues
Concentration of Risk
Number of principal customers	3
Net revenues | HUMIRA | Humira
Concentration of Risk
Concentrations risk (as a percent)	37%	37%	43%
Accounts receivable, net | Geographic Risk | Principal U.S. Customers
Concentration of Risk
Concentrations risk (as a percent)	82%	75%

Post-Employment Benefits - Addi

Post-Employment Benefits - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Accumulated benefit obligation	$ 7,700	$ 10,500
Defined benefit plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Projected benefit obligation	8,588	12,006	$ 11,792
Actuarial (gain) loss	(3,668)	(8)
Amendments	$ 0	0
Defined benefit plans | Equity securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Target investment allocations for Pension Plan (as a percent)	62.50%
Defined benefit plans | Debt securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Target investment allocations for Pension Plan (as a percent)	22.50%
Defined benefit plans | Asset allocation strategies and other holdings
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Target investment allocations for Pension Plan (as a percent)	15%
Other post-employment plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Projected benefit obligation	$ 667	850	795
Actuarial (gain) loss	(229)	10
Amendments	$ (2)		397
Pre Sixty Five Years of Age
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Annual rate of increase in the per capita cost of covered health care obligation benefits assumed in the current year (as a percent)	6.20%
Ultimate per capita trend rate for health care costs from 2030 and thereafter (as a percent)	4.50%
Annual rate of increase in the per capita cost of covered health care cost benefits assumed in the current year (as a percent)	5.90%
Ultimate per capita trend rate for health care costs from 2029 and thereafter (as a percent)	4.50%
Post Sixty Five Years of Age
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Annual rate of increase in the per capita cost of covered health care obligation benefits assumed in the current year (as a percent)	2%
Ultimate per capita trend rate for health care costs from 2030 and thereafter (as a percent)	1.80%
Annual rate of increase in the per capita cost of covered health care cost benefits assumed in the current year (as a percent)	2.10%
Ultimate per capita trend rate for health care costs from 2029 and thereafter (as a percent)	1.80%
AbbVie Savings Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined contribution plan expenses recorded	$ 474	267	$ 191
Foreign Plan [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Projected benefit obligation	$ 2,100	$ 3,200

Post-Employment Benefits - Bene

Post-Employment Benefits - Benefit Plan Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Amounts recognized on the consolidated balance sheets
Other long-term liabilities	$ (1,638)	$ (3,153)
Defined benefit plans
Projected benefit obligations
Beginning of period	12,006	11,792
Service cost	454	440	$ 370
Interest cost	297	237	264
Employee contributions	1	2
Amendments	0	0
Actuarial (gain) loss	(3,668)	(8)
Benefits paid	(294)	(281)
Other, primarily foreign currency translation adjustments	(208)	(176)
End of period	8,588	12,006	11,792
Fair value of plan assets
Beginning of period	10,655	9,702
Actual return on plan assets	(2,031)	1,000
Company contributions	357	376
Employee contributions	1	2
Benefits paid	(294)	(281)
Other, primarily foreign currency translation adjustments	(216)	(144)
End of period	8,472	10,655	9,702
Funded status, end of period	(116)	(1,351)
Amounts recognized on the consolidated balance sheets
Other assets	896	991
Accounts payable and accrued liabilities	(14)	(13)
Other long-term liabilities	(998)	(2,329)
Net obligation	(116)	(1,351)
Actuarial loss, net	(2,365)	(3,504)
Prior service cost (credit)	3	5
Accumulated other comprehensive loss	2,368	3,509
Other post-employment plans
Projected benefit obligations
Beginning of period	850	795
Service cost	51	48	42
Interest cost	23	19	34
Amendments	(2)		397
Actuarial (gain) loss	(229)	10
Benefits paid	(25)	(22)
Other, primarily foreign currency translation adjustments	(1)	0
End of period	667	850	$ 795
Fair value of plan assets
Company contributions	25	22
Benefits paid	(25)	(22)
Funded status, end of period	(667)	(850)
Amounts recognized on the consolidated balance sheets
Accounts payable and accrued liabilities	(27)	(26)
Other long-term liabilities	(640)	(824)
Net obligation	(667)	(850)
Actuarial loss, net	(205)	(461)
Prior service cost (credit)	(333)	(370)
Accumulated other comprehensive loss	$ (128)	$ 91

Post-Employment Benefits - Info

Post-Employment Benefits - Information For Pension Plans With A Projected Benefit Obligation And An Accumulated Benefit Obligation In Excess Of Plan Assets (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Postemployment Benefits [Abstract]
Accumulated benefit obligation	$ 1,211	$ 6,395
Fair value of plan assets	746	5,412
Projected benefit obligation	5,592	7,788
Fair value of plan assets	$ 4,580	$ 5,447

Post-Employment Benefits - Pret

Post-Employment Benefits - Pretax Gains and Losses Included in Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined benefit plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Actuarial loss (gain)	$ (925)	$ (345)	$ 701
Amortization of prior service credit (cost)	(2)	(2)	(2)
Amortization of actuarial loss	(231)	(288)	(227)
Foreign exchange loss (gain) and other	17	(27)	56
Total loss (gain)	(1,141)	(662)	528
Other post-employment plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Actuarial loss (gain)	(229)	10	40
Amortization of prior service credit (cost)	38	39	4
Amortization of actuarial loss	(26)	(32)	(26)
Prior service credit	(2)	0	(397)
Total loss (gain)	$ (219)	$ 17	$ (379)

Post-Employment Benefits - Net

Post-Employment Benefits - Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined benefit plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Service cost	$ 454	$ 440	$ 370
Interest cost	297	237	264
Expected return on plan assets	(712)	(663)	(575)
Amortization of prior service cost	2	2	2
Amortization of actuarial loss	(231)	(288)	(227)
Net periodic benefit cost	272	304	288
Other post-employment plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Service cost	51	48	42
Interest cost	23	19	34
Amortization of prior service cost	(38)	(39)	(4)
Amortization of actuarial loss	(26)	(32)	(26)
Net periodic benefit cost	$ 62	$ 60	$ 98

Post-Employment Benefits - Weig

Post-Employment Benefits - Weighted-Average Assumptions Used in Determining Benefit Obligation at Measurement Date (Details)	Dec. 31, 2022	Dec. 31, 2021
Defined benefit plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	5%	2.80%
Rate of compensation increases	5.50%	5.20%
Cash balance interest crediting rate	2.70%	2.70%
Other post-employment plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	5.30%	3.10%

Post-Employment Benefits - We_2

Post-Employment Benefits - Weighted-Average Assumptions Used in Determining Net Periodic Benefit Cost (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined benefit plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate for determining service cost	3%	2.60%	3.10%
Discount rate for determining interest cost	2.60%	2.20%	3%
Expected long-term rate of return on plan assets	7.10%	7.10%	7.10%
Expected rate of change in compensation	5.20%	4.60%	4.60%
Cash balance interest crediting rate	2.70%	2.80%	2.80%
Other post-employment plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate for determining service cost	3.30%	3%	3.70%
Discount rate for determining interest cost	2.70%	2.20%	3.20%

Post-Employment Benefits - Defi

Post-Employment Benefits - Defined Benefit Pension Plan Assets (Details) - Defined benefit plans - USD ($) $ in Millions		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets		$ 8,472	$ 10,655	$ 9,702
Fair value measured at Levels 1, 2 and 3
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets		3,360	4,503
Fair value measured at Levels 1, 2 and 3 | U.S. large cap
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[1]	949	1,428
Fair value measured at Levels 1, 2 and 3 | U.S. mid cap
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[2]	157	198
Fair value measured at Levels 1, 2 and 3 | International
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[3]	327	458
Fair value measured at Levels 1, 2 and 3 | U.S. government securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	237	228
Fair value measured at Levels 1, 2 and 3 | Corporate debt instruments
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	680	945
Fair value measured at Levels 1, 2 and 3 | Non-U.S. government securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	548	602
Fair value measured at Levels 1, 2 and 3 | Other fixed income securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	84	273
Fair value measured at Levels 1, 2 and 3 | Absolute return funds
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[5]	91	100
Fair value measured at Levels 1, 2 and 3 | Real assets
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets		9	10
Fair value measured at Levels 1, 2 and 3 | Other plan assets
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[6]	278	261
Quoted prices in active markets for identical assets (Level 1)
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets		2,419	3,302
Quoted prices in active markets for identical assets (Level 1) | U.S. large cap
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[1]	949	1,428
Quoted prices in active markets for identical assets (Level 1) | U.S. mid cap
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[2]	157	198
Quoted prices in active markets for identical assets (Level 1) | International
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[3]	327	458
Quoted prices in active markets for identical assets (Level 1) | U.S. government securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	69	95
Quoted prices in active markets for identical assets (Level 1) | Corporate debt instruments
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	144	179
Quoted prices in active markets for identical assets (Level 1) | Non-U.S. government securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	402	445
Quoted prices in active markets for identical assets (Level 1) | Other fixed income securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	81	268
Quoted prices in active markets for identical assets (Level 1) | Absolute return funds
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[5]	4	5
Quoted prices in active markets for identical assets (Level 1) | Real assets
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets		9	10
Quoted prices in active markets for identical assets (Level 1) | Other plan assets
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[6]	277	216
Significant other observable inputs (Level 2)
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets		941	1,201
Significant other observable inputs (Level 2) | U.S. large cap
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[1]	0	0
Significant other observable inputs (Level 2) | U.S. mid cap
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[2]	0	0
Significant other observable inputs (Level 2) | International
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[3]	0	0
Significant other observable inputs (Level 2) | U.S. government securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	168	133
Significant other observable inputs (Level 2) | Corporate debt instruments
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	536	766
Significant other observable inputs (Level 2) | Non-U.S. government securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	146	157
Significant other observable inputs (Level 2) | Other fixed income securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	3	5
Significant other observable inputs (Level 2) | Absolute return funds
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[5]	87	95
Significant other observable inputs (Level 2) | Real assets
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets		0	0
Significant other observable inputs (Level 2) | Other plan assets
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[6]	1	45
Significant unobservable inputs (Level 3)
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets		0	0
Significant unobservable inputs (Level 3) | U.S. large cap
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[1]	0	0
Significant unobservable inputs (Level 3) | U.S. mid cap
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[2]	0	0
Significant unobservable inputs (Level 3) | International
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[3]	0	0
Significant unobservable inputs (Level 3) | U.S. government securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	0	0
Significant unobservable inputs (Level 3) | Corporate debt instruments
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	0	0
Significant unobservable inputs (Level 3) | Non-U.S. government securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	0	0
Significant unobservable inputs (Level 3) | Other fixed income securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	0	0
Significant unobservable inputs (Level 3) | Absolute return funds
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[5]	0	0
Significant unobservable inputs (Level 3) | Real assets
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets		0	0
Significant unobservable inputs (Level 3) | Other plan assets
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[6]	0	0
Total assets measured at NAV
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets		$ 5,112	$ 6,152
[1]A mix of index funds and actively managed equity accounts that are benchmarked to various large cap indices.[2]A mix of index funds and actively managed equity accounts that are benchmarked to various mid cap indices.[3]A mix of index funds and actively managed equity accounts that are benchmarked to various non-U.S. equity indices in both developed and emerging markets.[4]Securities held by actively managed accounts, index funds and mutual funds.[5]Primarily funds having global mandates with the flexibility to allocate capital broadly across a wide range of asset classes and strategies, including but not limited to equities, fixed income, commodities, financial futures, currencies and other securities, with objectives to outperform agreed upon benchmarks of specific return and volatility targets.[6]Investments in cash and cash equivalents.

Post-Employment Benefits - Expe

Post-Employment Benefits - Expected Defined Benefit and Other Post-Employment Plan Payments (Details) $ in Millions	Dec. 31, 2022 USD ($)
Defined benefit plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
2023	$ 310
2024	333
2025	355
2026	378
2027	404
2028 to 2032	2,427
Other post-employment plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
2023	28
2024	31
2025	34
2026	37
2027	39
2028 to 2032	$ 244

Equity - Stock-Based Compensati

Equity - Stock-Based Compensation (Details) - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for issuance (in shares)	144
Retirement-eligible employees' age	55 years
Minimum number of years of services	10 years
Pre-tax compensation expense	$ 671	$ 692	$ 753
Tax benefit	122	126	131
After-tax compensation expense	549	566	622
Excess tax benefits realized from stock-based compensation	116	50	34
Cost of products sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pre-tax compensation expense	38	46	47
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pre-tax compensation expense	232	226	247
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pre-tax compensation expense	$ 401	$ 420	$ 459

Equity - Stock Options (Details

Equity - Stock Options (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	May 08, 2020
Allergan plc
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options issued to Allergan's equity award holders (in shares)	[1]				11,200
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term		10 years
Vesting period		3 years
Exercise price for awards granted as percentage of market value on the date of grant		100%
Weighted-average grant-date fair value of the stock options granted (in dollars per share)		$ 22.83	$ 16.28	$ 12.14
Options
Outstanding at the beginning of the period (in shares)		12,374
Granted (in shares)		863
Exercised (in shares)		(3,764)
Lapsed and forfeited (in shares)		(153)
Outstanding at the end of the period (in shares)		9,320	12,374
Exercisable at the end of the period (in shares)		7,120
Weighted- average exercise price
Outstanding at the beginning of the period (in dollars per share)		$ 81.98
Granted (in dollars per share)		144.54
Exercised (in dollars per share)		70.85
Lapsed and forfeited (in dollars per share)		107.65
Outstanding at the end of the period (in dollars per share)		91.84	$ 81.98
Exercisable at the end of the period (in dollars per share)		$ 84.54
Weighted-average remaining life (in years)
Outstanding		4 years 9 months 18 days	4 years 8 months 12 days
Exercisable		3 years 8 months 12 days
Aggregate intrinsic value
Outstanding		$ 650	$ 661
Exercisable		549
Aggregate intrinsic value of options exercised		295	$ 239	$ 186
Total fair value of options vested		21
Unrecognized compensation cost		$ 6
Period for recognition of unrecognized compensation cost		2 years
[1]Represents the pre-acquisition service portion of the fair value of 11 million AbbVie stock options and 8 million RSUs issued to Allergan equity award holders.

Equity - RSUs and Performance S

Equity - RSUs and Performance Shares (Details) $ / shares in Units, $ in Millions		12 Months Ended
		Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($)	May 08, 2020 shares
Allergan plc
Weighted-average grant date fair value
Granted in acquisition (in shares)	[1]				8,200,000
RSUs | Minimum vesting period
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
RSUs | Maximum vesting period
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years
Performance-vested RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance period		3 years
Common stock received for each vested award (in shares)		1
Weighted-average grant date fair value
Incremental vesting		0.33
Performance shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance period		3 years
Weighted-average grant date fair value
Incremental vesting		0.33
RSUs and performance shares
Share units
Shares units outstanding at the beginning of the period (in shares)		14,890,000
Granted (in shares)		5,943,000
Vested (in shares)		(6,958,000)
Forfeited (in shares)		(844,000)
Shares units outstanding at the end of the period (in shares)		13,031,000	14,890,000
Weighted-average grant date fair value
Weighted average fair value outstanding at the beginning of the period (in dollars per share) | $ / shares		$ 94.93
Granted (in dollars per share) | $ / shares		138.73
Vested (in dollars per share) | $ / shares		89.31
Forfeited (in dollars per share) | $ / shares		111.45
Weighted average fair value outstanding at the end of the period (in dollars per share) | $ / shares		$ 116.84	$ 94.93
Fair market value of awards vested | $		$ 1,000	$ 718	$ 618
Unrecognized compensation cost | $		$ 578
Period for recognition of unrecognized compensation cost		2 years
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Weighted-average grant date fair value
Period for recognition of unrecognized compensation cost		2 years
Incremental vesting		0.33
[1]Represents the pre-acquisition service portion of the fair value of 11 million AbbVie stock options and 8 million RSUs issued to Allergan equity award holders.

Equity - Cash Dividends (Detail

Equity - Cash Dividends (Details) - $ / shares													3 Months Ended	12 Months Ended
	Oct. 28, 2022	Sep. 09, 2022	Jun. 23, 2022	Feb. 17, 2022	Oct. 29, 2021	Sep. 10, 2021	Jun. 17, 2021	Feb. 18, 2021	Oct. 30, 2020	Sep. 11, 2020	Jun. 17, 2020	Feb. 20, 2020	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Cash dividends declared per common share (in dollars per share)	$ 1.48	$ 1.41	$ 1.41	$ 1.41	$ 1.41	$ 1.30	$ 1.30	$ 1.30	$ 1.30	$ 1.18	$ 1.18	$ 1.18	$ 1.48	$ 5.71	$ 5.31	$ 4.84

Equity - Share Repurchase Progr

Equity - Share Repurchase Program (Details) - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Feb. 16, 2023
Equity, Class of Treasury Stock [Line Items]
Payment for shares repurchased	$ 1,487	$ 934	$ 978
December 2018 Stock Repurchase Authorization
Equity, Class of Treasury Stock [Line Items]
Shares repurchased (in shares)	8	6	8
Payment for shares repurchased	$ 1,100	$ 670	$ 757
Remaining share repurchase authorization amount	$ 1,400
December 2018 Stock Repurchase Authorization | Subsequent event
Equity, Class of Treasury Stock [Line Items]
Stock Repurchase Program, Increase in Authorized Amount				$ 5,000

Equity - Accumulated Other Comp

Equity - Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
AOCI Attributable to Parent, Net of Tax
Beginning balance	$ 15,436	$ 13,097	$ (8,172)
Other comprehensive income (loss)	700	218	479
Ending balance	17,287	15,436	13,097
AOCI Attributable to Parent
AOCI Attributable to Parent, Net of Tax
Beginning balance	(2,899)	(3,117)	(3,596)
Other comprehensive income (loss)	700	218	479
Ending balance	(2,199)	(2,899)	(3,117)
Foreign currency translation adjustments
AOCI Attributable to Parent, Net of Tax
Beginning balance	(570)	583	(928)
Other comprehensive income (loss) before reclassifications	(943)	(1,153)	1,511
Net losses (gains) reclassified from accumulated other comprehensive loss	0	0	0
Other comprehensive income (loss)	(943)	(1,153)	1,511
Ending balance	(1,513)	(570)	583
Net investment hedging activities
AOCI Attributable to Parent, Net of Tax
Beginning balance	(91)	(790)	9
Other comprehensive income (loss) before reclassifications	629	720	(785)
Net losses (gains) reclassified from accumulated other comprehensive loss	(74)	(21)	(14)
Other comprehensive income (loss)	555	699	(799)
Ending balance	464	(91)	(790)
Pension and post-employment benefits
AOCI Attributable to Parent, Net of Tax
Beginning balance	(2,546)	(3,067)	(2,965)
Other comprehensive income (loss) before reclassifications	915	298	(300)
Net losses (gains) reclassified from accumulated other comprehensive loss	173	223	198
Other comprehensive income (loss)	1,088	521	(102)
Ending balance	(1,458)	(2,546)	(3,067)
Cash flow hedging activities
AOCI Attributable to Parent, Net of Tax
Beginning balance	308	157	288
Other comprehensive income (loss) before reclassifications	91	76	(108)
Net losses (gains) reclassified from accumulated other comprehensive loss	(91)	75	(23)
Other comprehensive income (loss)	0	151	(131)
Ending balance	308	308	157
Accumulated other comprehensive income (loss)
AOCI Attributable to Parent, Net of Tax
Beginning balance	(2,899)	(3,117)	(3,596)
Other comprehensive income (loss) before reclassifications	692	(59)	318
Net losses (gains) reclassified from accumulated other comprehensive loss	8	277	161
Other comprehensive income (loss)	700	218	479
Ending balance	$ (2,199)	$ (2,899)	$ (3,117)

Equity - Amounts Reclassified O

Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions		3 Months Ended	12 Months Ended
		Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Significant amounts reclassified out of each component of AOCI
Gain on derivative amount excluded from effectiveness testing			$ (2,044)	$ (2,384)	$ (2,280)
Tax expense (benefit)			1,632	1,440	(1,224)
Total reclassifications, net of tax		$ (2,473)	(11,836)	(11,542)	(4,616)
Losses (gains) on foreign currency exchange contracts			17,414	17,446	15,387
Other comprehensive income, net of tax			700	218	479
Pension and post-employment benefits
Significant amounts reclassified out of each component of AOCI
Amortization of actuarial losses and other	[1]		221	283	251
Tax benefit			(48)	(60)	(53)
Total reclassifications, net of tax			173	223	198
Other comprehensive income, net of tax			1,088	521	(102)
Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Total reclassifications, net of tax			(91)	75	(23)
Other comprehensive income, net of tax			0	151	(131)
Foreign currency translation adjustments
Significant amounts reclassified out of each component of AOCI
Total reclassifications, net of tax			0	0	0
Other comprehensive income, net of tax			(943)	(1,153)	1,511
Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Tax expense (benefit)			13	(12)	7
Total reclassifications, net of tax			(91)	75	(23)
Reclassification out of accumulated other comprehensive loss | Net investment hedges | Net investment hedging activities
Significant amounts reclassified out of each component of AOCI
Gain on derivative amount excluded from effectiveness testing	[2]		94	26	18
Tax expense (benefit)			20	5	4
Total reclassifications, net of tax			(74)	(21)	(14)
Foreign currency forward exchange contracts | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Losses (gains) on foreign currency exchange contracts	[3]		(82)	87	(23)
Treasury rate lock agreements | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Gain on derivative amount excluded from effectiveness testing	[2]		(23)	(24)	(24)
Interest rate swap contracts | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Gain on derivative amount excluded from effectiveness testing	[2]		$ 1	$ 24	$ 17
[1]Amounts are included in the computation of net periodic benefit cost (see Note 12).[2]Amounts are included in interest expense, net (see Note 11).[3]Amounts are included in cost of products sold (see Note 11).

Equity - Other (Details)

Equity - Other (Details)	Dec. 31, 2022 $ / shares shares
Equity [Abstract]
Preferred stock authorized (in shares)	200,000,000
Preferred stock par value (in dollars per share) | $ / shares	$ 0.01
Preferred stock issued (in shares)	0

Income Taxes - Earnings Before

Income Taxes - Earnings Before Income Tax Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Domestic	$ (4,608)	$ (1,644)	$ (4,467)
Foreign	18,085	14,633	7,865
Earnings before income tax expense	$ 13,477	$ 12,989	$ 3,398

Income Taxes - Income Tax Expen

Income Taxes - Income Tax Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current
Domestic	$ 2,647	$ 1,987	$ 907
Foreign	916	351	194
Total current taxes	3,563	2,338	1,101
Deferred
Domestic	(1,512)	(839)	(58)
Foreign	(419)	(59)	(2,267)
Total deferred taxes	(1,931)	(898)	(2,325)
Total income tax expense (benefit)	$ 1,632	$ 1,440	$ (1,224)

Income Taxes - Effective Tax Ra

Income Taxes - Effective Tax Rate Reconciliation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory tax rate	21%	21%	21%
Effect of foreign operations	(4.40%)	(5.40%)	2.40%
U.S. tax credits	(2.80%)	(2.80%)	(10.60%)
Impacts related to U.S. tax reform	0%	0%	(1.10%)
Non-deductible expenses	0.60%	0.30%	7.20%
Tax law changes and related restructuring	(2.40%)	(2.00%)	(48.50%)
Tax audits and settlements	0.90%	(0.40%)	(5.10%)
All other, net	(0.80%)	0.40%	(1.30%)
Effective tax rate	12.10%	11.10%	(36.00%)
Effective income Tax Rate Reconciliation Puerto Rico Act	$ 323
Amount of net tax benefit related to changes in tax laws and related restructuring, including certain intra-group transfers of intellectual property and deferred tax remeasurement			$ (1,700)

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets
Compensation and employee benefits		$ 497	$ 937
Accruals and reserves		1,023	667
Chargebacks and rebates		991	837
Advance payments		547	809
Net operating losses and other carryforwards		10,391	10,095
Other		1,710	1,234
Total deferred tax assets		15,159	14,579
Valuation allowances		(9,627)	(9,391)
Total net deferred tax assets		5,532	5,188
Deferred tax liabilities
Excess of book basis over tax basis of intangible assets		(3,590)	(4,711)
Excess of book basis over tax basis in investments		(340)	(308)
Other		(772)	(904)
Total deferred tax liabilities		(4,702)	(5,923)
Net deferred tax assets (liabilities)		830	(735)
Tax Credit Carryforward
Valuation allowances		(9,627)	$ (9,391)
Allergan plc
Tax Credit Carryforward
Measurement period adjustments to deferred income tax assets	$ 8,200
Measurement period adjustment to deferred tax assets valuation allowance	$ 8,200
U.S. Federal and State
Tax Credit Carryforward
Tax credit carryforwards		355
U.S. Federal, State and Non-U.S.
Tax Credit Carryforward
Operating loss carryforwards with expiration through 2041		33,200
U.S. Federal and Non-U.S.
Tax Credit Carryforward
Operating loss carryforwards		$ 6,000

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Unrecognized Tax Benefits
Beginning balance	$ 5,489	$ 5,264	$ 2,661
Increase due to acquisition	0	0	2,674
Increase due to current year tax positions	88	208	91
Increase due to prior year tax positions	243	137	59
Decrease due to prior year tax positions	(33)	(62)	(7)
Settlements	(7)	(24)	(141)
Lapse of statutes of limitations	(110)	(34)	(73)
Ending balance	5,670	5,489	5,264
Net amount of potential tax benefits that would impact the entity's effective tax rate	5,500	5,200
Interest and penalties	339	161	142
Accrued interest and penalties	1,100	$ 803	$ 642
Reasonably possible amount that gross unrecognized tax benefits may change within the next twelve months, high end of range	$ 162

Legal Proceedings and Conting_2

Legal Proceedings and Contingencies (Details) $ in Billions	1 Months Ended		12 Months Ended
	Aug. 31, 2019 company	Jun. 30, 2016 investment_fund	Dec. 31, 2022 claim lawsuit	Dec. 31, 2022 class_action claim	Dec. 31, 2022 direct_purchaser claim	Dec. 31, 2022 claim end_payor_purchaser	Dec. 31, 2022 company claim	Jun. 30, 2022 USD ($)
Niaspan
Legal Proceedings and Contingencies
Number of individual plaintiff lawsuits | lawsuit			4
Number of purported class actions | class_action				2
Number of healthcare benefit providers acting as plaintiff in lawsuit					1	1
AndroGel antitrust litigation, King Drug Co. of Florence, Inc. v. AbbVie Inc.
Legal Proceedings and Contingencies
Number of generic companies with whom certain litigation related agreements were entered into | company	3
Bystolic antitrust litigation
Legal Proceedings and Contingencies
Number of generic companies with whom certain litigation related agreements were entered into | company							6
Prescription drug abuse litigation
Legal Proceedings and Contingencies
Number of claims pending | claim			3,000	3,000	3,000	3,000	3,000
Prescription drug abuse litigation in state courts
Legal Proceedings and Contingencies
Number of claims pending | claim			270	270	270	270	270
Elliott Associates, L.P.
Legal Proceedings and Contingencies
Number of parties to lawsuit (in investment funds) | investment_fund		5
Selling, general and administrative | Prescription drug abuse litigation in state courts
Legal Proceedings and Contingencies
Loss Contingency, Estimate of Possible Loss | $								$ 2.1

Segment and Geographic Area I_3

Segment and Geographic Area Information - Additional Information (Details)	12 Months Ended
	Dec. 31, 2022 segment wholesaler
Segment Reporting [Abstract]
Number of Operating Segments | segment	1
Number of Principal US Customers | wholesaler	3

Segment and Geographic Area I_4

Segment and Geographic Area Information - Disaggregation of Revenue (Details) - USD ($) $ in Millions		3 Months Ended	12 Months Ended
		Dec. 31, 2022	Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2020
Disaggregation of Revenue
Net revenues			$ 58,054		$ 56,197		$ 45,804
Total net revenues		$ 15,121	58,054		56,197		45,804
United States
Disaggregation of Revenue
Net revenues			45,713		43,510		34,879
All other
Disaggregation of Revenue
Net revenues			4,137		5,019		5,119
Immunology | Humira
Disaggregation of Revenue
Net revenues			21,237		20,694		19,832
Immunology | Humira | United States
Disaggregation of Revenue
Net revenues			18,619		17,330		16,112
Immunology | Humira | International
Disaggregation of Revenue
Net revenues			2,618		3,364		3,720
Immunology | Skyrizi
Disaggregation of Revenue
Net revenues			5,165		2,939		1,590
Immunology | Skyrizi | United States
Disaggregation of Revenue
Net revenues			4,484		2,486		1,385
Immunology | Skyrizi | International
Disaggregation of Revenue
Net revenues			681		453		205
Immunology | Rinvoq
Disaggregation of Revenue
Net revenues			2,522		1,651		731
Immunology | Rinvoq | United States
Disaggregation of Revenue
Net revenues			1,794		1,271		653
Immunology | Rinvoq | International
Disaggregation of Revenue
Net revenues			728		380		78
Hematologic Oncology | Imbruvica
Disaggregation of Revenue
Net revenues			4,568		5,408		5,314
Hematologic Oncology | Imbruvica | United States
Disaggregation of Revenue
Net revenues			3,426		4,321		4,305
Hematologic Oncology | Imbruvica | International
Disaggregation of Revenue
Collaboration revenues			1,142		1,087		1,009
Hematologic Oncology | Venclexta
Disaggregation of Revenue
Net revenues			2,009		1,820		1,337
Hematologic Oncology | Venclexta | United States
Disaggregation of Revenue
Net revenues			1,009		934		804
Hematologic Oncology | Venclexta | International
Disaggregation of Revenue
Net revenues			1,000		886		533
Aesthetics | Botox Cosmetic
Disaggregation of Revenue
Net revenues	[1]		2,615		2,232		1,112
Aesthetics | Botox Cosmetic | United States
Disaggregation of Revenue
Net revenues	[1]		1,654		1,424		687
Aesthetics | Botox Cosmetic | International
Disaggregation of Revenue
Net revenues	[1]		961		808		425
Aesthetics | Juvederm Collection
Disaggregation of Revenue
Net revenues	[1]		1,428		1,535		718
Aesthetics | Juvederm Collection | United States
Disaggregation of Revenue
Net revenues	[1]		548		658		318
Aesthetics | Juvederm Collection | International
Disaggregation of Revenue
Net revenues	[1]		880		877		400
Aesthetics | Other Aesthetics
Disaggregation of Revenue
Net revenues	[1]		1,290		1,466		760
Aesthetics | Other Aesthetics | United States
Disaggregation of Revenue
Net revenues	[1]		1,122		1,268		666
Aesthetics | Other Aesthetics | International
Disaggregation of Revenue
Net revenues			168	[1]	198	[1]	94
Neuroscience | Botox Therapeutic
Disaggregation of Revenue
Net revenues	[1]		2,719		2,451		1,387
Neuroscience | Botox Therapeutic | United States
Disaggregation of Revenue
Net revenues	[1]		2,255		2,012		1,155
Neuroscience | Botox Therapeutic | International
Disaggregation of Revenue
Net revenues	[1]		464		439		232
Neuroscience | Vraylar
Disaggregation of Revenue
Net revenues			2,038		1,728		951
Neuroscience | Vraylar | United States
Disaggregation of Revenue
Net revenues	[1]		2,037		1,728		951
Neuroscience | Vraylar | International
Disaggregation of Revenue
Net revenues			1		0		0
Neuroscience | Duodopa
Disaggregation of Revenue
Net revenues			458		511		494
Neuroscience | Duodopa | United States
Disaggregation of Revenue
Net revenues			95		102		103
Neuroscience | Duodopa | International
Disaggregation of Revenue
Net revenues			363		409		391
Neuroscience | Ubrelvy | United States
Disaggregation of Revenue
Net revenues	[1]		680		552		125
Neuroscience | Qulipta | United States
Disaggregation of Revenue
Net revenues			158		0		0
Neuroscience | Other Neuroscience
Disaggregation of Revenue
Net revenues	[1]		475		685		539
Neuroscience | Other Neuroscience | United States
Disaggregation of Revenue
Net revenues	[1]		456		667		528
Neuroscience | Other Neuroscience | International
Disaggregation of Revenue
Net revenues	[1]		19		18		11
Eye Care | Lumigan/Ganfort
Disaggregation of Revenue
Net revenues	[1]		514		579		378
Eye Care | Lumigan/Ganfort | United States
Disaggregation of Revenue
Net revenues	[1]		242		273		165
Eye Care | Lumigan/Ganfort | International
Disaggregation of Revenue
Net revenues	[1]		272		306		213
Eye Care | Alphagan/Combigan
Disaggregation of Revenue
Net revenues	[1]		346		529		326
Eye Care | Alphagan/Combigan | United States
Disaggregation of Revenue
Net revenues	[1]		202		373		223
Eye Care | Alphagan/Combigan | International
Disaggregation of Revenue
Net revenues	[1]		144		156		103
Eye Care | Restasis
Disaggregation of Revenue
Net revenues	[1]		666		1,290		787
Eye Care | Restasis | United States
Disaggregation of Revenue
Net revenues	[1]		621		1,234		755
Eye Care | Restasis | International
Disaggregation of Revenue
Net revenues	[1]		45		56		32
Eye Care | Other Eye Care
Disaggregation of Revenue
Net revenues	[1]		1,175		1,169		693
Eye Care | Other Eye Care | United States
Disaggregation of Revenue
Net revenues	[1]		538		523		305
Eye Care | Other Eye Care | International
Disaggregation of Revenue
Net revenues	[1]		637		646		388
Other Key Products | Mavyret
Disaggregation of Revenue
Net revenues			1,541		1,710		1,830
Other Key Products | Mavyret | United States
Disaggregation of Revenue
Net revenues			755		754		785
Other Key Products | Mavyret | International
Disaggregation of Revenue
Net revenues			786		956		1,045
Other Key Products | Creon | United States
Disaggregation of Revenue
Net revenues			1,278		1,191		1,114
Other Key Products | Linzess/Constella
Disaggregation of Revenue
Net revenues	[1]		1,035		1,038		667
Other Key Products | Linzess/Constella | United States
Disaggregation of Revenue
Net revenues	[1]		1,003		1,006		649
Other Key Products | Linzess/Constella | International
Disaggregation of Revenue
Net revenues	[1]		$ 32		$ 32		$ 18
[1]Net revenues include Allergan product revenues after the acquisition closing date of May 8, 2020.

Segment and Geographic Area I_5

Segment and Geographic Area Information - Net Revenues to External Customers by Geographic Area (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues from External Customers and Long-Lived Assets
Net revenues	$ 58,054	$ 56,197	$ 45,804
United States
Revenues from External Customers and Long-Lived Assets
Net revenues	45,713	43,510	34,879
Germany
Revenues from External Customers and Long-Lived Assets
Net revenues	1,340	1,223	1,049
Canada
Revenues from External Customers and Long-Lived Assets
Net revenues	1,159	1,397	1,159
Japan
Revenues from External Customers and Long-Lived Assets
Net revenues	956	1,090	1,198
China
Revenues from External Customers and Long-Lived Assets
Net revenues	912	857	471
France
Revenues from External Customers and Long-Lived Assets
Net revenues	787	936	797
Australia
Revenues from External Customers and Long-Lived Assets
Net revenues	508	533	527
Spain
Revenues from External Customers and Long-Lived Assets
Net revenues	506	519	453
United Kingdom
Revenues from External Customers and Long-Lived Assets
Net revenues	462	497	509
Italy
Revenues from External Customers and Long-Lived Assets
Net revenues	444	506	379
Brazil
Revenues from External Customers and Long-Lived Assets
Net revenues	430	368	406
All other countries
Revenues from External Customers and Long-Lived Assets
Net revenues	$ 4,837	$ 4,761	$ 3,977

Segment and Geographic Area I_6

Segment and Geographic Area Information - Long-lived Assets by Geographic Region (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Revenues from External Customers and Long-Lived Assets
Total long-lived assets	$ 4,935	$ 5,110
United States and Puerto Rico
Revenues from External Customers and Long-Lived Assets
Total long-lived assets	3,243	3,369
Europe
Revenues from External Customers and Long-Lived Assets
Total long-lived assets	1,369	1,400
All other
Revenues from External Customers and Long-Lived Assets
Total long-lived assets	$ 323	$ 341

Fourth Quarter Financial Resu_3

Fourth Quarter Financial Results (unaudited) (Details) - USD ($) $ / shares in Units, $ in Millions													3 Months Ended	12 Months Ended
	Oct. 28, 2022	Sep. 09, 2022	Jun. 23, 2022	Feb. 17, 2022	Oct. 29, 2021	Sep. 10, 2021	Jun. 17, 2021	Feb. 18, 2021	Oct. 30, 2020	Sep. 11, 2020	Jun. 17, 2020	Feb. 20, 2020	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Net revenues													$ 15,121	$ 58,054	$ 56,197	$ 45,804
Gross margin													10,951
Net earnings attributable to AbbVie Inc.													$ 2,473	$ 11,836	$ 11,542	$ 4,616
Basic earnings per share (in dollars per share)													$ 1.39	$ 6.65	$ 6.48	$ 2.73
Diluted earnings per share (in dollars per share)													1.38	6.63	6.45	2.72
Cash dividends declared per common share (in dollars per share)	$ 1.48	$ 1.41	$ 1.41	$ 1.41	$ 1.41	$ 1.30	$ 1.30	$ 1.30	$ 1.30	$ 1.18	$ 1.18	$ 1.18	$ 1.48	$ 5.71	$ 5.31	$ 4.84